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Summary
Bone marrow (BM) transplantation is well established in the context of malignancies, how-
ever, the risks associated with this procedure mostly hampers widespread clinical application
in non-malignant conditions. This is an unfortunate situation, as many experimental studies
have shown considerable potential of this treatment in a wide array of diseases. Thus, eﬀorts
in developing reduced-intensity conditioning of BM recipients are needed in order to trans-
late the many promising experimental ﬁndings to the clinics in the future. During my PhD
project, I worked on diverse aspects of BM transplantation in non-malignant conditions.
One part of the project is settled in the ﬁeld of immunology. In organ transplantation, the
induction of tolerance towards donor tissues by transplanting BM is a promising strategy
to overcome the side eﬀects of life-long immunosuppression. I evaluated the prospects of
targeting speciﬁc lymphocyte populations with a pro-apoptotic drug, and the implications
of such targeting for allogenic BM transplantation. Furthermore, I embarked on studying
the engraftment process of syngeneic hematopoietic stem cells upon low-intensity condi-
tioning with this anti-apoptotic drug. In the second part of my PhD project, I evaluated
the potential of BM transplantation in improving an inborn kidney disease caused by an
intracellular transporter in proximal epithelial cells.
Section 1 gives a general introduction to apoptosis regulation in the immune system.
Furthermore, an overview about mechanisms and barriers involved in immunological tol-
erance and hematopoietic stem cell transplantation is given. Finally, Dent's disease, the
tubulopathy we tried to alleviate with BM transplantation, is introduced. Section 2 com-
prises the results of the experimental studies. We showed that memory T cells can be
successfully targeted with a pro-apoptotic drug, allowing to overcome an important bar-
rier to tolerance induction. Additionally, we found that regulatory T cells, crucial players
in mediating immunological tolerance, are resistant to Bcl-2/Bcl-xL inhibition. Thus, we
developed a novel concept for tipping the balance between eﬀector and regulatory T cells
directly in vivo, resulting in a favourable tolerogenic environment. Furthermore, we showed
an expansion of hematopoietic stem cells in the BM upon treatment with a pro-apoptotic
drug, and a strong synergism with cyclosporine A. However, we are still speculating about
the mechanisms that allow stem cell engraftment under myelosuppression-free recipient
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conditioning. Finally, we found that transplantation of healthy BM into mice with Dent's
disease signiﬁcantly improved all parameters of Fanconi syndrome. The detailed mecha-
nisms are still under investigation, but we have shown that the diseased kidneys recruited
increasingly healthy BM-derived cells that closely associated with tubuli, and thereby re-
covered the expression of megalin in the brush border membrane of proximal tubuli cells.
Section 3 summarizes the ﬁndings of this PhD project and integrates them in a greater
context.
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Zusammenfassung
Im Kontext von malignen Tumoren ist die Knochenmark (KM) Transplantation gut
etabliert. Allerdings verhindern die mit dieser Prozedur verbundenen Risiken eine weit
verbreitete klinische Anwendung bei nicht-malignen Krankheiten. Dies ist bedauernswert,
da bisher viele experimentelle Studien ein erhebliches Potenzial der KM-Transplantation
zur Behandlung zahlreicher Krankheiten gezeigt haben. Aus diesem Grund wäre es wichtig,
in die Entwicklung von neuen, weniger toxischen Protokollen für die KM-Transplantation
zu investieren, denn es würde erlauben, die vielversprechenden experimentellen Ansätze
eventuell in Zukunft in Patienten umzusetzen. Während meiner Doktorarbeit habe ich
mich mit verschiedenen Aspekten der KM-Transplantation für nicht-maligne Indikationen
befasst. Ein grosser Teil des PhDs ist auf dem Gebiet der Immunologie angesiedelt. In der
Organtransplantation kann Toleranz gegenüber dem Spendergewebe durch die Transplanta-
tion von KM vom selben Spender erreicht werden. Dies ist ein vielversprechender Ansatz, da
so die Nebenwirkungen einhergehend mit einer lebenslangen Immunsuppression verhindert
werden können. In meinen Projekten versuchte ich speziﬁsche Lymphozyten Populationen
mit einem pro-apoptotischen Medikament zu eliminieren, und untersuchte anschliessend
die Auswirkungen dieser Therapie auf die allogene KM-Transplantation. Außerdem ver-
suchte ich den Einnistungsprozess von syngenen hämatopoetischen Stammzellen im KM zu
verstehen. Im zweiten Teil meiner Doktorarbeit untersuchte ich die Anwendung der KM-
Transplantation zur Korrektur des Phänotyps einer angeborenen Nierenerkrankung, welche
durch einen defekten intrazellulären Transporter verursacht wird.
Kapitel 1 gibt eine Einführung in die Apoptose-Regulation im Allgemeinen und in
grösserem Detail im Immunsystem. Zudem gebe ich einen Überblick über die Mecha-
nismen und Hindernisse der immunologischen Toleranzinduktion und eine Einführung ins
Thema der hämatopoietischen Stammzelltransplantation. Zum Ende wird Dent's Disease
vorgestellt, jene Tubulopathie, die wir mit KM-Transplantation versuchten zu mildern.
Kapitel 2 enthält die Ergebnisse der experimentellen Arbeiten. Wir haben gezeigt, dass
Gedächtniszellen erfolgreich mit einem pro-apoptotischen Medikament eliminiert werden
können. Zusätzlich fanden wir heraus, dass regulatorische T-Zellen welche für die Im-
muntoleranz von Bedeutung sind, resistent gegenüber der Bcl-2/Bcl-xL Blockade sind.
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Wir etablierten somit ein neues Konzept um das Immungleichgweicht zwischen Eﬀek-
torzellen und regulatorischen Zellen zu verschieben. Weiter zeigten wir eine Expansion
von hämatopoietischen Stammzellen im Knochenmark bei der Behandlung mit einem pro-
apoptotischen Medikament, ein Eﬀekt der in Kombination mit Cyclosporin A noch verstärkt
wurde. Jedoch können wir über die Mechanismen, welche Stammzelltransplantation unter
myelosuppressionsfreien Bedingungen ermöglichen, zum jetzigen Zeitpunkt nur spekulieren.
Im letzten Projekt schliesslich fanden wir, dass Dent's Disese durch die Transplantation
von gesundem KM deutlich gemildert wird. Auch hier sind die genauen Mechanismen der
Verbesserung der Krankheit noch Gegenstand laufender Experimente. Wir haben jedoch
schon gezeigt, dass die kranken Nieren vermehrt gesunde KM Zellen rekrutiert haben, welche
sich dann in der Nähe der Tubuli niedergelassen haben. Dies führte interessanterweise zur
erneuten Expression von Megalin im Bürstensaum der proximalen Tubulizellen. Kapitel
3 fasst die Ergebnisse dieser Doktorarbeit zusammen und diskutiert sie in einem grösseren
Kontext.
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1 Introduction
1.1 Apoptosis
The general importance of apoptosis
For multicellular organisms, cell death is a
mechanism as essential as cell proliferation,
and for homeostasis, these two processes
must be tightly balanced. A genetically
programmed sequence of molecular events
has evolved in order to eliminate superﬂu-
ous or damaged cells in a well-controlled
manner, a process that is called apoptosis.
Apoptotic cells have been ﬁrst recognised by
their morphologic features [1]:(1) cell shrink-
age with condensation of the cytoplasm and
the chromatin, followed by a collapse of the
cytoskeleton and chromatin fragmentation,
(2) extensive membrane blebbing and sepa-
ration of cell fragments into apoptotic bodies
(budding), and ﬁnally (3) the rapid phagocy-
tosis of the apoptotic bodies by neighbouring
cells or macrophages [2]. In contrast to necro-
sis, apoptosis does not cause any damaging
inﬂammatory response.
In normal physiology, apoptosis is cru-
cial in many aspects. During development,
apoptosis is for example involved in morpho-
genesis by removing superﬂuous cells dur-
ing limb formation or by hollowing ducts.
In the nervous system, neurons are overpro-
duced and only cells that succeed in estab-
lishing functional synapses escape apopto-
sis [3]. In adults, programmed cell death
is involved in physiological processes such
as bone remodelling, wound healing or in-
volution of the mammary glands, but also
in protective processes such as removing mu-
tated, damaged or infected cells [4, 5]. Ex-
cessive or insuﬃcient apoptosis is a feature
of many human diseases, for example can-
cer, AIDS, neuro-degenerative diseases such
as Alzheimer's disease or Parkinson's disease,
just to name a few [2].
The extrinsic and intrinsic apoptosis
pathways
The decision of a cell to undergo apoptosis
is based on the integration of a multitude of
cell intrinsic and cell extrinsic stimuli, which
all culminate in the activation of caspases
that ﬁnally demolish the cell. Caspases are
endoproteases that use cysteine as their nu-
cleophilic group to hydrolyse protein bonds,
and they form a complex proteolytic system
similar to the complement or clotting sys-
tem. In healthy cells, caspases are present as
inactive proenzymes (zymogens called pro-
caspases) that require dimerization and often
additionally proteolytic processing for acti-
vation [6]. Once active, caspases orchestrate
cell death by cleaving major constituents of
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the cytoskeleton, the nuclear lamina, the ex-
tracellular matrix, as well as by targeting ge-
nomic DNA, proteins that are essential in
housekeeping functions (e.g. transcription
factors) and by fragmentation of organelles
[710]. All these processes result in the
macroscopic changes that are characteristic
for apoptotic cells [1]. The ﬁnal and proba-
bly most important step of cell death is the
clearance of the cell debris (apoptotic bodies)
by phagocytes without releasing any cellular
contents to the extracellular milieu [11].
Two main pathways lead to death; the ex-
trinsic (death-receptor) pathway and the in-
trinsic (mitochondrial) pathway. The extrin-
sic pathway is triggered by the binding of ex-
tracellular death ligands (e.g. FasL, TRAIL
or TNF-α) to transmembrane death recep-
tors belonging to the tumor necrosis fac-
tor receptor (TNF-R) family [12]. These
receptors contain a cytoplasmic death do-
main, which is essential to activate the apop-
totic program. Receptor ligation leads to
death receptor oligomerization and recruit-
ment of diﬀerent adaptor proteins, e.g. Fas-
associated death domain protein (FADD).
These adaptor proteins provide a link be-
tween the death receptors and procaspases
(mainly caspase-8), and altogether these ele-
ments form a large protein complex called
death-inducing signalling complex (DISC).
Within these DISCs, procaspases dimerize,
resulting in protease activation (induced
proximity model) [13]. These initiator cas-
pases then activate eﬃciently downstream
executioner caspases (mainly caspase-3, -6,
-7), leading to ampliﬁcation of the proteo-
lytic cascade (Figure 1.1). Furthermore, in-
hibitory molecules are produced to restrain
activation of the extrinsic apoptosis pathway
and prevent inappropriate cell death. c-FLIP
is such a molecule that mimics and dimerizes
with caspase-8, and thereby prevents auto-
activation of these caspases [14].
The intrinsic apoptosis pathway is acti-
vated by many diﬀerent signals, such as
growth-factor deprivation, DNA damage, vi-
ral infection, altered redox status, ER stress
or developmental cues [15]. Upon activation
of this death pathway, pores are formed in
the mitochondrial outer membrane (MOM),
leading to the release of apoptogenic proteins
that are contained in the intermembrane
space of mitochondria. The most impor-
tant molecules are cytochrome C, which is
involved in mitochondrial oxidative phospho-
rylation, and SMAC/DIABLO [16]. Upon
mitochondrial release, cytochrome C binds
to Apaf1, which leads to a conformational
change of this molecule, and oligomeriza-
tion into wheel-like structures called apop-
tosome. The apoptosome then recruits ini-
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Figure 1.1: The extrinsic apoptosis path-
way is activated upon death receptor liga-
tion, leading to recruitment and activation
of caspase-8. The Bcl-2 regulated intrin-
sic apoptosis pathway is activated upon cell
intrinsic or extrinsic stimuli such as DNA
damage or cytokine deprivation. The two
pathways converge at the level of down-
stream eﬀector caspases, which ﬁnally dis-
mantle the cell.
Adapted from Youle et al. [15]
tiator procaspase-9, promotes their dimer-
ization and activation, similar to the acti-
vation process of procaspase-8 at the DISC.
Caspase-9 further activates the same execu-
tioner caspases as caspase-8, thus the ﬁnal
path to death converges in both apoptosis
pathways.
As MOM permeabilization is usually a
point-of-no-return in cell survival, the pro-
cesses responsible for pore formation must
be very tightly regulated, and members of
the Bcl-2 protein family are in charge of this
task. These proteins integrate signals from
outside or within the cell and set a threshold
for apoptosis by interacting with each other
at the MOM. Bcl-2 proteins are evolutionary
conserved and can be subdivided into three
structurally and functionally diﬀerent sub-
groups:(1) the pro-apoptotic Bcl-2 homology
3 (BH3)-only proteins, (2) the anti-apoptotic
Bcl-2 factors and (3) the pro-apoptotic eﬀec-
tor proteins Bak and Bax [17]. The latter two
groups share three to four blocks of Bcl-2 se-
quence homology called BH1-BH4 domains,
whereas the BH3-only group, as their name
implies, contain only the BH3 domain. BH3
is a amphipathic helix that interacts with a
hydrophobic surface groove of the multido-
main Bcl-2 members [18, 19].
The interaction between the members of
the three subgroups is complex and the pro-
posed models that illustrate the regulation
of MOM permeabilization evolved over time.
In the beginning, a simple rheostat model
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was proposed (ratio between pro- and anti-
apoptotic factors), which later, with the dis-
covery of more pro- and anti-apoptotic fac-
tors, was replaced by more complex mod-
els. Nowadays, the current consensus is the
integration of diverse models called uniﬁed
model (Figure 1.2). Bax and Bak (eﬀec-
tors) are activated by pro-apoptotic BH3-
only proteins Bim, Puma and tBID (ac-
tivators), which leads to extensive confor-
mational changes and oligomerisation into
pore-like structures at the MOM. In healthy
cells, anti-apoptotic Bcl-2 family members
(guardians: Bcl-2, Bcl-xL, A1, Mcl-1 and
Bcl-w) prevent MOM permeabilization by se-
questering Bak at the MOM and restrain-
ing Bax in the cytosol. The pro-apoptotic
sensitizers Bad and Noxa cannot directly
activate Bax/Bak pore formation, but to-
gether with all the other BH3-only proteins,
they de-repress Bak/Bax indirectly by bind-
ing and inhibiting anti-apoptotic Bcl-2 fam-
ily members [1517, 20]. In certain cell types,
the intrinsic apoptosis pathway can be acti-
vated by caspase-8 mediated cleavage of pro-
apoptotic BID, enabling a crosstalk between
the extrinsic and intrinsic apoptosis pathway
(Figure 1.1) [21].
Enormous complexity is added to the sys-
tem by the fact that BH3-only factors have
binding speciﬁcity for certain Bcl-2 homo-
logues, and binding avidity varies among
binding partners. Furthermore, the stim-
uli that activate or promote expression of
the diverse factors diﬀer, for example Bim
is induced due to growth factor deprivation,
while Noxa and Puma are induced by p53
upon DNA damage [17, 22, 23], and post-
transcriptional processing is also of impor-
tance. The role of individual Bcl-2 factors is
often non-redundant, and their relative im-
portance varies greatly in distinct cell popu-
lations [24]. And ﬁnally, many Bcl-2 factors
play also a role in cell physiology outside of
apoptosis regulation.
Non-apoptotic cell death
Besides apoptosis, various forms of non-
apoptotic cell death exist. Necrosis was long
considered to be the counterpart of apop-
tosis, being an accidental or passive form
of cell death upon chemical or physical in-
sults, and leading to inﬂammation and tissue
damage [26]. Recent research however has
described many modes of regulated necro-
sis that are controlled genetically, similar to
apoptosis. All these forms of cell death share
morphological features with necrosis [26].
Necroptosis is the best studied mode of
such programmed necrosis. It is a well regu-
lated active cell death that occurs under con-
ditions of caspase inhibition [27]. It seems
10
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Figure 1.2: Pro-apoptotic BH3-only fac-
tors de-repress Bax/Bak-mediated pore
formation by blocking anti-apoptotic Bcl-2
factors or by directly activating Bax/Bak.
Adapted from Czabotar et al. and Chi et
al. [17, 25]
to be a protective mechanism for the host
that has co-evolved with viruses, which of-
ten encode potent caspase inhibitors. Thus,
necroptosis allows virus-infected cells to un-
dergo cell death [28]. It is triggered by death-
receptor ligands such as TNF or Fas, and
the downstream signalling involves receptor-
interacting kinases (RIPK) 1 and 3 [2830].
However, how necroptosis is eventually ex-
ecuted remains controversial. It has been
suggested that mitochondrial dysfunction or
plasma membrane permeabilisation are in-
volved [31].
Pyroptosis is an inﬂammatory pro-
grammed cell death that involves the acti-
vation of caspase-1 and -11 [32]. Caspase-1
is is mainly known for processing inactive
IL-1β, a potent pro-inﬂammatory cytokine.
Activation of pyroptosis results in swelling of
the cell, rapid lysis of the plasma membrane
and extensive DNA fragmentation [33]. How
active caspase-1 kills the cell is completely
unknown to date.
Other less well understood modes of pro-
grammed necrosis are ferroptosis, oxytosis,
parthanatos, just to name a few, and the bi-
ological relevance of these processes is un-
known [26].
Another mode of non-apoptotic cell death
is autophagy; Bax/Bak KO cells that are
subjected to cytotoxic stimuli form double-
membrane vesicles, that have been shown to
be autophagosomes [34]. But again, the role
of autophagic cell death under physiological
conditions is not well understood yet.
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Apoptosis regulation in the immune
system
Apoptosis regulation is crucial for the de-
velopment, maintenance and function of the
immune system. Immune cells are overpro-
duced during development, and highly reg-
ulated processes select the right cells, al-
lowed or needed in speciﬁc contexts, while
all unwanted cells are removed. Selection
and removal of immune cells is carried out
to a major part by dynamic expression of
pro-and anti-apoptotic Bcl-2 factors, and the
relative importance of these factors changes
over the lifetime of immune cells (Figure 1.3).
A wide range of developmental cues, such as
cytokines or immune receptor ligation, ac-
count for this dynamic regulation of Bcl-2
factors. Genetic manipulation of these fac-
tors has shown that all cells are fated to die,
and their survival depends on one or more
anti-apoptotic family members. In contrast,
BH3-only proteins mediate cytotoxic or de-
velopmental cues, and ﬁnally the relative bal-
ance between pro-and anti-apoptotic factors
determines the fate of a cell [17]. The current
knowledge of the importance and function of
Bcl-2 factors in physiology and particularly
in immune cells, derives to a big part from
gain- or loss-of-function studies in mice [24].
Hematopoietic stem cells (HSC) stand at
the apex of hematopoiesis and are in charge
of continuously replenishing all blood cells.
Apoptosis is crucially involved in regulat-
ing the size of the HSC pool, as ectopic
expression of Bcl-2 caused HSC accumula-
tion, increased in vivo reconstitution poten-
tial and enhanced colony forming potential
in vitro [35]. However, under physiological
conditions, Bcl-2 seems to be less impor-
tant, as lack of Bcl-2 does not aﬀect early
hematopoiesis [36]. In contrast, Mcl-1 is the
critical survival factor in HSCs. This factor
is highly expressed in HSCs and to a lesser
extent in early progenitor populations (com-
mon lymphoid and common myeloid pro-
genitors, CLP and CMP). Conditional dele-
tion of Mcl-1 in mixed chimeras with syn-
geneic labelled wild-type (WT) bone mar-
row (BM) cells resulted in loss of peripheral
cells derived from the Mcl-1 deleted popula-
tion. Furthermore, mice became very ane-
mic within two to three weeks after com-
plete Mcl-1 deletion due to BM failure [37].
Other cell populations that critically depend
on Mcl-1 are natural killer (NK) cells [38],
mast cells [39] and plasma cells [40], germinal
centre and memory B cells [41]. Mcl-1 is al-
ready important in early B-cell development,
as Mcl-1 deletion results in a developmental
arrest at the pro-B cell stage [42].
Regarding Bcl-xL, the erythroid lineage
seems to be most dependent on this survival
12
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factor. Platelets critically depend on Bcl-xL,
and loss of this factor results thrombocytope-
nia [43]. Furthermore, Bcl-xL is needed in
erythrocytes at the end of maturation, thus
loss of Bcl-xL results in hemolytic anemia
[44]. Additionally, reduced plasma cell num-
bers have been reported in knock-out (KO)
animals [41].
Bcl-2 plays an important role in the lym-
phoid system, as Bcl-2 KO mice loose their
mature lymphocyte population [36, 45], but
otherwise it has an surprisingly restricted
role in normal physiology [24].
Mice have an A1 gene locus quadruplica-
tion, encoding for three functional A1 pro-
teins and one pseudo-gene. This hindered
the generation of genetic KO models so far,
and thus the role of A1 in steady state of
immune cell populations is still elusive [46].
Apoptosis modulation during the life
of a T cell
T cells undergo a highly orchestrated and
complex development and maturation pro-
cess, and programmed cell death plays a cen-
tral role in it. Thymocytes have to pass sev-
eral critical checkpoints to guarantee a func-
tional T cell receptor (TCR) repertoire in
the absence of non-functional or autoreac-
tive TCRs. It is assumed that about 95%
of thymocytes undergo apoptosis during de-
velopment.
Immature T cell precursors migrate from
the BM to the thymus. These early T cells
are in the double negative (DN) development
stage and do not express a TCR nor CD4
or CD8 co-receptors. The survival of these
cells depends on IL-7 signalling, which di-
rectly induces anti-apoptotic Mcl-1 and Bcl-
2 expression in early DN stages, that then
counteract Bim mediated apoptosis [4749].
Later, DN thymocytes rearrange their TCRβ
locus and present a pre-TCR at their sur-
face. Successful signalling through the pre-
TCR results in upregulation of A1, sustained
Mcl-1 expression and protection from apop-
tosis [50, 51], while death receptor signalling
deletes cells that fail to present a functional
pre-TCR [52].
At the double positive (DP) stage, thymo-
cytes concurrently express CD4 and CD8 co-
receptors and rearrange their TCRα chain,
which is followed by rigorous TCR test-
ing steps. Only a few thymocytes success-
fully generate a functional TCR and pass
positive selection by recognizing MHC:self-
peptide complexes presented by thymic epi-
thelial cells, while the vast majority of thy-
mocytes activate the intrinsic death pathway
and undergo apoptosis by neglect. Sponta-
neous thymocyte apoptosis involves the pro-
apoptotic action of Bim and Bax/Bak [53,
13
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Figure 1.3: Dynamic change of the importance of Bcl-2 factors during hematopoiesis and immune cell
diﬀerentiation.
Adapted from Sochalska et al. [24]
54], while survival is mediated by high levels
of Bcl-xL expressed in DP thymocytes [55].
Following successful positive selection, DP
thymocytes downregulate either their CD4
or CD8 receptor and undergo as single pos-
itive (SP) cells further maturation steps.
Cells that express a TCR with high aﬃnity
to MHC:self-peptide complexes are deleted
from the T cell repertoire in order to min-
imize the risk of self-reactivity in the pe-
riphery [56]. Bim is critical for this dele-
tion process, as it is upregulated upon high-
aﬃnity TCR ligation and thus neutralizes
anti-apoptotic Bcl-xL [57]. This process,
which is the most important checkpoint for
central tolerance, is called negative selection.
Taken together, apoptosis is a fundamen-
tal process involved in the development of
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a functional T cell repertoire in the thymus.
Mature CD4 or CD8 T cells that survive
the stringent selection processes in the thy-
mus migrate to the periphery. Homeostasis
and maintenance of the naïve T cell pool re-
quires IL-7 and TCR-MHC signalling, and
Bcl-2 is considered to be the most impor-
tant eﬀector downstream of these signals [58
60]. But also expression of Mcl-1 is essential
for the survival of mature T cells, as speciﬁc
deletion of Mcl-1 in lymphocytes results in
severe lymphopenia [47]. In contrast, Bcl-
xL deletion leads only to a minor reduction
of mature T cells [51]. Upon cognate antigen
encounter, CD8 T cells become activated and
undergo vigorous proliferation and diﬀeren-
tiation into cytotoxic eﬀector T cells (Teﬀ).
Following TCR stimulation, anti-apoptotic
A1 and Bcl-xL are upregulated, while an in-
creased Bim level primes cells to death [61,
62].
In order to prevent immunopathology, the
eﬀector T cell pool contracts after the peak
of the immune response, and 90-95% of
Teﬀs are eliminated. Activation-induced cell
death by Fas ligand has been proposed to
be one of the mechanisms controlling eﬀector
pool contraction; however, in vivo contrac-
tion is not aﬀected in animals that lack death
receptor signalling [6365]. On the contrary,
the intrinsic apoptosis pathway is activated
as cytokines become a limiting factor to-
wards the end of an immune response. Cells
enter a pro-apoptotic state that is mediated
by:(1) already high Bim levels as a result
of TCR stimulation, (2) cytokine-deprivation
mediated Puma upregulation and (3) con-
comitant Bcl-2 and Bcl-xL cleavage [6568].
Only few cells survive the contraction phase
and diﬀerentiate into long-lived memory cells
(Tm). The balance between IL-7 and IL-15
driven Bcl-2 expression and Bim is responsi-
ble for maintenance of Tms [60, 69]. Diﬀer-
ential apoptosis regulation among diﬀerent
T cell subsets (e.g. the various T helper cell
subsets) has not been investigated in detail
to date. However, a recent publication iden-
tiﬁed Mcl-1 as the predominant survival fac-
tor in regulatory T cells (Tregs). Mcl-1 can
be considered as rheostat for controlling the
Treg homeostatic niche, and it is positively
regulated by a IL-2 feedback loop [70]. Treg-
speciﬁc deletion of Mcl-1 led to rapid onset of
fatal autoimmunity, and Bim was identiﬁed
as the main antagonist of Mcl-1 in Tregs [70].
Although this publication states that Bcl-
xL is dispensable for Treg survival, an other
publication showed increased Bcl-xL mRNA
expression levels in CD4+FoxP3+ cells in
comparison to CD4+FoxP3- cells [71].
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Diseases caused by defective
apoptosis regulation in lymphocytes
As apoptosis is fundamental to such a wide
extent in taking life-versus-death decisions
in lymphocytes, one can well conceive the
severe consequences of dysregulated or de-
fective apoptosis. Indeed, apoptosis de-
fects are at the basis of many immunologi-
cal diseases and hematological malignancies.
Mouse knock-out or knock-in models have
provided insights into disease mechanisms.
Apoptosis seems to play a pivotal role in
the pathogenesis of autoimmunity. As ex-
plained above, on one hand, functional apop-
tosis results in the clearance of cell debris
of dying cells without inducing inﬂamma-
tion in surrounding tissues. On the other
hand, both apoptotic pathways are respon-
sible for establishing central tolerance and
maintaining peripheral tolerance. Defects
in both processes can result in breakdown
of tolerance to self-antigens. Lpr and gld
mice lack Fas or FasL, respectively. These
mice develop massive lymphadenopathy and
splenomegaly associated with proliferation of
aberrant T cells, and B cells produce large
amounts of autoantibodies that cause arthri-
tis and immune complex glomerulonephrosis
[7274]. Human autoimmune lymphoprolif-
erative disease (ALPS) involves mutations in
the same genes, while mice also present phe-
notypic but non-orthologous similarities with
human systemic lupus erythematosus (SLE)
[75]. SLE, Sjorgen's syndrome and systemic
sclerosis may all result from defective burial
phases of apoptosis, which might be a con-
tinuous source of autoantigens that trigger
lymphocyte activation [76]. The Bcl-2 fam-
ily forms a barrier against autoimmune dis-
ease [77]. The lack of Bim or overexpression
of Bcl-2 in mice leads to an SLE-like dis-
ease due to perturbed B and T cell develop-
ment and homeostasis [53, 78]. So far, over-
expression of various anti-apoptotic factors
have been reported in SLE patients, and this
overexpression was often mediated by a dys-
regulated cytokine milieu [7982]. No loss-
of-function mutations in autoimmune dis-
eases have been reported, however, acceler-
ated degradation and thus decreased Bim
levels led to ALPS-like disease in one patient
[83].
Another area where dysregulated apopto-
sis can have devastating consequences is can-
cer, as evasion of apoptosis is one of the
hallmarks of cancer [84]. Transgenic over-
expression of Bcl-2 in T and B cells results
in increased cell numbers and higher inci-
dence of malignant transformation in mice
[85, 86]. Accordingly, the t(14;18) transloca-
tion, which results in Bcl-2 overexpression,
is the most common translocation in human
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lymphoid malignancies and deﬁnes Bcl-2 as
oncogene [87].
Pharmacological modulation of the
intrinsic apoptosis pathway
Speciﬁc targeting of overexpressed anti-
apoptotic Bcl-2 family members in cancers
bears great therapeutic potential, as it can
overcome drug resistance to chemo- and ra-
diotherapy. The ﬁrst strategy to target
Bcl-2 was its downregulation by an anti-
sense oligonucleotide. A compound called
oblimersen sodium entered clinical trials, but
its success was limited [88]. Much more suc-
cessful was the strategy to target the BH3-
binding groove present on anti-apoptotic
Bcl-2 proteins with small molecule inhibitors
termed BH3 mimetics. If not blocked, the
hydrophobic BH3-binding groove (recep-
tor) interacts with the conserved BH3 do-
main (ligand) present on all pro-apoptotic
proteins, and thereby prevents MOM pore
formation and apoptosis [89].
So far, more than 20 BH3 mimetics
with diﬀerent potencies and selectivities have
been developed and tested in vitro and in
pre-clinical cancer models, and some have
entered (more or less successful) clinical tri-
als. Figure 1.4 shows some of these com-
pounds and their targets. Maritoclax, MIM1
and the recently discovered A-1210477 are
speciﬁc and potent Mcl-1 inhibitors [91, 92],
ABT-199 is very speciﬁc in targeting Bcl-
2 [93], and A-1155463 is a Bcl-xL inhibitor
[94]. An A1 inhibitor has not been developed
yet. Obatoclax (GX15-070), gossypol (AT-
101) and its derivatives (e.g. sabutoclax)
are pan-Bcl-2 inhibitors. While obatoclax
shows oﬀ-target toxicity (killing of Bax/Bak
KO cells), sabutoclax seems to be much more
speciﬁc [95, 96].
ABT-737 and its oral analogue ABT-263
(navitoclax) are the best characterized BH3
mimetics so far. ABT-263 is used in clin-
ical studies, while for pre-clinical research
the company AbbVie usually only provides
ABT-737. This compound selectively binds
Bcl-2, Bcl-xL and Bcl-w with a very high
aﬃnity (Ki below 1nM) and Mcl-1 and A1
with a much lower aﬃnity [97]. In contrast
to some other BH3 mimetics, ABT-737 kills
cells only via the intrinsic apoptosis path-
way and shows no oﬀ-target toxicity [96]. In
clinical trials, ABT-263 was safe and gener-
ally well tolerated. However, a dose-limiting
side eﬀect was reversible thrombocytopenia
caused by the Bcl-xL dependence of platelets
[98].
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Figure 1.4: BH3 mimetics and their targets: All these compounds have been reported to induce apoptosis
in preclinical cancer models or clinical trials.
Adapted from Vela and Marzo [90].
1.2 Mechanisms and barriers
involved in immunological
tolerance
The immune system has evolved to pro-
tect us by mounting eﬀective immune re-
sponses against foreign pathogens, while at
the same time showing no reactivity against
our own tissues. This fundamental paradigm
is called immune tolerance. Immune toler-
ance is achieved through the complementary
action of deletion and regulation, encompass-
ing both, central and peripheral mechanisms
(Figure 1.6) [99]. In the context of organ
transplantation, the initial deﬁnition of toler-
ance has been expanded. Here, the ultimate
goal is to extend the immune-self and render
the immune system speciﬁcally unresponsive
towards the allograft [100].
Several non-redundant mechanisms ensure
immunological tolerance. The most impor-
tant one is central tolerance. Random re-
combination of the α- and β-chain gener-
ates a wide diversity of TCRs, of which
a large part is self-reactive. Thus as out-
lined earlier, T cells must undergo a strin-
gent selection process in the thymus in or-
der to assure a self-recognising and -tolerant
T cell pool. DP thymocytes that recog-
nize MHC:self-peptide complexes are posi-
tively selected and become SP cells. Dur-
ing negative selection (also known as clonal
deletion), self-reactive T cell precursors are
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Figure 1.5: The peripheral T cell pool is generated through the selection of self-restricted (positive selec-
tion) and self-tolerant (negative selection) T cell progenitors in the thymus. Most developing cells possess
TCRs that don't recognize MHC:self-peptide complexes, thus they don't receive survival signals and die by
neglect (grey). High aﬃnity binding to MHC:self-peptide complexes induces apoptosis (negative selection,
red). Thymocytes that bind MHC:self-peptide complexes with low aﬃnity are positively selected (blue) and
develop into mature T cells.
Adapted from Palmer and Naeher [101].
deleted, and for this process the transcrip-
tion factor Aire is crucial. Aire is selectively
expressed in medullary thymic epithelial cells
(mTEC) and drives the ectopic expression of
tissue-speciﬁc antigens. Recognition of these
antigens results in deletion of developing thy-
mocytes [102]. Taken together, weak TCR
signalling protects thymocytes from death
by neglect, while high-aﬃnity interactions
delete the cells (Figure 1.5). Slightly higher
aﬃnity for MHC:self-peptide complexes are
permissive for Treg diﬀerentiation, leading to
a Treg-speciﬁc TCR repertoire that is skewed
towards self-reactivity [103].
However, some self-reactive T cells are
released into the periphery as the Aire-
dependent deletion process is not perfect.
Thus, several peripheral immune tolerance
mechanisms come into operation. An impor-
tant basic mechanism is ignorance, which
is the physical separation of self-reactive T
cells from parenchymal cells that express tis-
sue antigens [104]. Naïve CCR7+ CD62L+
T cells recirculate between blood, secondary
lymphoid organs and the lymph system and
thus not necessarily come into contact with
peripheral antigens. Anergy (functional in-
activation) or deletion occurs as result of
TCR-stimulation in the absence of costimu-
lation. Tissue-resident dendritic cells (DCs)
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Figure 1.6: There are four major mechanisms for induction and maintenance of T cell tolerance. Clonal
deletion, anergy and ignorance are passive tolerance mechanisms and suppression by Tregs is actively
maintained tolerance. Clonal deletion is mainly taking place in the thymus (central tolerance) but also in
the periphery e.g. after antigen encounter. Anergy, Treg-mediated suppression and ignorance are important
for peripheral tolerance.
phagocyte cell debris from apoptotic cells
that arise from normal cell turnover and
present the antigens to naïve T cells in
the draining lymph nodes. In the absence
of an infection, DCs are not activated and
thus only express low levels of costimulatory
molecules, resulting in anergy or apoptosis of
T cells [105]. Finally, Treg-mediated active
suppression of self-reactive T cells another
essential tolerance mechanism (Figure 1.6).
Regulatory T cells
The best studied regulatory cell population
in mice are CD4 Tregs that are deﬁned by
their constitutive expression of the FoxP3
transcription factor and the high-aﬃnity α-
chain IL-2 receptor (CD25) at their sur-
face [106, 107]. Furthermore, expression of
several molecules that are needed for the
immunosuppressive function are character-
istic for Tregs. They represent between 5-
10% of the peripheral CD4 T cell popula-
tion, and most Tregs arise from the thymus
and thus are termed thymus-derived Tregs
(tTregs). Under certain conditions, Tregs
can develop from conventional eﬀector CD4
cells in the periphery (peripherally-derived
Tregs pTregs) or in vitro (iTregs). The cru-
cial importance of Tregs in peripheral tol-
erance is demonstrated in patients with the
X-linked immunodeﬁciency syndrome IPEX
and in scurfy mice. Both have mutations
in the FoxP3 locus and present an autoim-
mune disease in multiple endocrine organs,
inﬂammatory bowel disease, severe allergy
with dermatitis, and fatal infections [108,
109]. But also minor genetic abnormalities
that aﬀect Treg diﬀerentiation, maintenance
or function by direct or indirect means can
predispose to (organ-speciﬁc) autoimmunity,
e.g. polymorphisms in the genes encoding for
CTLA-4, IL-2, IL-2Rα or TGF-β [110113].
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Four basic mechanisms have been pro-
posed of how Tregs exert their immunosup-
pressive function: suppression by inhibitory
cytokines, cytolysis, metabolic disruption
and modulation of DC maturation or func-
tion (Figure 1.7). Three inhibitory cytokines
(IL-10, IL-35 and TGF-β) are the key me-
diators of Treg suppressive function. De-
spite intensive research, the relative impor-
tance of each cytokine under diﬀerent condi-
tions in not completely understood yet. IL-
10 is expressed by eﬀector Tregs that lo-
calize to mucosal tissues and thus seems to
control inﬂammation at barrier tissues [114,
115]. IL-35 is a potent cytokine required for
maximal regulatory activity of Tregs [116],
whereas the importance of TGF-β for sup-
pressive function is still controversial [117].
In diverse experimental settings, Tregs have
been shown to express granzyme B, perforin,
TRAIL and galectin-1, and loss of either
mechanism resulted in reduced suppressive
activity of Tregs [118121]. By constitutively
expressing CD25, Tregs have been shown
to deprive dividing eﬀector cells from IL-2,
which leads to apoptosis of these cells [122].
And ﬁnally, Tregs are able to inﬂuence eﬀec-
tor cell activation indirectly by modulating
the maturation and activity of DCs. For ex-
ample, Treg can induce the expression of the
immunoregulatory enzyme 2,3-dioxygenase
(IDO) in DCs, which then is secreted and
thereby suppresses Teﬀ function [123]. Ad-
ditionally, CTLA-4 expressed on Tregs can
interact with CD80 and CD86 on DCs, and
by a process called trans-endocytosis, Tregs
thereby remove CD80/86 from the surface
of DCs. Hence, DCs cannot provide T cells
with costimulation through CD28, which in-
hibits excessive activation of Teﬀs [124].
Tolerance induction strategies in
transplantation
Transplantation is often the best treatment
option for patients with end stage organ fail-
ure. However, the transplanted organ primes
innate and adaptive immune responses due
to tissue injury and the foreign antigens pre-
sented on the tissue. With current immuno-
suppressive treatments, acute rejection can
be prevented eﬃciently [125]. In the long-
term however, little progress has been made
and chronic rejection is still causing consid-
erable organ loss. Furthermore, the general-
ized immunosuppression bears an increased
risk for infections (including opportunistic
infections) and certain cancers [126]. For
these reasons, one of the most important
goals in the transplantation ﬁeld is the in-
duction of tolerance, which is immunological
unresponsiveness towards the allograft with-
out the need for immunosuppression. The
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Figure 1.7: Four basic mechanisms of Treg-mediated suppression of eﬀector T cell viability and function.
Adapted from Vignali et al. [117]
detailed understanding of the processes that
mediate and maintain self-tolerance can be
exploited to develop strategies to induce allo-
speciﬁc tolerance.
Two immunological barriers have to be
breached for successful tolerance induction.
On one hand, the pre-existing T cell pool
in the periphery needs to be tolerized to al-
loantigens, while on the other hand, newly
developing allo-reactive T cells in the thy-
mus need to be eliminated. The power of
the peripheral T cell pool is illustrated by the
fact that thymectomized rats still can reject
skin grafts [127]. Thus, several peripheral
tolerance approaches that target mature T
cells have been proposed. Early approaches
targeted either CD4, or CD4 plus CD8 co-
receptors, with depleting or non-depleting
antibodies, which allowed prolonged heart
and skin graft survival [128, 129]. Later,
combined blockade of the CD28 (CTLA-4
Ig) and CD40 (anti-CD154, MR1) costimula-
tory pathways proofed successful in prevent-
ing heart (>80 days) and skin (>50 days)
allograft rejection [130]. Another strat-
egy was to combine donor-speciﬁc transfu-
sion (DST) with monoclonal antibodies such
as non-depleting anti-CD4, MR1 or CTLA-
4 Ig [131133]. Depending on the trans-
plant model and the strain combination used,
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graft rejection could be delayed or prevented.
With the DST plus MR1 approach, func-
tional tolerance was only achieved in less
stringent transplants like heart or islet cells,
while long-term skin graft survival required
concomitant thymectomy [134]. Similar to
physiological tolerance induction, peripheral
allo-tolerance is based on deletion/anergy
and active regulation [99]. Especially sup-
pression of allo-reactivity by Tregs is an im-
portant mechanism in most approaches that
aim at inducing peripheral tolerance. In fact,
it has been stated that the current paradigm
is that the balance of alloantigen-reactive
Treg cells and Teﬀ cells ultimately deter-
mines whether the graft is accepted or re-
jected [135]. Thus, direct pharmacological
targeting of pathways that promote Treg de-
velopment or expansion in vivo, or ex vivo
generation and/or expansion of Tregs repre-
sent other promising strategies to promote
graft survival.
Tolerance is a graded condition. For ex-
ample, tolerance can be operational , which
means that a graft may be accepted without
immunosuppression, but a second graft will
be rejected. Although peripheral tolerance
strategies allow successful operational toler-
ance induction, eﬀective long-term and sys-
temic tolerance can only be achieved with
central tolerance mechanisms (at least in
higher animals and humans). This approach
will be discussed in detail in section 1.3.
Memory T cells
Immunological memory is a key feature of
adaptive immunity. Upon antigen encounter,
naïve T cells proliferate extensively and most
of them diﬀerentiate into short-lived Teﬀs
that undergo apoptotic cell death after anti-
gen clearance. In contrast, a small subset
of the Teﬀ pool diﬀerentiates into memory
cells by activating a distinct pattern of tran-
scription factors [136], resulting in longevity,
a distinct dependency on cytokines (mainly
IL-7 and IL-15) and diﬀerential migration
patterns as compared to naïve T cells [137].
There are three main subsets of CD8 Tm:
central and eﬀector memory cells (Tcm and
Tem), both recirculate in the blood, and non-
circulatory tissue-resident Tm [137, 138].
Upon re-encounter of their cognate antigen,
Tms show a rapid and robust immune re-
sponse with a low activation threshold [139].
Besides their need for lower antigen doses for
activation, Tm are also less dependent on
conventional costimulatory signals (CD28
and CD154) compared to naïve T cells [140
142]. For these reasons, Tm can be fully acti-
vated by non-professional antigen-presenting
cells in tissues (e.g. endothelial or parenchy-
mal cells). Once re-activated, Tm acquire an
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eﬀector phenotype and thereby exert impor-
tant functions in protecting the host from re-
infection with previously encountered anti-
gens.
While Tm are well equipped for ﬁghting
infections and certainly are important for
protection, they pose problems in the trans-
plantation ﬁeld. Individuals with a normal
infection and vaccination history are likely
to possess alloreactive memory T cells in
their T cell repertoire, and these cells are
diﬃcult to circumvent by immunosuppres-
sion and pose a barrier towards tolerance in-
duction strategies. Several mechanisms lead
to the generation of alloreactive Tm in an
individual:(1) direct sensitization with allo-
antigens, (2) antigen-independent Tm gen-
eration, or (3) cross-reactivity with another
antigen [143]. Direct sensitization can oc-
cur upon contact with allogenic antigens, e.g.
prior grafts, blood or platelet transfusions or
during pregnancy, where the mother can be
primed against paternal antigens carried by
the foetus [144146]. Interestingly, cells with
Tm-like properties and phenotype can also
develop in an antigen-independent manner
during homeostatic proliferation after non-
speciﬁc T cell depletion. Naïve alloreactive T
cells proliferate under such lymphopenic con-
ditions in response to IL-7 and diﬀerentiate
into Tms [147149]. This ﬁnding is impor-
tant, as lymphocyte depletion is frequently
used as induction therapy in sensitized trans-
plant patients.
The most important process of alloreac-
tive Tm generation is termed heterologous
immunity [150]. During the course of an
infection, virus-speciﬁc Tm are generated.
Because cross-reactivity is a common phe-
nomenon, many cells of a patient's Tm pool
possess TCRs that are cross-reactive to al-
loantigens [151154]. Indeed, several stud-
ies have shown speciﬁc cross-reactivity be-
tween pathogen-derived epitopes and allo-
genic human leukocyte antigens (HLA) [155
157]. More recent studies further showed
that recognition of unrelated peptide epi-
topes by T cell clones is based on molecular
mimicry [158160]. Thus, a large proportion
of Tm clones present in a patient possesses
cross-reactivity for allo-antigens.
Tm-related problems in
transplantation
As Tm require lower antigen doses and less
costimulatory signals for re-activation, they
are perfectly suited to rapidly respond to
a recurrent infection [161]. However, these
unique features allow alloreactive Tm to traf-
ﬁc rapidly into grafts, recruit innate immune
cells and damage the tissue. Conventional
immunosuppressive drugs usually target cel-
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lular checkpoints that are required for the
activation and clonal expansion of naïve T
cells, and thus might be less eﬀective in con-
trolling Tm activation [162]. This notion
is supported by the fact that immunosup-
pressed transplant recipients still receive vac-
cinations that mediate protection at least
partially by Tm [163].
Importantly, Tm prevent tolerance induc-
tion in protocols that are based on blockade
of the CD40-CD154 and CD28-CD80/86 cos-
timulatory axes. As explained before, cos-
timulation blockade with or without DST
were successful in inducing tolerance to var-
ious grafts. However, mice that were previ-
ously primed with allo-antigens or pathogens
remained refractory to these experimental
strategies [150, 154, 164]. Heterologous im-
munity thus is a potent barrier to tolerance
induction. It explains the diﬃculties encoun-
tered when protocols that were successful in
naïve mice are translated to non-human pri-
mates or patients.
1.3 Hematopoietic stem cell
transplantation
In 1951, researchers noticed that intravenous
injection of BM cells from an adult mouse
can protect the recipient from lethal irradia-
tion [165]. Since then, HSCs have been stud-
ied extensively, they are the best studied so-
matic stem cell type and can be considered as
the stem cell prototype. The concept that
all types of blood cells (e.g. erythrocytes,
platelets and all the immune cells) derive
from a common pool of self-renewing HSCs
has long been established [166, 167]. HSCs
cannot be identiﬁed based on their morphol-
ogy, but ﬂow cytometry allows to character-
ize these cells based on their surface marker
expression. On a functional level, the gold
standard test to proof the identity of a HSC
is the competitive repopulation unit assay,
where one single cell is transplanted into a
lethally irradiated animal. This allows test-
ing whether the cell of interest is able to re-
generate and maintain long-term blood pro-
duction [168]. However, recent research ques-
tions this approach [169]. Also the notion
of the HSC is wrong, because there ex-
ist diverse HSC subsets with a considerable
heterogeneity in self-renewal and diﬀerenti-
ation potential, which is a subject of inten-
sive research and much debate [168]. Some
reports claim transdiﬀerentiation of HSC-
derived cells into non-hematological tissues,
however experts in the ﬁeld of HSCs question
such observations [170].
The BM microenvironment harbours not
only rare HSCs and their progeny, but
also non-hematopoietic cells belonging to
the mesenchymal lineage that support
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hematopoiesis. Mesenchymal stromal cells
(MSCs) show self-renewal and have a great
diﬀerentiation potential. They can give rise
to osteoblasts, chondrocytes and adipocytes,
but true stemness is diﬃcult to prove ex-
perimentally [171, 172]. Nevertheless, MSCs
have attracted great interest in regenerative
medicine. They can be easily isolated from
the BM and injected systemically. It is con-
troversial whether MSCs speciﬁcally home to
tissues, however it has been shown that they
are recruited to sites of acute injury, e.g. to
the kidney [173]. MSCs secrete a vast di-
versity of soluble factors, and their regener-
ative capacities have mainly been attributed
to their paracrine/endocrine eﬀects. Reports
claim transdiﬀerentiation of MSCs into other
tissues such as neurons or muscles, but this
is a topic of much debate. What is clear how-
ever, is the fact that MSCs have a profound
impact on immunity by interacting with al-
most all immune cells [174].
When we perform experimental BM trans-
plantation in mice, most of the time we iso-
late all the cells from donor BM and inject
the complete mixture (unfractionated BM)
intravenously into a pre-conditioned recipi-
ent. This cell cocktail consists of a few HSCs,
many progenitors of the diﬀerent blood lin-
eages at various development stages, ery-
throcytes, platelets and mature immune cells
such as T and B lymphocytes. In addition,
there are MSCs and their progeny. After
systemic injection, HSCs and possibly also
early progenitors readily home to the BM
of the recipient, while mature lymphocytes
persist for quite a long time in the periph-
ery. Preparatory irradiation of the recipient
results in damage of MSCs and disruption
of the HSC niche, but endogenous MSCs are
not killed [175]. Co-injected donor MSCs do
not home to the BM, therefore MSCs remain
of host origin [176]. But co-transplanted
MSCs have an important function in pro-
moting HSC engraftment, supporting re-
constitution of hematopoiesis by producing
cytokines, and possibly also by preventing
graft-versus-host disease (GVHD) [177].
As alternative to using unfractionated BM
for transplantation, HSCs can be enriched
by depleting all lineage-positive cells from
the BM suspension by MACS, or by FACS
sorting of highly puriﬁed HSCs populations
based on surface marker expression. In clin-
ics, mostly peripherally mobilized and puri-
ﬁed CD34+ HSCs, sometimes in conjunction
with T cells, are transplanted. In an ex-
perimental therapeutic/regenerative setting,
BM-derived cells might be administered not
necessarily with the aim to have permanent
engraftment (without preparative condition-
ing, as explained in detail later in this sec-
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tion), but to proﬁt from short-term eﬀects.
These positive eﬀects may derive from both
populations present in the BM, HSCs and
MSCs.
Clinical indications for HSC
transplantation
Indications for HSC transplantation are di-
verse. Hematologic malignancies that are re-
fractory to other treatments are the main
indication for HSC transplantation. Here,
maximally tolerated myelotoxic doses of
chemo- and radiotherapy are needed to elim-
inate the cancer, and the resulting marrow
aplasia is treated with the transplantation of
autologous or allogenic HSCs [170].
Additionally, there is wide variety of
non-malignant conditions that (potentially)
proﬁt from HSC transplantation. Depend-
ing on the severity of the condition and other
treatment opportunities, more or less toxic
preparatory regimen and the associated side
eﬀects are acceptable. It can be performed
in transplant recipients to deliberately repro-
gram their immune system and render it tol-
erant to allo-antigens. This approach will be
discussed in the following section. Addition-
ally, there are many diseases of the immune
system or the hematopoietic system that can
be directly improved by HSC transplanta-
tion, for example sickle cell anemia (Fig-
ure 1.8) [170].
Important examples of diseases that can
be improved indirectly by HSC transplan-
tation are lysosomal storage diseases (LSD).
This is a group of devastating systemic dis-
eases that are caused by gene defects in hy-
drolytic enzymes in lysosomes. Many of
these diseases can be improved by enzyme
replacement therapies, but HSC transplan-
tation is sometimes the only eﬀective long-
term therapy. Already 1980, a child with se-
vere Hurler syndrome was HSC transplanted,
and this great success paved the way to es-
tablish HSC transplantation in several LSDs
during the past 35 years [170, 178]. LSDs are
improved by HSC transplantation by healthy
cells that engraft to the tissues and secrete
functional lysosomal enzymes that are taken
up by recipient cells, leading to a metabolic
correction [179].
The potential of HSC transplantation is
immense, however in non-malignant condi-
tions the risks associated with the procedure
limit its application. For this reason, various
reduced intensity transplantation strategies
are being developed.
HSC transplantation for tolerance
induction
If only the periphery is tolerized, novel allo-
reactive T cells will arise and eventually re-
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Figure 1.8: Indications for HSC transplantation: Besides malignancies, HSC transplantation is performed
to directly correct diseases of the hematopoietic system and the immune system. It has also great potential
in correcting diseases indirectly, e.g. it is an established procedure for treatment of several LSDs and it
might potentially improve Dent's disease. HSC transplantation for tolerance induction has been successfully
performed in patients, but reduced toxicity conditioning is desirable.
ject transplanted, highly immunogenic tis-
sues like the skin. However, it is possible
to re-program the immune system by trans-
planting HSCs derived from the organ donor.
The phenomenon of central immune toler-
ance has been discovered 70 years ago by
Owen and coworkers. They made the ob-
servation that cattle dizygotic twins display
chimerism (mosaicism) and long-term tol-
erance towards each other's skin grafts [180].
Experimentally, tolerance was induced by ex-
posing mouse foetuses to homogenized allo-
genic tissues, an experiment that was per-
formed by Billingham, Brent and Medawar
[181].
In adults, immune tolerance can be
achieved by lethal irradiation followed by re-
constitution with allogeneic HSCs, leading
to full chimerism. However, this treatment
is very toxic due to the complete ablation
of the host's immune system and the high
risk for GVHD, and thus not acceptable for
the purpose of tolerance induction. An el-
egant alternative is the induction of mixed
chimerism, a state where recipient and donor
HSCs co-exist (Figure 1.9) [182]. Physio-
logical mechanisms come into play, where
host- and donor-derived antigen-presenting
cells (APCs) migrate to the thymus and
take place in the process of central deletion
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Figure 1.9: Strategies for tolerance induction: The side eﬀects associated with myeloablative conditioning
are not acceptable for the purpose of tolerance induction. Mixed chimerism induction requires less intensive
conditioning of the recipient and has been successfully translated to clinics.
of self- and donor-reactive thymocytes, re-
sulting in robust donor-speciﬁc tolerance in
addition to self-tolerance [182]. However,
lethal irradiation for mixed chimerism induc-
tion is unacceptable when considering clin-
ical translation of this tolerance approach.
Thus, much eﬀort was given during the past
30 years in developing alternative proto-
cols that allow donor BM engraftment un-
der non-myeloablative, reduced-toxicity con-
ditioning regimens. For successful allo-HSC
transplantation, two requirements have to be
met:(1) in order to prevent rejection of the
transplanted BM, peripheral and thymic al-
loreactivity needs to blocked, (2) it is gen-
erally assumed, that there is a need to
open some stem cell niche space for the
transplanted HSCs [183]. Allogeneic BM
cells transferred into an unconditioned re-
cipient are rapidly rejected. To block pe-
ripheral reactivity, diﬀerent approaches have
been proposed, e.g. T cell depleting an-
tibodies, in some instances combined with
thymic irradiation (depending on the irra-
diation dose of concomitant total body ir-
radiation (TBI)), or costimulation blockade
[183186]. When using costimulation block-
ade, only alloreactive T cells undergo periph-
eral deletion, which is clearly an advantage
compared to the complete deletion of the
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T cell pool obtained with anti-T cell anti-
bodies [187]. Regarding the second point,
there exists however some controversy. Most
conditioning protocols involve sublethal TBI
(between 1.5 and 6 Gy) or cytotoxic drugs.
This is thought to remove some endogenous
HSCs and create space for the transplanted
HSCs, while additionally having an immuno-
suppressive eﬀect. However, it is possible to
omit myelosuppression under certain condi-
tions: e.g. by administrating mega doses
of BM cells (200x 106) under costimulation
blockade [188], or MR1 in combination with
sirolimus or CsA plus 4x 106 BM cells [189],
or Tregs together with MR1, CTLA-4 Ig,
sirolimus and 2x 106 BM cells [190].
We have recently developed a novel
myelosuppression-free strategy to induce al-
logeneic chimerism and robust tolerance by
pharmacological apoptosis modulation in pe-
ripheral lymphocytes [191]. By combining
a two-week treatment of ABT-737 and CsA
with one injection of MR1 at the time of BM
infusion (25x 106 cells), we were able to in-
duce stable mixed chimerism (Figure 1.10).
ABT-737 tolerized the peripheral T cell pool
by several mechanisms. It reduced the pre-
cursor frequency of allo-reactive T cells by
unspeciﬁc deletion of peripheral T cells. Fur-
ther, it boosted the function of pro-apoptotic
Bim, which is required for eﬃcient deletion
of allo-reactive T cells under MR1 costim-
ulation blockade [191]. As described later
in the Results section, Tregs are also im-
portant players in ABT-737 mediated tol-
erance induction. The mechanisms that al-
low engraftment of allogenic HSCs under this
myselosuppresion-free situation is under in-
vestigation.
As outlined above, clinical translation of
tolerance strategies has proven diﬃcult be-
cause of the presence of allo-reactive Tm.
Furthermore, many pre-clinical protocols
rely on blocking anti-CD154 signalling. How-
ever, blockade of this pathway resulted in
thromboembolic events in non-human pri-
mates [192]. Thus, of the many tolerance
induction strategies reported in mice, only
few were successful in large animals and
solely two (a third one is questioned) mixed
chimerism approaches are used for renal allo-
graft tolerance induction in patients. These
protocols were developed initially in the con-
text of hematologic malignancies and later
used solely for tolerance induction.
The Stanford group around Samuel
Strober has developed a successful proto-
col to transplant HLA-matched G-CSF mo-
bilized HSCs. Conditioning is based on
total lymphoid irradiation (TLI) and anti-
thymocyte globulin (ATG), plus immuno-
suppression with CsA for 6 months, my-
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Figure 1.10: Myelosuppression-free mixed chimerism induction with a two-week ABT-737 treatment, low-
dose CsA, MR1 and the transplantation of 25x 106 BM cells. The low chimerism levels obtained with this
protocol were suﬃcient to promote robust skin graft tolerance.
Adapted from Cippà, Gabriel et al. [191]
cophenolate mofetil for one month and pred-
nison [193]. In 16 out of 22 patients, per-
sistent chimerism for more than 6 months
was established and these patients could be
completely weaned from immunosuppression
without graft loss and signs rejection (Fig-
ure 1.11) [194].
Another group at Massachusetts General
Hospital around David Sachs and Megan
Sykes has also successfully developed a
clinical tolerance protocol. This protocol
includes induction with cyclophosphamide,
ATG, thymic irradiation, and immunosup-
pression with CsA for 2-3 months for the
transplantation of HLA-matched stem cells
[195]. For HLA-mismatched stem cells,
the induction protocol includes rituximab
(anti-CD20 mAB) and siplizumab (anti-CD2
mAB) instead of ATG, prolonged CsA for
9 months and short-term prednisone [196].
In an initial study, patients with renal fail-
ure secondary to multiple myeloma received
HLA-matched stem cells, which resulted in
long-term kidney graft acceptance in most
patients [195]. Following HLA-mismatched
stem cell transplantation, only transient
chimerism was achieved, which was however
suﬃcient to induce long-term allograft sur-
vival and function (>11 years until now)
[196].
Taken together, these clinical trials rep-
resent a proof-of-principle that tolerance in-
duction in organ recipients is an achievable
goal. However, its application is limited to
living-donor organ recipients. Given the fact
that nowadays rejection can be well con-
trolled with immunosuppressive drugs, it is
diﬃcult to incorporate such a novel approach
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Figure 1.11: HLA-matched kidney graft sur-
vival
Patients were either enrolled in the Stanford toler-
ance protocol for mixed chimerism induction (20 pa-
tients, red) or they underwent standard immunosup-
pressive treatment in Stanford (49 patients, blue).
The Kaplan-Meier curve shows death censored graft
survival.
Adapted from Scandling et al. [194]
into clinical practice. And it is further com-
plicated as there are still some safety issues
to be resolved (e.g. profound leukopenia).
Eﬀorts to further reduce toxicity of the con-
ditioning regimen are needed for a broad use
of HSC transplantation in benign conditions.
HSC transplantation for the
correction of kidney diseases
The use of stem cells in the regenerative
and therapeutic setting has high potential,
and thus receives a lot of attention from
the research community. Many studies have
suggested that BM-derived stem cells dis-
play plasticity and diﬀerentiate into cells of
other lineages such as myocytes, endothe-
lium, hepatocytes, neurons and glia [197
201], while other studies present evidence for
fusion of these cells with other cell types
[202205]. However, transdiﬀerentiation of
both, HSCs and MSCs, is questioned by ex-
perts because such studies often cannot be
reproduced by other laboratories, and results
may arise from false detection methods (e.g.
superposition of cells on microscopic slides).
Based on their reparative and angiogenic
properties, BM-derived stem cells are consid-
ered an attractive therapy for renal repair af-
ter injury or for the therapy of renal diseases.
Especially MSCs have been shown to pre-
vent or attenuate acute kidney injury such
as ischemia/reperfusion injury (I/R injury),
cisplatin-induced acute kidney injury or anti-
Thy1.1 glomerulonephritis [173, 206208]. In
these instances, MSCs were systemically or
locally infused, which reduced acute injuries
by paracrine or endocrine mechanisms rather
than by engraftment. HSCs have been shown
to improve recovery upon acute renal injury
[209211]. However, all the mentioned stud-
ies have used animal models with artiﬁcial
kidney injuries and thus might be of limited
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translational importance.
In contrast, a fascinating study by Syres
et al. has presented evidence that stem
cells can correct a tubulopathy in a clini-
cally relevant cystinosis model [212]. Cysti-
nosis is a hereditary LSD that is caused
by defects in the CTNS gene that encodes
a cystine transporter (cystinosin) located
in lysosomes [213, 214]. Upon defects in
cystinosin, cysteine accumulates in lysosmes,
which leads to the formation of cysteine crys-
tals that cause organ-speciﬁc damage. The
kidneys are severely aﬀected by the muta-
tion, and patients show generalized proximal
tubular dysfunction (Fanconi syndrome) and
progress to end-stage renal disease in child-
hood [215]. In the above mentioned study,
Ctns KO mice, which recapitulate well the
disease phenotype of cystinosis, were trans-
planted with syngeneic WT BM cells, and
cystine content in organs and renal function
were measured twice in four months. The
authors show engraftment of transplanted
BM-derived cells in diﬀerent organs along
with a marked reduction of cysteine crys-
tals. In the kidneys of Ctns KO mice, trans-
planted cells were located in the interstitial
space, but only a few of the cells were of
lymphoid or macrophage lineage. Moreover,
cells were found in close proximity and in co-
localisation with proximal and distal tubu-
lar cells. Regarding kidney function, treated
mice displayed reduced creatinine and urea
levels in their plasma, while creatinine clear-
ance, serum phosphate and alkaline phos-
phatase did not signiﬁcantly improve. Fur-
thermore, proteinuria and urinary phosphate
remained unchanged [212].
Improvements of chronic kidney injuries
in LSDs upon HSC transplantation have
been shown before [216, 217]. However, this
study is important by the fact that cysti-
nosis is caused by a defect in a membrane-
bound transporter in lysosomes of epithelial
cell. Thus, in contrast to other LSDs where
probably functional enzymes are secreted by
donor-derived cells and then taken up by re-
cipient cells, the mechanism of action in this
case has to be diﬀerent. It is important to
test whether the ﬁndings of Syres et al. can
be expanded to other kidney diseases that
are caused by defects of membrane-bound
transporters.
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1.4 Dent's disease
The renal Fanconi syndrome is character-
ized by the loss of substances that pass
the glomerular ﬁltration barrier, such as low
molecular weight (LMW) proteins, includ-
ing albumin and transferrin, enzymes, hor-
mones, and substances such as glucose and
electrolytes [219, 220]. The massive loss of
substances in the urine is caused by a gen-
eralized dysfunction of renal proximal tubuli
(PT) cells. The reabsorption of ﬁltered sub-
stances requires an extensive endocytic appa-
ratus in PT cells. Many proteins (e.g. albu-
min, hemoglobin, apolipoproteins) are reab-
sorbed by clathrin-mediated endocytosis, a
process that involves binding to the megalin
and cubilin scavenger receptors present at
the apical brush border membrane, followed
by internalization of the receptor/protein
complex and dissociation in acidiﬁed endo-
somes/lysosomes [221]. The scavenger re-
ceptors are recycled back to the membrane,
while the proteins are subjected to lysoso-
mal degradation. Defects in the endosomal
and/or lysosomal pathway prevent this recy-
cling of megalin and cubilin, and thus often
result in the clinical manifestations of Fan-
coni syndrome.
ClC-5 is considered to play a central role
in orchestrating receptor-mediated uptake of
ﬁltered substances in the kidneys. It is
an electrogenic 2Cl-/H+ exchanger that is
mainly localized in intracellular vesicles of
PT epithelial cells [222] and exploits the H+
gradient generated by V-ATPase (a proton
pump) to move Cl- ions into endosomes (Fig-
ure 1.12) [223]. Mice with inactivating mu-
tations of ClC-5 show severe defects in endo-
cytosis due to loss of the multiligand recep-
tors megalin and cubilin at the brush border
membrane, and impaired lysosomal process-
ing of internalized ligands [224]. The exact
mechanism leading to this defective PT en-
docytosis in ClC-5 KOmice is not completely
understood to date [219], but it has been
shown that impaired Cl- ﬂux and a lack of
endosomal acidiﬁcation both cause Fanconi
syndrome [225, 226].
Dent's disease is rare X-linked congenital
disorder, which is caused in approximately
60% of aﬀected males by inactivating mu-
tations in the CLCN5 gene [227]. Patients
show a similar disease phenotype as ClC-5
KO mice, including renal Fanconi syndrome
with loss of LMW proteins, calcium, amino
acids, phosphate, potassium and glucose in
the urine. LMW proteinuria involves the
loss of clara cell protein (CC16), α1 and β2
microglobulins, retinol-binding protein and
vitamin D binding protein, and it is the
most consistent manifestation of Dent's dis-
ease [228]. Secondary to loss of all these sub-
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Figure 1.12: Dent's diseases is caused by defective receptor-mediated endocytosis in PT cells due to
mutations in the ClC-5 exchanger in early endosomes.
Adapted from Devuyst and Pirson [218].
stances, patients may suﬀer from rickets, os-
teomalacia, kidney stones or calciﬁcations, or
vitamin A deﬁciency due to loss of retinol-
binding protein in the urine [228230]. Be-
tween the age of 30 to 50 years, patients may
progress to end-stage renal disease, requir-
ing dialysis or renal transplantation [229].
There is no curative treatment for Dent's dis-
ease, thus care of patients is solely supportive
with focus on the prevention of nephrolithi-
asis [228].
The encouraging results obtained with
BM transplantation in the pre-clinical mouse
model of cystinosis prompted us to question
whether this might also be a treatment op-
tion for Dent's disease.
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Abstract
Memory T cells (Tm) represent a major barrier for immunosuppression and tolerance in-
duction after solid organ transplantation. Taking into consideration the critical role of the
intrinsic apoptosis pathway in the generation and maintenance of Tm, we developed a new
concept to deplete alloreactive Tm by targeting Bcl-2 proteins. The small-molecule Bcl-
2/Bcl-xL inhibitor ABT-737 eﬃciently induced apoptosis in alloreactive Tm in vitro and in
vivo and prolonged skin graft survival in sensitized recipients. A short course of ABT-737
induction therapy prevented Tm-mediated resistance in a donor-speciﬁc transfusion model
and allowed mixed chimerism induction across Tm barriers. Since Bcl-2 inhibitors yielded
encouraging safety results in cancer trials, this novel approach might represent a substantial
advance to prevent allograft rejection and induce tolerance in sensitized recipients.
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Introduction
The translation of experimental therapies
into the clinic inevitably depends on the abil-
ity to understand and overcome biological
diﬀerences between laboratory animals and
humans. The memory T cell (Tm) compart-
ment has been recognized as a major hur-
dle for the translation of immunomodulatory
therapies [231]: the adaptive immune system
of laboratory mice - young animals that have
barely been exposed to pathogens - mostly
consists of naïve lymphocytes, whereas in
large animals and humans, a progressive shift
from naïve to memory lymphocytes occurs
during life, after exposure to pathogens and
as a result of a progressive thymic function
decline [232, 233]. Tm are less dependent
on costimulation [234] and are less eﬃciently
inhibited by regulatory T cells [235]. This
has broad clinical implications for solid or-
gan transplantation, since Tm generated in
response to pathogens can react against allo-
antigens in a process called heterologous im-
munity [150]. Standard immunosuppressive
agents and lymphocyte depleting antibod-
ies have a limited impact on memory cells
[236], and the eﬃcacy and safety of new
strategies to inhibit Tm by targeting adhe-
sion molecules such as CD2 [237] and LFA-1
[238] remain to be proven. Therefore, inno-
vative and eﬀective strategies to inhibit or
deplete Tm are required.
Apoptosis, and particularly the regula-
tion of the intrinsic apoptosis pathway by
pro- and anti-apoptotic factors of the Bcl-
2 family, is critically involved in the phys-
iological T cell contraction at the end of
the immune response, in the selection of T
cell clones for memory generation and in
Tm maintenance. More precisely, the bal-
ance between the pro-apoptotic Bim and
the anti-apoptotic Bcl-2 and Bcl-xL controls
Tm survival [60, 66, 239, 240], and a di-
rect inhibition of Bcl-2 and Bcl-xL reduced
the number of T cells with a memory phe-
notype in mice [241]. Therefore, we hy-
pothesized that a pharmacological modula-
tion of the intrinsic apoptosis pathway us-
ing recently developed pro-apoptotic small
molecule Bcl-2 inhibitors, such as ABT-737
and ABT-263 (navitoclax), might represent
a promising opportunity to control memory
T cell responses [97, 98, 242, 243]. The
application of this approach in transplanta-
tion medicine seems particularly promising,
since Bcl-2 inhibitors suppressed allogeneic
immune responses and promoted the induc-
tion of donor-speciﬁc tolerance in combina-
tion with costimulation blockade [191, 244].
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Materials and Methods
Mice
C57BL/6 (B6, H-2b), CBA (H-2k), BALB/c
(H-2d) and BM3.3 (CBA, H-2k) mice were
housed in speciﬁc pathogen-free conditions
at the University of Zürich. The BM3.3
mouse, which expresses on all CD8 T cells
a transgenic T cell receptor (TCR) selective
for a naturally processed octapeptide bound
to the allogeneic MHC class I molecule H-
2b, was kindly provided by A.-M. Schmitt-
Verhulst [245, 246]. All animal experiments
were performed according to protocols ap-
proved by the legal authority (Veterinary Of-
ﬁce, Canton of Zürich, Switzerland).
Fluorescence activated cell sorting (FACS)
FACS analyses were performed with a BD-
FACSCanto II (Becton Dickinson, Basel,
CH). Anti-mouse CD3-FITC, CD3-PE-Cy7,
CD4-PE, CD4-FITC, CD8-APC, CD8-APC-
Cy7, CD25-FITC, CD25-PE, CD25-APC,
CD44-FITC, CD44-PE-Cy7, CD62L-PE,
CD62L-APC, CD69-FITC, IFN-γ-FITC and
propidium iodide (PI) were purchased from
eBioscience (Frankfurt, Germany). Intra-
cellular IFN-γ staining was performed ac-
cording to manufacturer's instructions (ﬁxa-
tion and permeabilization wash buﬀers from
BioLegend, Lucerne, Switzerland). BM3.3
CD8 T cells were detected using the clono-
typic antibody Ti98, which selectively binds
to the BM3.3 TCR and was kindly provided
by A.-M. Schmitt-Verhulst [247]. A sec-
ondary rat anti-mouse IgG-PE antibody was
purchased from Becton Dickinson (Basel,
Switzerland). Chimerism was analyzed in
white blood cells at diﬀerent time points
after bone marrow transplantation. Back-
ground signal measured in a naïve CBA
mouse was subtracted to determine the %
of donor-derived cells. Donor-derived cells
were identiﬁed by anti-H-2Kb-FITC (Becton
Dickinson, Basel, Switzerland cells.
Mixed lymphocyte reaction (MLR)
MLRs were performed in 96-well plates with
responder splenocytes stimulated by CD3- or
CD8-depleted splenocytes from donor, 3rd
party or syngeneic mice at a ﬁnal concen-
tration of 4 x106 cells/ml in culture medium
containing 10% fetal bovine serum, peni-
cillin 100 U/ml, streptomycin 100 µg/ml,
2-mercaptoethanol 50 µM. For IFN-γ de-
tection, responder cells from memory mice
were stimulated with CD3-depleted spleno-
cytes and 10 ng/ml rIL-2 (RnD systems Inc.,
Minneapolis, USA) for 15h. Brefeldin A
(10 µg/ml) was added to cultures for the
last 3h of stimulation. T cell prolifera-
tion was measured by incorporation of 3H-
thymidine (Perkin Elmer, Waltham, USA)
added to the culture on day 4 after stimula-
tion. All cell separations were performed by
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automatic magnetic cell sorting using an au-
toMACS pro separator according to the pro-
tocols of MiltenyiBiotec (BergischGladbach,
Germany).
Generation of alloreactive memory cells
In vitro, BM3.3 splenocytes were stimulated
with CD8-depleted B6 splenocytes in tissue-
culture ﬂasks with culture medium. Two
days later, CD8 T cells were positively se-
lected by magnetic cell sorting, washed and
cultured in fresh tissue-culture ﬂasks in the
same medium supplemented with 20 ng/ml
rIL-15 or rIL-2 (RnD systems Inc., Min-
neapolis, USA) for additional 5 days [248].
In vivo, Tm were generated either by skin
transplantation or by i.v. injection of 107 al-
logeneic splenocytes as indicated.
ABT-737 sensitivity in vitro
Splenocytes or in vitro generated memory
cells were cultured in 96-wells plates at a ﬁ-
nal concentration of 4 x 106 cells/ml in the
presence of diﬀerent concentrations of ABT-
737 or vehicle. ABT-737 was dissolved in
DMSO at a concentration of 5 mM and then
diluted in culture medium. After 12h incuba-
tion, cell viability was assessed by PI exclu-
sion in FACS, and % of values measured in
corresponding vehicle-exposed cultures was
calculated. ABT-737 was provided by Abb-
vie Bioresearch (Worcester, USA).
Quantitative RT-PCR
Reverse transcription and qPCR were per-
formed as reported earlier [249]. Pre-
developed TaqMan reagents were used for
mouse Bcl-2 (Mm00477631 m1), Bcl-XL
(Mm00437783 m1), Mcl-1 (Mm01257352 g1)
and for the housekeeper gene 18S rRNA (Ap-
plied Biosystems Europe, Rotkreuz, Switzer-
land). For mouse A1, the following oligonu-
cleotide primers and probe were designed
to simultaneously detect Bcl-2A1a, Bcl-2A1b
and Bcl-2A1d: sense primer 5'-ATG GAG
GTT GGG AAG ATG G-3', anti-sense
primer 5'-GAG CCA AGG TTC TCT CTG
GTC-3', ﬂuorescence-labelled probe (FAM)
5'-GGC TGG CTG ACT TTT CTG CAG
ATG A-3'. The expression of candidate
genes in alloantigen-stimulated cells of cul-
ture was normalized by 18S rRNA.
Skin grafting, donor speciﬁc transfusion
(DST), bone marrow transplantation and in
vivo treatment
For skin transplantation, mice were shaved
and anesthetized with ketamine/xylazine.
Full thickness tail skin (about 1 cm2) was
grafted and considered rejected when <10%
of the graft remained viable. DST was per-
formed by i.v. injection of 107 splenocytes.
Bone marrow was transplanted by tail vein
injection of 50 x106 fully MHC-mismatched
B6 bone marrow cells into CBA recipients.
Hamster anti-mouse CD154 (MR1, Bio-X-
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cell, West Lebanon, NH, USA) was admin-
istered i.p. as indicated. For in vivo appli-
cation, ABT-737 was dissolved in polyethy-
lene glycol, Tween 80, dextrose solution and
DMSO and injected i.p. at 50 mg/kg.
Statistics
Student t-test or Mann-Whitney test were
used to compare values between groups. Half
maximal inhibitory concentration (IC50) was
calculated using a log(inhibitor) vs. response
model. Skin graft survival was compared us-
ing log-rank test. P<0.05 was considered sig-
niﬁcant. Graph Pad Prism Software Version
5.0 was used for calculations.
Results
Bcl-2/Bcl-xL inhibition induces apoptosis in
alloreactive memory T cells
To evaluate the sensitivity of alloreactive
Tm to Bcl-2/Bcl-xL inhibition we ﬁrst es-
tablished an in vitro model to generate al-
loreactive CD8 Tm by modifying a previ-
ously reported protocol [248]. BM3.3 CD8
T cells, which express a transgenic TCR spe-
ciﬁc for the MHC class I molecule H-2Kb and
can be detected with the monoclonal anti-
body Ti98 [245, 246] were stimulated with
CD8-depleted B6 splenocytes in a classical
MLR. After 2 days of culture, BM3.3 CD8 T
cells were positively selected by magnetic cell
sorting and further cultured in the presence
of IL-15 to generate central memory T cells
(Tcm) or IL-2 to generate eﬀector memory
T cells (Tem). After 5 days, we obtained
a homogeneous population of CD8+Ti98+
cells with the phenotypic characteristics of
Tcm (CD25-CD69-CD44+CD62L+) or Tem
(CD25+CD69+CD44+) (Figure 2.1 A). We
compared the sensitivity to ABT-737 in Tm
with activated T cells (2 days of MLR
without additional cytokine incubation) and
naïve T cells, by measuring cell viabil-
ity by propidium iodide (PI) exclusion in
FACS after 12h of incubation with diﬀerent
concentrations of ABT-737 (Figure 2.1 B-
C). According to our previous reports [61],
CD8 T cells were resistant to ABT-737 in-
duced apoptosis in the ﬁrst days after al-
logeneic stimulation. This correlated with
the increased expression of Bcl-2A1, an anti-
apoptotic factor not inhibited by ABT-737.
In contrast, in vitro generated central mem-
ory CD8 T cells were as sensitive to ABT-
737 as naïve CD8 T cells, with apoptosis
induction in nanomolar ABT-737 concentra-
tions. Tem were slightly but signiﬁcantly
more resistant to ABT-737 than naïve cells
or Tcm. This correlated with the expression
of anti-apoptotic Bcl-2 factors. In both, Tcm
and Tem, we observed a progressive down-
regulation of the resistance factor Bcl-2A1
as compared to early-activated cells. In con-
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Figure 2.1: In vitro generated alloreactive Tm are sensitive to ABT-737
BM3.3 splenocytes were stimulated with CD8-depleted B6 splenocytes. Two days later, activated CD8 T
cells (activated) were positively selected by MACS and further cultured in the presence of IL-15 to generate
Tcm or IL-2 to generate Tem. (A) Phenotype characterization of naïve T cells, activated T cells, Tem and
Tcm. (B-C) After incubation with diﬀerent concentrations of ABT-737 or vehicle for 12h, cell viability was
assessed by PI exclusion in FACS (duplicates, one representative experiment of two is shown, IC50: half
maximal inhibitory concentration, CI: conﬁdence interval). (D) After 5 days of IL-2 or IL-15 incubation,
cells were lyzed for mRNA isolation. The expression proﬁle of Bcl-2 family genes was assessed by RT-PCR.
Relative gene expression compared to early activated cells is shown (one representative experiment of two
is shown).
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trast, expression of Bcl-2, which is inhib-
ited by ABT-737, was increased after 5 days
of incubation with IL-2. The expression of
the anti-apoptotic factors Bcl-xL and Mcl-
1 and of the pro-apoptotic factor Bim was
similar in early-activated T cells, Tem and
Tcm (Figure 2.1 D). These results were vali-
dated ex vivo. CBA mice were primed with
an injection of B6 splenocytes. Eight weeks
after priming ABT-737 sensitivity in diﬀer-
ent T cell populations was assessed in vitro
by measuring viability in FACS after 12h of
incubation with ABT-737. Naïve (CD44-)
and memory (CD44+) CD4 or CD8 T cells
displayed a similar sensitivity to ABT-737
(suppl. Figure 2.6). Consistently, in primed
mice treated with ABT-737 we observed a
parallel depletion of naïve, Tcm and Tem
with a statistically non-signiﬁcant increase of
Tem in mice exposed to ABT-737 compared
to vehicle (data not shown). Thus, Bcl-2
and Bcl-xL, which are selectively inhibited
by ABT-737, represent a potential molecu-
lar target to deplete Tm. The relevance of
these ﬁndings was further investigated at the
functional level.
Bcl-2/Bcl-xL inhibition suppresses allo-
geneic memory T cell responses
Allogeneic polyclonal memory recall re-
sponses were investigated ex vivo and in
vivo. In a ﬁrst experiment, CBA mice
were primed with B6 skin grafts. Four
months later recipient mice were treated with
ABT-737 or vehicle for 5 days and then
euthanized. Their splenocytes were stim-
ulated in vitro overnight with T cell de-
pleted syngeneic (CBA), donor-derived (B6)
or 3rd party (BALB/c) splenocytes. Donor-
reactive CD8 T cells were detected by intra-
cellular IFN-γ staining in FACS (Figure 2.2
A). For quantitative analysis, the percentage
of CD8+ IFN-γ+ cells among T cells after al-
logeneic stimulation was divided by the value
measured after syngeneic stimulation. Com-
pared to vehicle treated memory mice, the
5-day ABT-737 treatment inhibited donor-
speciﬁc memory recall response, as shown in
a 40% lower ratio of IFN-γ positive cells. In
contrast, ABT-737 treatment did not inﬂu-
ence the response against 3rd party stimu-
lators (Figure 2.2 B). Thus, the depleting
eﬀect of ABT-737 on Tm in vivo was suf-
ﬁcient for a signiﬁcant inhibition of memory
recall responses. This ﬁnding was conﬁrmed
in a skin graft model. B6 mice were primed
with BALB/c skin and 7 weeks later re-
transplanted with BALB/c skin under treat-
ment with ABT-737 or vehicle, starting 5
days before transplantation. According to
our prior observations [61], ABT-737 did not
signiﬁcantly inhibit rejection in naïve recip-
ients in a fully MHC-mismatched combina-
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Figure 2.2: Inhibition of allogeneic memory recall responses by ABT-737
(A) CBA mice were primed with B6 skin. Four months later, splenocytes were stimulated in vitro with T
cell depleted CBA (syn), B6 (donor) or BALB/c (3rd party) cells. FACS plots of 3 representative examples
are shown, indicating the percentages of CD8+ IFN-γ+ cells among T cells after overnight stimulation. (B)
For a quantitative analysis, the % of CD8+ IFN-γ+ cells among T cells after allogeneic stimulation was
divided by the value measured after syngeneic stimulation (allo/syn). Values obtained using cells isolated
from mice treated for 5 days with ABT-737 or vehicle before splenocyte isolation are shown (n=2). (C)
Seven weeks after priming with BALB/c skin grafts, B6 recipients were re-transplanted with BALB/c skin
on the contra-lateral site. ABT-737 or vehicle were administered starting on day 5 before transplantation
with daily i.p. injections. Skin graft survival in primed mice treated with ABT-737 or vehicle was compared
with the results obtained in naïve mice (n=5-9 /group, 2 independent experiments).
tion. However, ABT-737 signiﬁcantly pro-
longed skin graft survival in primed mice,
resulting in a similar skin graft survival in
primed mice treated with ABT-737 and in
naïve mice (Figure 2.2 C).
Since the regulation of the intrinsic apop-
tosis pathway is not only critically involved
in Tm maintenance, but also in Tm genera-
tion during the contraction phase at the end
of the immune response [66, 239], we hy-
pothesized that exposure to ABT-737 dur-
ing priming might inﬂuence later memory re-
call responses in primed recipients. Naïve B6
mice were transplanted with BALB/c skin
grafts and subsequently treated with ABT-
737 or vehicle for 14 days. Four months
later, recipients were euthanized and spleno-
cytes were isolated for further in vitro exper-
iments. Re-stimulation of splenocytes iso-
lated from recipient mice treated with ABT-
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Figure 2.3: ABT-737 during priming inhibits memory recall responses
(A) CBA mice were transplanted with B6 skin grafts and immediately treated with ABT-737 or vehicle for
14 days. Four months after priming, recipients were euthanized and their splenocytes re-stimulated in vitro.
For a quantitative analysis the % of CD8+ IFN-γ+ cells among T cells after allogeneic stimulation was
divided by the value measured after syngeneic stimulation (allo/syn). Values obtained using cells isolated
from mice treated with ABT-737 or vehicle during priming are shown (n=2). (B) Cell proliferation was
assessed by incorporation of 3H-Thymidine in the same experimental setting, but using cells isolated from
B6 mice previously primed with BALB/c skin grafts under the eﬀect of ABT-737 or vehicle. Counts per
minute measured using cells isolated from mice treated with ABT-737 or vehicle during priming are shown
(allo/syn, *p<0.05, n=5). (C) B6 mice were transplanted with BALB/c skin grafts and immediately treated
with ABT-737 or vehicle for 14 days. After more than 6 months, the same recipients were transplanted
with a second BALB/c skin graft without additional treatment. Mean skin graft survival was 6 days in
mice treated with vehicle and 9 days in mice treated with ABT-737 during priming (pooled data from two
independent experiments, n=8-9 /group).
737 during priming, showed a 52% reduc-
tion in the number of IFN-γ positive cells
as compared to vehicle treated mice (Fig-
ure 2.3 A). Similarly, exposure to ABT-737
signiﬁcantly reduced proliferation after re-
stimulation in vitro in the same experimen-
tal setting, but in a diﬀerent mouse strain
combination (Figure 2.3 B, B6 recipients,
BALB/c donors). Moreover, secondary skin
transplantation performed several months af-
ter priming without any additional treat-
ment resulted in a modest but statistically
signiﬁcant prolonged skin graft survival in
mice treated with ABT-737 during priming
(Figure 2.3 C). Thus, ABT-737 treatment
during or late after priming signiﬁcantly in-
hibited allogeneic memory immune responses
in a stringent, fully MHC-mismatched skin
graft model.
Bcl-2/Bcl-xL inhibition restores sensitivity
to costimulation blockade
Tm are notoriously less dependent on costim-
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Figure 2.4: continued on next page
ulation than naïve T cells, and therefore rep-
resent an important barrier for immunomod-
ulatory strategies based on the inhibition
of CD28/CD80/CD86 or CD154/CD40 sig-
nalling [234]. We tested the possibility to
overcome this obstacle by Bcl-2/Bcl-xL in-
hibition in a model including DST, costimu-
lation blockade with anti-CD154 (MR1) and
skin transplantation [132]. To selectively in-
vestigate the eﬀect on Tm while excluding
the eﬀect of pre-existing donor-reactive an-
tibodies, an adoptive transfer approach was
chosen (Figure 2.4 A). In a ﬁrst step, CBA
mice were adoptively transferred with 107
BM3.3 splenocytes and primed with B6 skin
grafts. BM3.3 derived CD8 T cells, which ex-
press a transgenic TCR speciﬁc for the MHC
class I molecule H-2Kb in a CBA background
and can be detected with the monoclonal an-
tibody Ti98, were used to track a deﬁned
population of donor-reactive T cells along
the experiment. Eight weeks after prim-
ing, recipient mice were euthanized and T
cells were isolated by non-touch magnetic cell
sorting and transferred into naïve CBA re-
cipients. A total of 5x 106 cells/mouse were
transferred, including about 800'000 T cells
with a memory phenotype (Figure 2.4 B).
About 2'000 of the adoptively transferred
cells were Ti98+ and >85% of these trans-
genic cells had a memory phenotype (Fig-
ure 2.4 C). After adoptive transfer, recip-
ient mice received a 2-day induction ther-
apy with ABT-737. The following day (day
0), mice were injected with MR1 and donor-
type (B6) splenocytes (DST). MR1 (0.25
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Figure 2.4: ABT-737 restores sensitivity to costimulation blockade after adoptive transfer of
Tm
(A) Experimental setup: naïve CBA mice were transferred with syngeneic BM3.3 splenocytes and primed
with B6 skin grafts. After 14 weeks, the primed mice were euthanized, T cells isolated from the spleen by
non-touch T cell MACS sorting and transferred into naïve CBAmice. Control mice did not receive additional
cells. Induction therapy with ABT-737 (5 injections of 50 mg/kg ABT-737 over 2 days) was started on the
same day. The recipients received DST (107 B6 splenocytes), and 7 days later skin transplantation from
B6 and BALB/c donors was performed. Anti-CD154 (MR1, 0.25 mg/injection, i.p.) was administered at
day 0, 3, 6, 11 and 14 after DST. Quantitative characterization of the transferred lymphocytes is reported
in (B) for polyclonal T cells and in (C) for transgenic Ti98+ cells (one representative experiment of two).
Survival of donor-type (B6, ﬁlled circles) and third party (BALB/c, empty circles) skin graft is shown in
DG (n=7/group): (D) vehicle, DST, MR1, (E) Tm adoptive transfer, vehicle, DST, MR1, (F) ABT-
737, DST, MR1, (F) Tm adoptive transfer, ABT-737, DST, MR1. To monitor the fate of donor-speciﬁc
Tm during the conditioning phase, recipient mice were euthanized on day 0, 3 and 6 after DST and the
splenocytes analyzed by ﬂuorescence activated cell sorting. The percentage of Ti98+ cells among CD8 in
the spleen at diﬀerent time points is reported in (H) (n=3). One representative example is shown in (I).
DST, donor-speciﬁc transfusion; Tm, memory T cells.
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mg) was injected on day 0, 3, 6, 11 and
14 after DST. On day 7 after DST, donor-
(B6) and third party-derived (BALB/c) skin
grafts were transplanted. Naïve mice with-
out T cell transfer rejected both skin grafts
within 20 days (Figure 2.4 D). Tm trans-
fer resulted in an accelerated donor-type
skin graft rejection, indicating that trans-
ferred Tm were functional (Figure 2.4 E).
Mice additionally treated with ABT-737 dis-
played a marked donor-speciﬁc hyporespon-
siveness (Figure 2.4 F). Notably, ABT-737
completely abrogated the deleterious eﬀect
of Tm in this model (Figure 2.4 G).
To follow the fate of adoptively transferred
Ti98+ cells in the same experimental setting,
recipient mice were euthanized at diﬀerent
time points during the conditioning phase for
FACS analysis. After ABT-737 conditioning
and before DST (day 0) we found about 500
CD8+Ti98+ cells/spleen. ABT-737 induced
lymphopenia progressively resolved in the
following days, resulting in an absolute in-
crease in the number of Ti98+ cells, but the
percentage of Ti98+ cells among CD8 cells
did not signiﬁcantly change on day 3 and 6
after DST (Figure 2.4 H-I). Thus, ABT-737
induced a substantial, but incomplete dele-
tion of donor-reactive memory T cells. This
was suﬃcient to overcome Tm-mediated re-
sistance to costimulation blockade in a DST
model. A similar approach was tested in a
mixed chimerism protocol.
Bcl-2/Bcl-XL inhibition allows mixed chi-
merism induction across memory barriers
A combined transplantation of a solid or-
gan and hematopoietic stem cells to induce
mixed chimerism is the only strategy to in-
duce immunological tolerance that has found
a clinical application so far [250, 251]. Cos-
timulation blockade is a promising option
to induce mixed chimerism with a reduced
toxicity [188], but the translation of this
approach to non-human primates and hu-
mans was particularly challenging, at least
in part because of the presence of Tm [231].
We used a similar conditioning protocol to
induce mixed chimerism in mice after Tm
adoptive transfer as described in the previ-
ous section (Figure 2.5 A). First, CBA mice
were adoptively transferred with 107 BM3.3
splenocytes and 2 days later primed with an
i.v. injection of 107 B6 splenocytes. Af-
ter 3 months T cells were isolated and 5x
106 cells were transferred into naïve CBA
mice. After a 2-day ABT-737 or vehicle con-
ditioning, recipient mice were injected with
107 B6 splenocytes (DST) under costimula-
tion blockade. MR1 (0.25mg/injection, i.p.)
was injected on day 0, 3, 6, 11 and 14 after
DST. Seven days after DST, recipients re-
ceived 50x 106 B6 bone marrow cells. Four
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weeks later, skin transplantation from B6
and BALB/c donors was performed. Adop-
tive transfer of Tm impaired the eﬃcacy of
this tolerance induction protocol: the level
of chimerism was very low in most recipients
treated with vehicle, and both donor-type
and third partyderived skin grafts were re-
jected (Figure 2.5 B and C). In contrast, mice
additionally treated with ABT-737 after Tm
transfer displayed a signiﬁcantly higher level
of chimerism in peripheral blood (Figure 2.5
B), and all recipients developed a donor-
speciﬁc tolerance, as shown by the long-term
survival of donor-derived skin grafts (Fig-
ure 2.5 D). The maintenance of a robust, sys-
temic form of tolerance, as typically observed
in mixed chimeras, was conﬁrmed by trans-
plantation of secondary skin grafts: all B6
grafts were accepted long term, whereas the
third party controls were promptly rejected
after re-transplantation (Figure 2.5 E).
Discussion
Sensitization toward HLA molecules repre-
sents an important limitation to the access to
a potential organ. Several options are avail-
able to inhibit antibody-mediated rejection
in sensitized recipients [252], but the thera-
peutic options to control Tm responses are
limited. In this study, we developed a novel
approach to suppress alloreactive Tm.
Fundamental studies about the role of
apoptosis in Tm generation and maintenance
prompted us to target the intrinsic apopto-
sis pathway to achieve a functionally rele-
vant Tm depletion. Bcl-2/Bcl-xL inhibitors
such as ABT-737 represent a new class of
immunomodulatory drugs with a particu-
lar relevance in the ﬁeld of transplantation
[241]. ABT-737 inhibited allogeneic immune
responses in naïve mice [244] and promoted
the induction of mixed chimerism and tol-
erance in combination with costimulation
blockade [191]. The present study demon-
strates that the same approach is eﬀective to
control memory recall responses in virtue of
the pro-apoptotic eﬀect of ABT-737 on Tm.
One of the most important applications
of this approach is related to the possi-
ble combination with costimulation block-
ade. Several studies demonstrated that the
need of costimulation for T cell activation de-
pends on intrinsic characteristics of diﬀerent
cell types (i.e. Tm are less costimulation-
dependent than naïve T cells [234]), but also
on the antigen-speciﬁc precursor frequency
[253]. The marked skin graft survival prolon-
gation observed in mice treated with ABT-
737, MR1 and DST might be related to a re-
duced precursor frequency due to ABT-737-
induced lymphopenia [243] or to the activa-
tion of regulatory mechanisms. Importantly,
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Figure 2.5: Mixed chimerism and tolerance induction after Tm transfer
(A) Experimental setup: naïve CBA mice were transferred with syngeneic BM3.3 splenocytes and primed
with B6 splenocytes (107 cells, i.v. injection). After 812 weeks, these mice were euthanized, T cells isolated
from the spleen by non-touch T cell MACS sorting and transferred into naïve CBA mice. Induction therapy
with vehicle or ABT-737 (4 injections of 50 mg/kg ABT-737 over 2 days) was started at the same day.
Recipients were injected with 107 B6 splenocytes (DST) on day 0 and with MR1 (0.25 mg/injection, i.p.)
on day 0, 3, 6, 11 and 14 after DST. On day 7 after DST, recipients received 50x 106 B6 bone marrow
cells. Four weeks later, skin transplantation from B6 and BALB/c donors was performed. (B) Level of
chimerism in peripheral blood was measured 14 weeks after BMT (n=7/group). Skin graft survival in the
vehicle and in the ABT-737 group is reported in (C) and (D),respectively (n=7/group). (E) Tolerant mice
initially treated with ABT-737 were re-transplanted with BALB/c and B6 skin grafts 141 days after ﬁrst
transplantation. Skin graft survival after re-transplantation is shown in (E) (n=7/group).
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this process was not precluded by adoptive
transfer of Tm. Although the intrinsic prop-
erties of memory cells do not represent a bar-
rier for the pro-apoptotic eﬀect of ABT-737
(Figure 2.1), our data indicate that a short
conditioning therapy with ABT-737 did not
induce a complete Tm depletion (Figure 2.4
H and I). It seems rather that ABT-737 in-
duced a suﬃcient clone size reduction in the
alloreactive Tm pool to restore sensitivity to
costimulation blockade. In a clinical perspec-
tive, this is an important ﬁnding, since it
supports the hypothesis that a potentially
harmful complete Tm depletion is not re-
quired to overcome memory barriers in trans-
plantation.
The mixed chimerism experiment pre-
sented in Figure 2.5 represents another im-
portant potential application of this concept.
Among the diﬀerent experimental strategies
to induce tolerance in mice, only mixed
chimerism was successfully translated into
clinical protocols [250, 251]. However, a
broad clinical application of this approach is
currently hampered by the toxicity of the in-
duction therapy that is required to tolerize
the peripheral T cell compartment and to
achieve engraftment of allogeneic bone mar-
row, which is necessary for the establishment
of central deletional tolerance [254]. The
establishment of a clinical protocol to in-
duce mixed chimerism based on costimula-
tion blockade would represent a major ad-
vance in the ﬁeld, but is currently precluded
at least in part because of the barrier pro-
vided by Tm [231]. A short induction ther-
apy to reduce Tm by using Bcl-2 inhibitors
might therefore represent the optimal solu-
tion to this central problem, particularly be-
cause of the beneﬁcial eﬀect of ABT-737 on
mixed chimerism induction in combination
with cyclosporine A [191, 243].
In consideration of phase I clinical trials
with navitoclax (the orally bioavailable coun-
terpart of ABT-737), it seems that an induc-
tion therapy with Bcl-2 inhibitors should also
have an acceptable toxicity in the context
of a non-malignant condition, and therefore
may ﬁnd an application in other indications
with a critical role of Tm, such as transplan-
tation or autoimmunity. For a clinical appli-
cation our data need to be validated in hu-
man cells, but since the apoptosis pathway is
highly conserved throughout evolution, sim-
ilar results are likely to be obtained in large
animals and humans.
Other immunological barriers typically en-
countered in sensitized recipients cannot be
addressed using this approach: particularly,
donor-speciﬁc antibodies cannot be reduced
by Bcl-2 inhibitors. This aspect does not
seem to play a critical role in skin graft rejec-
50
2.1 Bcl-2 inhibition to overcome memory cell barriers in transplantation
Figure 2.6: (Supplementary) In vivo generated
Tm are sensitive to ABT-737
(A, B) To assess the sensitivity of in vivo gener-
ated Tm to ABT-737, CBA mice were primed with
B6 splenocytes. Eight weeks after priming, sensitivity
to ABT-737 was determined by measuring cell viabil-
ity after 12h incubation with ABT-737. Sensitivity
to ABT-737 induced apoptosis of naïve (CD44-) and
memory (CD44+) CD4 and CD8 T cells is shown.
CI, conﬁdence interval; IC50, half maximal inhibitory
concentration.
tion, but it is generally considered a major
problem for bone marrow transplantation in
mice [255]. For this reason we were not able
to induce mixed chimerim in sensitized re-
cipients with circulating donor-speciﬁc anti-
bodies (not shown). Notably, the same prob-
lem can be controlled more eﬃciently in pa-
tients using peritransplant plasmapheresis or
immunoadsorption and should therefore not
limit the clinical applicability of this strat-
egy. However, studies including memory B
cells are required to further develop this prin-
ciple toward a clinical protocol.
In conclusion, Tm reduction by Bcl-2 inhi-
bition might represent an important advance
in the ﬁeld of transplantation. Potential clin-
ical applications are wide, from the desen-
sitization of HLA-sensitized patients to the
further development of tolerance induction
protocols.
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Abstract
The molecular characterization of functionally diﬀerent lymphocytes is critical for iden-
tifying novel pharmacological targets for immunotherapy. We found diﬀerences in the reg-
ulation of the intrinsic apoptosis pathway among eﬀector and regulatory T cells. Targeted
pharmacological modulation of this pathway with a small molecule Bcl-2/Bcl-xL inhibitor
(ABT-737) allowed selective depletion of eﬀector T cells and consecutive enrichment of
regulatory T cells in vivo. Treatment with ABT-737 resulted in a tolerogenic milieu in pe-
ripheral lymphatic tissues, which was exploited to prevent allograft rejection in a stringent
fully MHC-mismatched skin transplantation model, to induce immunological tolerance in
combination with bone marrow transplantation and to alleviate graft-versus-host disease.
This concept has the potential to ﬁnd various applications for immunotherapy, since it al-
lows pharmacologic exploitation of the immunomodulatory properties of regulatory T cells
without the need for cell manipulation ex vivo.
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Introduction
Maintenance of immunological tolerance re-
quires functional CD4+CD25+FoxP3+ reg-
ulatory T cells (Tregs). Lack of Tregs re-
sults in fatal autoimmune lymphoprolifera-
tive disorder in mice and the IPEX syndrome
in humans [108, 109]. The immunomodula-
tory potency of Tregs attracted great interest
for immunotherapy in autoimmunity, allergy
and transplantation [256]. The promising re-
sults obtained by adoptive transfer of Tregs
in experimental models are currently being
translated into clinical pilot studies of type 1
diabetes, graft-versus-host disease (GVHD)
and solid organ transplantation [257, 258].
However, individualized cell therapy requires
speciﬁc infrastructure for Treg isolation and
expansion, bears high costs and potential
risks regarding stability, homogeneity and
fate of transferred Tregs [259, 260]. A bet-
ter understanding of the physiological mech-
anisms determining Treg development and
survival might lead to alternative strategies
to exploit their immunomodulatory proper-
ties directly in vivo.
Apoptosis is instrumental in shaping the
immune cell repertoire and maintaining im-
mune homeostasis. The intrinsic apoptosis
pathway comprising pro- and anti-apoptotic
Bcl-2 factors is critically involved in control-
ling deletional tolerance in the thymus [54,
261, 262], selection of high aﬃnity clones
[240], contraction of the Teﬀ pool after anti-
genic clearance [66], and maintenance of
long-lived memory T cells [60]. Importantly,
distinct T cell subpopulations express diﬀer-
ent levels of Bcl-2 family proteins. A direct
comparison of the gene expression proﬁle in
Teﬀs and Tregs revealed a slightly higher ex-
pression of all anti-apoptotic factors in naïve
Tregs with the most relevant diﬀerence in
Bcl-xL [71].
IL-2 is pivotal in Treg biology. It promotes
Treg development in the thymus [263], com-
petitive ﬁtness [264], and peripheral home-
ostasis of Treg cell populations [261, 265]
. Defective IL-2 signalling in mice lack-
ing either IL-2 production or components
of the IL-2 receptor (Il-2Rα or Il-2Rβ) suf-
fer from lymphoproliferative syndrome [264].
Furthermore, reduced IL-2 production in in-
ﬂamed islets and the consequential decrease
in Treg/eﬀector T cell (Teﬀ) ratio and Treg
dysfunction results in type 1 diabetes in
NOD mice [266]. Notably, IL-2 signaling
was involved in the maintenance of Treg sur-
vival and homeostatic proliferation through
the regulation of the anti-apoptotic Bcl-2 fac-
tor Mcl-1 [70].
We hypothesized that the diﬀerential ex-
pression of Bcl-2 factors among lympho-
cyte subpopulations with distinct immuno-
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logical functions, might represent a novel tar-
get for immunotherapy. Particularly, small
molecules Bcl-2 inhibitors selectively target-
ing determined Bcl-2 family members might
provide a novel pharmacological tool for im-
munomodulation through a selective deple-
tion of lymphocyte subsets.
Materials and Methods
Mice C57BL/6 (B6, H-2b), CBA (H-
2k), BALB/c (H-2d) B6xCBA F1 (H-2b/k),
B6.Cg-FoxP3tm1Mal/J (FoxP3-GFP, H-2b)
and B6-Tg(FoxP3-DTR/EGFP)23.3Spar (DE-
REG, H-2b) mice were housed under
pathogen-free conditions at the University of
Zürich and used for experiments at age 8
to 16 weeks, always in age and sex matched
groups. FoxP3-GFP mice express an eGFP
under the control of the FoxP3 transcrip-
tion factor [267] and were kindly provided
by Bernard Malissen (Centre d'Immunologie
de Marseille-Luminy, France). With ageing,
these mice seem to express higher percentage
of Tregs. For this reason, FoxP3-GFP mice
were always perfectly age-matched within
one experiment. DEREG mice express a
FoxP3 BAC-driven primate diphtheria toxin
(DT) receptor fused to eGFP, allowing to
speciﬁcally depleting FoxP3+ cells with DT
administration [268]. DEREG mice were
purchased from The Jackson Laboratory and
B6, CBA, BALB/c and B6xCBA F1 mice
were purchased from Harlan Laboratories.
All animal experiments were performed ac-
cording to protocols approved by the local
legal authority (Veterinary oﬃce, Canton of
Zürich, Switzerland).
Fluorescent activated cell sorting (FACS)
FACS analyses were performed with a FACS
Canto II or LSR Fortessa II (Becton Dick-
inson). The following antibodies were used
to stain 1x 106 cells of single cell suspensions
of spleen or peripheral blood: CD4 (GK1.5)
-PE, -APC, -AF700, CD8 (eBioH35.-17.2) -
APC, B220 (RA3-6B2) -PE, CD25 (PC61.5)
-PE/Cy7, -APC, F(ab')2-FITC anti-rabbit
IgG, FoxP3 (FJK-16s) -biotin, streptavidin-
APC (all eBioscience), H-2Kk (AF3-12.1.3)
-FITC, CD8 (53-6.7) -APC/Cy7 (all BioLe-
gend), Bcl-2 (3F11) -FITC (Becton Dickin-
son), Mcl-1 (Y37), Bcl-2A1 (EP517Y) (both
Abcam), Bcl-xL (54H6) -Alexa488, Bim
(polyclonal) (both Cell Signaling Technolo-
gies). For live-dead discrimination PI, 7-
AAD or Zombie Aqua ﬁxable viability kit
(BioLegend) were used. Mice were bled sub-
lingual and chimersim was analyzed in pe-
ripheral leukocytes at diﬀerent time points
after BM transplantation, and donor-derived
cells were identiﬁed by staining of donor H-
2Kk. From the signal measured in a pos-
itive control (CBA) the background signal
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of a negative control (B6) was subtracted
and converted to be 100%. The same for-
mula was then used to calculate the percent-
age of donor-derived cells in mixed chimeras.
For intracellular stainings, a FoxP3 staining
buﬀer set (eBioscience) was used according
to the manufacturer's instructions.
ABT-737 sensitivity in vitro
For in vitro experiments, ABT-737 (Abb-
Vie Bioresearch) and sabutoclax (Bl-97C1,
AdooQ Bioscience) were dissolved in DMSO
at a concentration of 5 mM and then fur-
ther diluted in RPMI medium containing
10% fetal bovine serum, 100 U/ml peni-
cillin, 100 ug/ml streptomycin, 50 µM 2-
mercaptoethanol. Either freshly isolated,
in vitro IL-2 (RnD Systems, PeproTech)
stimulated (3 days with 100 U/ml) or
alloantigen stimulated FoxP3-GFP spleno-
cytes (see below) were plated in 96-well
plates in culture medium at a concentra-
tion of 2.5x 106 cells/ml. Diﬀerent amounts
of ABT-737/sabutoclax or DMSO vehicle
control were added to cells and incubated
for 12 h at 37 degrees and 5% CO2.
Cells were washed 3x, stained, and viability
of CD4+(CD25+)GFP+ and CD4+(CD25-
)GFP- cell populations was assessed by PI
or 7-AAD exclusion. Absolute cell counts
per well were determined by the addition of
absolute counting beads (Invitrogen). Sur-
viving cell numbers of each population were
normalized to the corresponding vehicle con-
dition.
iTreg generation
For iTreg generation, mixed lymphocyte re-
actions were performed in 24-well plates.
CBA splenocytes (stimulators) were depleted
of T cells (CD3 microbeads) and FoxP3-
GFP splenocytes (responders) were depleted
of CD25+ cells by automatic magnetic cell
separation according to manufacturer's in-
structions (Miltenyi Biotec) and then plated
at a 1:1 ratio at a concentration of 4x 106
cells/ml. Anti-CD154 antibody (50 µg/ml,
MR1, Bio-X-cell) was added and cells were
incubated at 37 degrees and 5% CO2 . After
24 h of stimulation, 5 ng/ml TGF-β (RnD
Systems, PeproTech) and 100 U/ml IL-2
were added to the cultures. After another
72 h of stimulation, all cells were pooled and
plated in 96-well plates in order to test ABT-
737 sensitivity (see above).
In vivo antibody and drug treatments
Antibodies against CD154 (MR1), CD25
(PC61.5) (Bio-X-cell) and GITR (DTA-1,
provided by S. Sakaguchi [269]) were diluted
in PBS and injected i.p. as described below.
Diphtheria toxin (DT, 1 µg, Calbiochem) was
administered by i.p. injection on two con-
secutive days [270]. For in vivo application,
ABT-737 was dissolved in polyethylene gly-
56
2.2 Apoptosis modulation to induce immunological tolerance
col, Tween 80, DMSO and dextrose solution
and injected i.p. at 50 mg/kg. CsA (Enzo
Life Sciences) was dissolved in a Cremaphor
EL/ethanol solution, then diluted in HBSS
and injected s.c. at 10 mg/kg. Control mice
were treated with the corresponding vehicles.
Short- and long-term ABT-737 treatment
For short term ABT-737 treatment, mice re-
ceived 5 ABT-737 injections from day -3 to
day -1, before their spleens were harvested
and analysed on day 0. For longterm ABT-
737 treatment, mice received injections for
four weeks every other day and were bled
sublingual on day 0, day 7, day 14, day 21
and day 28.
Skin grafting
In all in vivo skin graft experiments, B6
or DEREG mice were recipients, CBA mice
were donors and BALB/c mice were 3rd
party controls. CBA and BALB/c are
fully MHC-mismatched to B6/ DEREG and
among each other. For skin transplanta-
tions, recipient mice were anesthetized with
ketamine/xylazine, pain treated with carpro-
fen (NSAID) and shaved. Full thickness tail
skin (about 1 cm2) of donors and 3rd party
controls was grafted to the back and consid-
ered rejected, when <10% of the graft re-
mained viable (non-blinded).
Donor-speciﬁc transfusion (DST)
In the DST experiment, recipient mice were
treated with a total of 5 injections of ABT-
737/vehicle on days -3 to -1, and anti-CD154
antibodies on day 0, 6, 11 and 14 (0.25 mg
each). On day 0 recipients received 1x 107
donor splenocytes in Media 199 containing
10 mM HEPES, 10 µg/ml DNAse and 4
µg/ml Gentamycin by tail vein injection. B6
recipients received anti-GITR (4 mg) anti-
bodies on day 6 and DEREG recipients DT
on day 6/ 7 and skin was grafted on day 7.
Bone marrow transplantation (BMT)
The ABT-737 tolerance protocol was de-
scribed in detail previously [191]. The con-
ditioning of mice consisted of ABT-737 and
CsA treatment with a total of 5 injections
on days -3 to -1, and 1 daily injection until
day 11. Anti-CD154 antibodies (2 mg) were
administered once 6 hours before the trans-
plantation of 25x 106 donor BM cells by tail
vein injection on day 0 (in the same medium
as described above for DST). Tregs were de-
pleted with anti-CD25 antibodies (1.25 mg)
or blocked with anti-GITR antibodies (4 mg)
on day -1. Peripheral blood chimerism was
monitored and 8 weeks after BMT all mice
received skin grafts.
Graft-versus-host disease (GVHD)
On day 0 B6xCBA F1 recipient mice were
lethally irradiated (900cGy) with a Cs
source. 6h later, mice were transplanted
with 10 mio DEREG BM cells and 20 mio
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DEREG splenocytes by tail vein injection
(in the same medium as described above for
DST), which corresponded to 5.7 mio T cells
in total. Furthermore, mice received cefa-
zolin (antibiotic, 1 mg) after transplantation
on day 0 and on day 2. ABT-737 and/or CsA
treatment started on day-1 and was contin-
ued until day 10, and following doses were
injected; day -1: 75 mg/kg ABT-737 and
15 mg/kg CsA, day 0: 100 mg/kg ABT-
737 and 15 mg/kg CsA, day 1 to day 3: 50
mg/kg ABT-737 and 10 mg/kg CsA, day 4
to day 10: 25-50 mg/kg ABT-737 (mostly
35 mg/kg) and 10 mg/ml CsA. Thereafter,
mice continued to receive 10 mg/kg CsA un-
til death. In the initial phase after irradia-
tion and T cell transfer, some of the already
weakened animals did not well tolerate ABT-
737 treatment and about 25% of animals died
during the ﬁrst few days after transplanta-
tion. Accordingly, ABT-737 dose was ad-
justed to the condition of individual animals.
Tregs were depleted on day 14/15 by DT ad-
ministration. Mice were monitored daily and
severity of GVHD was assessed non-blinded
by a score consisting of (a) posture/activity,
(b) fur texture, (c) skin integrity, (d) body
weight loss, as previously described in [271].
In vivo MLR
For the in vivo MLR experiment, F1
(B6xCBA) recipient mice received anti-
CD154 antibodies (2 mg) 6 hours before
tail vein injection of 30x 106 B6.FoxP3-
GFP splenocytes (in the medium as de-
scribed above for DST). The following 3
days, mice received 1 daily injection of ABT-
737/vehicle, and CsA. Spleens were har-
vested and analyzed on day 4.
Hemisplenectomy
For hemisplenectomy, mice where anes-
thetized by isoﬂurane inhalation, pain
treated with buprenorphine and treated with
cefazolin (antibiotic). The abdomen was
opened by midline incision, and two liga-
tions were placed around the inferior vascu-
lar pedical and the middle of the spleen, be-
fore half of the spleen was removed inferior
to the intrasplenic ligation. The abdominal
wall was closed with continuous suture.
Statistics
Statistical analysis was performed with
GraphPad Prism software. Unpaired two-
tailed Student's t-test was used to assess
statistical diﬀerences between groups. IC50
values were calculated using a log(inhibitor)
vs. (normalized) response model (variable
slope) for in vitro ABT-737 and sabuto-
clax sensitivity analysis. Survival in Kaplan-
Meier survival curves was compared using
Log-Rank test. In animal experiments, each
data point represents results from one single
mouse, whereas in in vitro experiments, one
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data point represents the mean of technical
replicates (usually triplicates). P<0.05 was
considered signiﬁcant, *P<0.05; **P<0.01;
***P<0.001, n.s., not signiﬁcant.
Results
Distinctive expression of anti-apoptotic Bcl-
2 factors in T cell subtypes
We compared the protein expression pattern
of Bcl-2 factors in naïve Tregs (CD4+CD25+
FoxP3+) vs. Teﬀs (CD4+CD25-FoxP3-) and
upon stimulation with IL-2. Unstimulated
cells displayed similar expression levels of
anti-apoptotic Bcl-2 factors with the excep-
tion of Bcl-xL, of which the previously re-
ported higher gene expression in Tregs [71]
was conﬁrmed on the protein level (Fig-
ure 2.7 A). In contrast, IL-2 stimulation for
three days dramatically changed the expres-
sion of Bcl-2 family proteins. Tregs displayed
higher expression of Bcl-xL and Bcl-2, and
to a smaller extent of Mcl-1 and Bcl-2A1
(A1) (Figure 2.7 B). This distinctive molec-
ular phenotype among Tregs and Teﬀs was
exploited as pharmacological target for Treg
enrichment.
Enrichment of Tregs by Bcl-2/Bcl-xL inhi-
bition in vitro and in vivo
The small molecule ABT-737 binds Bcl-2,
Bcl-xL and Bcl-w proteins with high aﬃn-
ity, and Mcl-1 and A1 with much lower aﬃn-
ity (Figure 2.7 C) [97]. Thus, cell popula-
tions whose survival depends primarily on
anti-apoptotic Mcl-1 and A1 are resistant
to ABT-737-mediated apoptosis [61, 272].
Moreover, although ABT-737 binds Bcl-2
and Bcl-xL with similar aﬃnity, increased
Bcl-xL expression in lymphocytes was shown
to confer resistance to ABT-737-mediated
killing [273]. Based on the higher Bcl-xL
levels in naïve and activated Tregs and the
predominant importance of Mcl-1 in Treg
survival [70, 71], we hypothesized that the
Treg compartment would be protected from
the pro-apoptotic eﬀect of ABT-737. For
quantitative analysis in vitro, we assessed
cell viability after overnight incubation of
freshly isolated splenocytes with ABT-737.
Tregs displayed a consistent survival advan-
tage over Teﬀs as reﬂected in a 13.2x higher
IC50 value (Figure 2.7 D). As a result, ABT-
737 treatment led to a relative enrichment of
Tregs in vitro (from 14.5% to 29.7% Tregs
among CD4+ cells with increasing ABT-737
concentrations, Figure 2.7 D). This eﬀect was
even more pronounced after IL-2 stimulation.
After a three-day IL-2 incubation, Tregs were
extremely resistant to ABT-737 compared
to Teﬀs (approx. 3300x higher IC50 value),
leading to a further Treg enrichment in vitro
(up to 47%, Figure 2.7 F, G). Resistance to
Bcl-2 inhibition in IL-2 stimulated Tregs was
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Figure 2.7: continued on next page
markedly reduced when ABT-737 was re-
placed by the pan-Bcl-2 inhibitor subatoclax,
which binds also Mcl-1 and A1 with high
aﬃnity (Figure 2.7 C, H, I) [96]. This ﬁnd-
ing is well illustrated by comparing IC50 val-
ues of Tregs and Teﬀs under these diﬀerent
conditions: Resistance of Tregs in compar-
ison to Teﬀs under ABT-737 treatment in-
creased several magnitudes upon IL-2 stimu-
lation, while sabutoclax resistance increased
only slightly (Figure 2.7 J). This indicates
that the diﬀerential expression of Bcl-2 fam-
ily proteins among Tregs and Teﬀs, and par-
ticularly the up-regulation of Mcl-1 and A1
upon IL-2 stimulation, was responsible for
resistance to ABT-737-mediated killing.
This intrinsic property of Tregs was con-
ﬁrmed in vivo. Naïve mice were treated
for three days with a total of ﬁve injec-
tions of ABT-737. This resulted in mod-
erate lymphopenia and in a reduced num-
ber of CD4+ cells in the spleen (Figure 2.8
A) [241, 243]. However, mice treated with
ABT-737 had a signiﬁcantly higher percent-
age of Tregs among CD4+ cells in compar-
ison to vehicle controls (Figure 2.8 B, C).
Hemisplenectomy allowed analyzing spleno-
cytes at two diﬀerent time points in the
same mouse, and it showed that this ef-
fect was temporary; ten days after stopping
ABT-737 treatment, the Treg/Teﬀ balance
was re-established to a similar level as in
vehicle-treated animals (Figure 2.8 D). Fur-
thermore, prolonged treatment with ABT-
737 resulted in a transient Treg enrichment
with a peak after two weeks (Figure 2.8 E).
Thus, Bcl-2/Bcl-xL inhibition resulted in a
relative temporary enrichment of Tregs in
vitro and in vivo.
Antigen-stimulated Tregs are resistant to
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Figure 2.7: Diﬀerential expression of Bcl-2 factors among Tregs and Teﬀs mediates resistance
of Tregs to ABT-737 in vitro.
(A, D, E, H) FoxP3-GFP splenocytes without stimulation or (B, F, G, I) upon 3 days IL-2 stimulation
were used for in vitro experiments. (A, B) Representative FACS plots showing CD25 and FoxP3 expres-
sion in viable CD4+ cells. Quantiﬁcation of median expression of Bcl-xL, Bcl-2, Mcl-1, A1 and Bim in
CD4+CD25+FoxP3+ cells (black) and CD4+CD25-FoxP3- cells (white). The stainings were performed in
triplicates and repeated three times, one representative experiment is shown. FACS plots showing Mcl-1 and
A1 expression in Tregs (grey) and Teﬀs (white) upon IL-2 stimulation. (C) Binding proﬁles of ABT-737
and sabutoclax. (D, F, H, I) Cells were incubated for 12h with the indicated concentrations of ABT-
737 or sabutoclax, respectively. The number of viable CD4+FoxP3+ (black) and CD4+FoxP3- (white)
cells per well was assessed by FACS and normalized to corresponding vehicle controls. Curve represents a
log(inhibitor) vs. normalized response curve. (E, G) The percentage of FoxP3+ cells among CD4+ cells
was assessed after 12h ABT-737/vehicle incubation. In vitro titration experiments were performed 2 to 4
times, representative experiments are shown. (J) Illustration of the ratio of IC50 of Tregs over IC50 of
Teﬀs in naïve cells (white) and after IL-2 stimulation (black). All data represent mean +/- s.e.m., *P<0.05,
**P<0.01, t-test was used to assess diﬀerences between cell populations (A, B) and treatment groups at
certain concentrations (E, G)
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Figure 2.8: ABT-737 resistance of Tregs in vivo.
(A-D) FoxP3-GFP mice were treated with vehicle or ABT-737 i.p. for 3 days prior to harvesting. (A)
Total counts of CD4+ cells per spleen and (B) the percentage of FoxP3+ cells among CD4+ cells. Pooled
data of two out of four independent experiments, n = 8/group. (C) Representative FACS plots of viable
CD4+ splenocytes in vehicle and ABT-737 treated animals. (D) Percentage of FoxP3+ cells among CD4+
cells in half spleen, n = 3/group. (E) Percentage of FoxP3+ cells among peripheral blood CD4+ cells
during four-week ABT-737 treatment, n = 4. All data represent mean +/- s.e.m., *P<0.05, **P<0.01,
***P<0.001. Diﬀerences between treatment groups were assessed with t-test.
ABT-737-mediated apoptosis
In contrast to naturally occurring thymus-
derived Tregs (nTregs), peripherally-derived
Tregs (pTregs) convert in peripheral lym-
phoid tissues from naïve CD4+FoxP3-CD25-
T cells. Minimal requirements for pTreg
generation are antigenic stimulation, TGF-
β and IL-2 [274276]. Inhibition of the
CD40-CD154 costimulatory pathway further
favours the induction of Tregs [277, 278].
Similar stimuli allow the generation of in
vitro-induced Tregs (iTregs). To investi-
gate the impact of selective Bcl-2/Bcl-xL in-
hibition on survival of iTregs, we induced
Tregs from CD25-depleted naïve spleno-
cytes by allogeneic stimulation under cos-
timulation blockade (anti-CD154, MR1) and
TGF-β/IL-2 cytokines. ABT-737 incuba-
tion revealed high resistance of alloantigen-
activated iTregs, similar to the previously ob-
served resistance of activated CD25+ Teﬀs
(IC50 value 36'000x higher than in CD25-
Teﬀs, Figure 2.9 A) [61]. To investigate the
properties of pTregs, we took advantage of an
in vivo mixed-lymphocyte reaction model.
B6.FoxP3-GFP splenocytes were transferred
into F1 (B6xCBA) recipients under costim-
ulation blockade with anti-CD154 antibod-
ies, followed by ABT-737 or vehicle treat-
ment for three days. Low-dose cyclosporine
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A (CsA) was combined with ABT-737 to
prevent T cell receptor-calcineurin-NFAT1-
dependent upregulation of A1 in Teﬀs, and
thus preventing resistance of Teﬀs upon
antigenic stimulation [61]. ABT-737 treat-
ment resulted in moderate lymphopenia and
in a marked enrichment of donor-derived
Tregs among transferred cells (Figure 2.9 B).
Taken together, antigen-stimulated iTregs
and pTregs were resistant to Bcl-2/Bcl-xL in-
hibition, and exposure to ABT-737 resulted
in a shift of the balance between Tregs and
Teﬀs in favour of the Treg compartment.
Treg enrichment by ABT-737 inhibits
GVHD
Tregs are recognized for alleviating the
course of GVHD, and Treg therapy has been
successfully tested in this condition [258].
Therefore, as ﬁrst functional application of
our concept, we aimed to investigate whether
ABT-737 mediated Treg enrichment has a
favourable impact on GVHD in a classical
model. Recipient F1 (B6xCBA) mice were
lethally irradiated and reconstituted with al-
logenic B6.DEREG bone marrow and T cells.
DEREG mice express a FoxP3-driven pri-
mate diphtheria toxin (DT) receptor, which
allows selective Treg depletion by DT admin-
istration [268]. Body weight and a GVHD
score consisting of activity/posture, fur tex-
ture, skin integrity and weight loss was as-
sessed daily. Mice were either treated with
combined ABT-737 and low-dose CsA or
CsA alone, starting one day before cell trans-
fer and continued for ten days (Figure 2.9 C).
GVHD onset was about ten days after trans-
plantation in control mice treated only with
CsA, and the disease progressed to lethality
within three weeks (Figure 2.9 D-F). ABT-
737 and CsA treated animals presented a
markedly attenuated course of GVHD. Im-
portantly, Tregs were integral in mediating
this positive eﬀect of treatment, as Treg de-
pletion at day 14 after transplantation in-
duced a rapid onset of GVHD (median sur-
vival time (MST) in ABT-737 + CsA treated
group 49.5 days vs. 25.5 days in Treg de-
pleted group, p = 0.0006). None of the ABT-
737 treated animals developed skin lesions,
and thus they did not reach the maximal
GVHD score. In conclusion, Tregs enrich-
ment in vivo resulted in an important atten-
uation of GVHD across full MHC barriers.
Treg enrichment by ABT-737 induces
donor-speciﬁc hyporesponsiveness
To investigate whether this immunomodu-
latory eﬀect was antigen-speciﬁc, we took
advantage of an established model of full
MHC-mismatched skin transplantation after
donor-speciﬁc transfusion (DST) under cos-
timulation blockade [132]. B6 or B6.DEREG
recipient mice received donor-type spleno-
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Figure 2.9: Alloantigen-activated Tregs are resistant to ABT-737-mediated apoptosis and
alleviate GVHD.
(A) iTregs were generated in an mixed-lymphocyte reaction with CD25-depleted B6.FoxP3-GFP responders,
CD3-depleted CBA stimulators and anti-CD154 antibodies for 24h, and additional IL-2/TGF-β for 3 days.
After 12h incubation with ABT-737 or vehicle, viable cell counts were assessed by FACS and normalized
to corresponding vehicle controls. Curve represents a log(inhibitor) vs. response curve. Representative
FACS plot of iTregs. One of two independent experiments is shown (B) B6.FoxP3-GFP splenocytes were
transferred to F1 (B6xCBA) recipients under anti-CD154 costimulation blockade and treated with ABT-737
or vehicle, and CsA for 3 days. Spleens were analyzed on day 4 by FACS. The ratio between the absolute
number of FoxP3+ and FoxP3- cells per spleen among transferred cells (H-2Kk-) is shown. Pooled data of
two independent experiments, n = 6/group. (C) Experimental setup for GVHD experiment: F1 (B6xCBA)
mice received DEREG bone marrow cells and T cells after lethal irradiation on day 0 and treatment from
day -1 until day 10 with ABT-737, and/or CsA until death. Tregs were depleted by DT administration on
day 14/15. (D) GVHD score, (E) body weight loss and (F) survival, n = 6-8/group. All data represent
mean +/- s.e.m., **P<0.01. Diﬀerences between treatment groups was assessed with t-test (B) and log-rank
test (F).
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cytes (CBA) under the eﬀect of anti-CD154
antibody (Figure 2.10 A). This induction
therapy leads to deletion/anergy of donor-
speciﬁc Teﬀs, favours the generation of Tregs
and results in transient donor-speciﬁc hy-
poresponsiveness [279]. We combined this
protocol with a three-day ABT-737 treat-
ment prior to i.v. splenocyte injection.
Seven days after DST, recipient mice re-
ceived donor-type (CBA) and 3rd party con-
trol (BALB/c) skin grafts. In this stringent
strain combination, the original DST proto-
col (vehicle group) did not signiﬁcantly pro-
long skin graft survival (Fig. 4B). However,
the short additional treatment with ABT-
737 was suﬃcient to markedly prolong donor-
type skin graft survival up to more than 100
days in some recipients (MST 39/87 days for
ABT-737 and 12 days for vehicle, Figure 2.10
B, D). Notably, this eﬀect was donor-speciﬁc
and not due to generalized immunosuppres-
sion, as demonstrated by the only slightly
delayed rejection of 3rd party grafts. To
assess the importance of Tregs in ABT-
737-induced donor-speciﬁc hyporesponsive-
ness in this model, we depleted Tregs by
DT injection in DEREG recipients or inhib-
ited their function by GITR (glucocorticoid-
induced TNFR family related gene) liga-
tion the day prior to skin transplantation
[280]. In absence of a functional Treg com-
partment, all skin grafts were rapidly re-
jected, and no diﬀerence between donor-
type and 3rd party grafts was observed (Fig-
ure 2.10 C, E). Thus, although ABT-737
might have additional Treg-independent ef-
fects inﬂuencing graft survival, we show here
that the ABT-737-induced hyporesponsive-
ness was critically dependent on Tregs, and
the transient alteration of the Treg/Teﬀ bal-
ance after ABT-737 treatment was suﬃcient
to create a strong tolerogenic milieu.
ABT-737-mediated Treg enrichment al-
lows induction of transplantation tolerance
A transient state of Treg-mediated donor-
speciﬁc hyporesponsiveness might represent
an ideal environment to promote engraft-
ment of allogeneic bone marrow cells. We
previously showed that a two-week condi-
tioning treatment with ABT-737, low-dose
CsA, costimulation blockade (anti-CD154)
and transplantation of 25x 106 bone mar-
row cells resulted in stable mixed lympho-
hematopoietic chimerism and complete dele-
tion of donor-reactive CD8+ cells in a fully
MHC-mismatched strain combination (Fig-
ure 2.11 A) [191]. Grafting of donor-type
(CBA) and 3rd party control (BALB/c) skin
grafts to B6 recipients eight weeks later con-
ﬁrmed stable donor-speciﬁc immunological
tolerance in most animals (Figure 2.11 B).
We hypothesized that ABT-737 mediated
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Figure 2.10: ABT-737 induces Treg-mediated donor-speciﬁc hyporesponsiveness.
(A) Experimental setup for DST experiment: B6 or DEREG mice were treated with ABT-737 or vehicle for
3 days prior transfer of CBA splenocytes on day 0 and anti-CD154 treatment. On day 7, mice received CBA
(donor-type) and BALB/c (3rd party) skin grafts, and graft survival was monitored until rejection. (B, D)
Survival of CBA and BALB/c grafts after ABT-737 and vehicle treatment (B) or ABT-737 treatment (D).
(C) Tregs were blocked with anti-GITR antibodies (day -1, B6 recipients) or (E) by DT injection (day -1
and 0, DEREG recipients). n = 7/group, diﬀerences between treatment groups were assessed with log-rank
test (B, D).
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Treg enrichment is a critical factor for toler-
ance induction in this myelosuppression-free
protocol. To test this hypothesis, Tregs were
either depleted with anti-CD25 antibody or
functionally inhibited by GITR ligation the
day prior to bone marrow transplantation.
This antibody treatment indeed precluded
the establishment of tolerance to skin grafts
in all animals, because mixed chimerism in-
duction was hampered in the absence of a
functional Treg compartment (Figure 2.11
C, D). Thus, the transient tolerogenic mi-
lieu caused by Treg enrichment through Bcl-
2/Bcl-xL inhibition was required to induce
mixed chimerism without myelosuppressive
conditioning.
Discussion
A dysregulated balance between regulatory
and eﬀector cell populations is often involved
in overshooting immune activation, such as
in transplant rejection, autoimmunity or al-
lergies. Thus, the achievement of functional
dominance of Tregs over Teﬀs is a major aim
in a wide range of clinical conditions. Treg
therapy has proven successful in various ex-
perimental models and in human pilot stud-
ies [257260]. Large scale ex vivo genera-
tion or expansion of Tregs is feasible, but re-
lated to logistical and ﬁnancial hurdles that
may preclude wide-spread clinical applica-
tion. An alternative strategy to manipulate
the Treg/Teﬀ balance and to achieve Treg-
mediated tolerance, is the selective reduc-
tion or functional inhibition of Teﬀs in vivo
while preserving the Treg population. To
achieve this goal, pathways that are diﬀer-
entially regulated among these two cell pop-
ulations need to be identiﬁed and pharmaco-
logically manipulated. For example, cellular
metabolism reﬂected in diﬀerential mTOR
activity has been proposed to be such a path-
way [281], and low-dose IL-2 administration
selectively favoured expansion of Tregs [282].
In the present study, we identiﬁed the in-
trinsic apoptosis pathway as promising novel
target to exploit the immunomodulatory po-
tency of Tregs. Although there are no single
anti-apoptotic factors with a non-redundant
function in deﬁned lymphocyte populations,
it is generally presumed that the relative
importance of apoptotic factors varies dur-
ing T cell development and among diﬀerent
subpopulations [24]. According to previous
studies, Tregs have a diﬀerential gene expres-
sion pattern of apoptotic factors compared to
their eﬀector counterparts with the biggest
diﬀerence in Bcl-xL expression, which might
account for diﬀerences in sensitivity to cyto-
toxic stress [71]. Importantly on a functional
level, anti-apoptotic Mcl-1 was the predom-
inant survival factor in Tregs, and loss of
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Figure 2.11: ABT-737 mediated Treg enrichment allows tolerance induction.
(A) Experimental setup of mixed chimerism tolerance protocol: B6 recipients were treated with ﬁve in-
jections of ABT-737 and CsA during the 3 days prior transplantation of CBA bone marrow cells on day
0. Anti-CD154 antibodies were administered 6h before bone marrow transplantation, and ABT-737/CsA
treatment was continued until day 11 after transplantation. Tregs were blocked by anti-GITR antibodies
or depleted by anti-CD25 antibody administration at day -1. Eight weeks after transplantation, mice re-
ceived CBA (donor-type) and BALB/c (3rd party) skin grafts and survival of grafts was monitored until
rejection. (B) Graft survival of control group and (C) of Treg blocked/depleted groups, n = 7/group. (D)
Representative FACS plots of peripheral CD4+ cell chimerism in control mouse and Treg depleted mouse
two months after bone marrow transplantation.
Mcl-1 resulted in drastic reduction of Treg
numbers. In contrast, loss of Bcl-2 did not
result in a relative reduction of Tregs [70].
Thus, the relative importance of Mcl-1 and
Bcl-2 varies among Tregs and Teﬀs. In this
study, we exploited these ﬁndings to estab-
lish a novel pharmacological target for im-
munomodulation. Combined inhibition of
the anti-apoptotic Bcl-2 and Bcl-xL induced
a functionally important Treg enrichment in
vivo. This concept was tested in very strin-
gent immunological models: short-term Bcl-
2/Bcl-xL inhibition was suﬃcient to inhibit
GVHD, to inhibit allogeneic immune re-
sponses against fully MHC-mismatched skin
grafts and to allow bone marrow engraft-
ment without myelosuppression in a mixed
chimersm model across full MHC barriers.
Importantly, iTregs were even more resis-
tant to ABT-737 than nTregs, and these
iTregs are presumably responsible for the
donor-speciﬁcity observed in skin graft ex-
periments. This fact oﬀers the opportunity
to generate an antigen-speciﬁc tolerogenic
environment with broad clinical implication
for immunomodulatory therapies. In trans-
plantation medicine, donor-speciﬁc immuno-
suppression represents an important step to-
wards the prevention of rejection without the
risks for infections and cancers related to
non-selective immunosuppression. Evasion
of apoptosis is one of the hallmarks of cancer,
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as Bcl-2 factors are often overexpressed in
malignant cells. Thus, large eﬀorts are taken
for developing highly selective Bcl-2 family
inhibitors. To date, little is known about
apoptosis regulation in human T cell sub-
sets. For clinical translation of the proposed
immunomodulatory concept, closer research
on human cells will be needed, but tailored
Bcl-2 inhibition is likely to translate into
clinical therapies. Several Bcl-2 inhibitors
have already entered clinical trials for various
cancers and recently, a phase I study with
ABT-199 in systemic lupus erythematosus
patients has been completed [98, 283]. Bcl-2
inhibitors showed a very favourable toxicity
proﬁle so far. The present study might stim-
ulate further research on the eﬀect of these
inhibitors on T cells subsets directly in pa-
tients and importantly, it might draw atten-
tion to the tumor immunology point-of-view
when using these compounds in cancer ther-
apy.
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Abstract
Induction therapy with a Bcl-2/Bcl-xL blocking small-molecule drug in combination
with low-dose cyclosporine A and one injection of costimulation-blocking antibodies al-
lowed the establishment of mixed chimerism in mice. The ﬁnding that such a minimal
myelosuppression-free recipient conditioning was suﬃcient to prevent rejection of trans-
planted allogeneic stem cells, while promoting the engraftment of these cells in the host's
bone marrow, is intriguing. In the present study, we are investigating the eﬀects of both,
Bcl-2/Bcl-xL and calcineurin inhibition, in syngeneic bone marrow transplantation. We are
studying the direct eﬀect of drug treatment on hematopoietic stem cells and the progeni-
tor compartment, and we are testing diﬀerent hypotheses that might explain the eﬃcient
engraftment of transplanted stem cells. Better understanding of the mechanisms that pro-
mote stem cell engraftment may be important for the development of novel low-toxicity
conditioning protocols for bone marrow recipients.
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Introduction
The transplantation of bone marrow (BM)
stem cells ﬁnds application in numerous, po-
tentially life-threatening conditions. Myelo-
toxic doses of irradiation and chemother-
apy are needed for the eradication of hema-
tological malignancies, and the ablated
hematopoietic system needs to be reconsti-
tuted with transplanted hematopoietic stem
cells (HSCs), but also inborn defects in
blood cells can be corrected by BM trans-
plantation. With the advent of reduced-
intensity preparatory regimen of BM recip-
ients, novel indications for BM transplan-
tation could be envisaged, such as the in-
duction of transplantation tolerance that
has been successfully introduced in clini-
cal pilot studies [194]. As hematopoietic
lineage-derived cells are also involved in tis-
sue homeostasis, for example in the kidneys,
the potential of BM transplantation for im-
provement of non-hematologic inborn dis-
eases may be even bigger [284, 285]. How-
ever, the risks associated with BM transplan-
tation currently circumvent clinical transla-
tion of such experimental approaches.
HSCs stand at the apex of hematopoiesis
and replenish immune cells, erythrocytes
and platelets that are lost due to constant
turnover. In order to fulﬁl their task, HSCs
undergo asymmetric cell division. They self-
renew to sustain the stem cell pool, and
give rise to lineage-restricted, quickly cycling
progenitors that terminally diﬀerentiate into
the various hematopoietic lineages. As such,
HSCs are integral for the maintenance of
homeostasis in steady state and in response
to situations that demand increased blood
cell production [286]. Diﬀerent stem cell
populations can be discriminated based on
their proliferative behaviour and self-renewal
potential. Long-term HSCs (LT-HSCs) are
mostly quiescent, while short-term HSCs
(ST-HSCs) proliferate much more. LT-HSCs
that additionally express CD150 (SLAM)
have been suggested to sit at the uppermost
part of the stem cell hierarchy, possessing the
greatest self-renewal potential [287].
HSCs reside in a highly specialized mi-
croenvironment called the stem cell niche,
which consists of cellular and molecular com-
ponents that regulate stem cell function by
complex interactions. Both, the cells of the
niche and the HSCs are well-equipped to in-
tegrate signals from the periphery, and stem
cell behaviour is adopted accordingly. The
thrombopoietin (TPO) feedback-loop exem-
pliﬁes this concept. TPO is constitutively
expressed in the liver, and it is cleared from
the peripheral circulation by platelets that
express the TPO receptor c-mpl [288, 289].
If the platelet mass decreases, for example
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due to bleeding, the TPO level rises. As
HSCs, early progenitors of all lineages and
megakaryocytes also express c-mpl, the ris-
ing TPO levels stimulate megakaryopoiesis
and platelet production directly in the BM
compartment. Further, TPO is needed for
the maintenance of HSCs in steady state, as
TPO KO and c-mpl KO mice both display
largely reduced HSC numbers [290]. Inter-
estingly, LT-HSCs have been shown to ex-
press higher levels of c-mpl than ST-HSCs
and multipotent progenitors (MPPs) [291].
The general perception is that stem cell
niches need to be opened at least partially
prior transplantation, in order to create
space for the transplanted stem cells. This
is often achieved by irradiation of the recip-
ient. It has been shown that approximately
1-5% of HSCs leave their niche each day to
enter peripheral circulation [292]. Thus, a
small number of niches is constantly unoc-
cupied, which potentially can absorb trans-
planted syngeneic HSCs present in the cir-
culation in unconditioned hosts. This ex-
plains why repeated infusion of BM cells re-
sulted in higher chimerism than one single
bolus of a higher cell dose [292, 293]. How-
ever, a mega dose of 200 mio allogenic BM
cells under costimulation blockade equally al-
lowed to achieve chimerism [188]. The mech-
anisms of how such a mega dose can result
in a high engraftment level is not understood
yet. Maybe the vast number of transplanted
HSCs displaced endogenous HSCs from their
niche, or the HSCs persisted for some time
in the blood and continuously ﬁlled freshly
opened niches.
In a recently published article, we pro-
posed a conditioning regimen consisting
of the combined treatment of the small-
molecule Bcl-2/Bcl-xL inhibitor ABT-737
with low-dose cyclosporine a (CsA) and
one injection of a CD154-blocking antibody.
This treatment was suﬃcient to allow en-
graftment of allogenic HSCs upon transplan-
tation of a reasonable number of BM cells
(20-25 mio cells), leading to low-level periph-
eral chimerism [191]. However, the under-
lying mechanisms that allowed this mixed
chimerism induction remain elusive. Lym-
phopenia as a result of Bcl-2/Bcl-xL inhi-
bition, and immunosuppression by low-dose
CsA might have prevented rejection of al-
logenic cells and the development of Graft-
versus-Host Disease (GVHD). Survival of
HSCs has been shown to critically depend
on Mcl-1, and this anti-apoptotic factor is
not inhibited by ABT-737 [37, 97]. In con-
trast, loss-of-function studies suggest that
Bcl-2 is not required for HSC maintenance
[294]. Thus, Bcl-2/Bcl-xL blockade should
not result in loss of HSCs. Indeed, clinical
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trials have not reported myelotoxicity of nav-
itoclax, the orally bioavailable analogue of
ABT-737. Thus, we assume that this con-
ditioning protocol based on ABT-737 and
CsA treatment, does not involve elimination
of endogenous HSCs, which is remarkable.
Understanding the mechanisms that are in-
volved in the engraftment process of trans-
planted HSCs without creating space in the
BM environment might help to further de-
velop low-toxicity conditioning protocols. In
the present study, we embarked on studying
the eﬀects of ABT-737 (with or without CsA)
on the early hematopoietic compartment in
the BM. The project is still ongoing, thus I
will present the diﬀerent approaches we took
so far, trying to understand the phenomenon,
comment on yet open questions, limitations
and planned experiments.
Materials and Methods
Mice
C57BL/6 (B6, Ly5.2), B6.Cg-FoxP3tm1Mal
(FoxP3-GFP), B6-Tg(UBC-GFP)30Scha
(GFP), C57BL/6-Ly5.1 (Ly5.1) and
Ly5.1xLy5.2 F1 mice were housed under
pathogen-free conditions at the University
of Zürich and used for experiments at age 8
to 16 weeks, always in age and sex matched
groups. FoxP3-GFP mice express eGFP
under the control of the FoxP3 transcription
factor [267] and were kindly provided by
Bernard Malissen (Centre d'Immunologie
de Marseille-Luminy, France). With ageing,
these mice seem to express higher percent-
age of Tregs. For this reason, FoxP3-GFP
mice were always perfectly age-matched
within one experiment. All animal ex-
periments were performed according to
protocols approved by the local legal au-
thority (Veterinary oﬃce, Canton of Zürich,
Switzerland).
Fluorescent activated cell sorting (FACS)
FACS analyses were performed on a LSR
II Fortessa (Becton Dickinson). The fol-
lowing antibodies were used to stain 1x 106
cells of thymus or peripheral blood: CD4
(GK1.5) -PE, -AF700, B220 (RA3-6B2) -
PerCP-eFluor710, CD11b (RA3-6B2) -PE-
Cy7, FoxP3 (FJK-16s) -biotin, streptavidin-
APC (all from eBioscience), and CD8
(53-6.7) -APC-Cy7, CD45.1 (A20) -APC,
CD45.2 (104) -FITC (all from BioLegend).
For BM stainings, the following antibod-
ies were used: Ly6A/E (sca-1, D7) -
BV421, CD16/32 (93) -APC, CD127 (IL-
7Rα, A7R34) -BV605, CD135 (A2F10) -
PE, CD150 (SLAM, TC15-12F12.2) -BV650
and lineage cocktail in AlexaFluor700 (all
from BioLegend), and CD117 (c-kit, 2B8)
-PerCP-eFluor710, CD34 (RAM34) -biotin,
-eFluor450, streptavidin-PE-Cy7 (all from
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eBioscience). For live-dead discrimination
PI, 7-AAD or Zombie Aqua ﬁxable viability
kit (BioLegend) were used. Mice were bled
sublingual and chimersim was analyzed in
peripheral leukocytes at diﬀerent time points
after BM transplantation, and donor-derived
cells were identiﬁed by endogenous expres-
sion of GFP or by staining of congenic mark-
ers. For intracellular stainings, a FoxP3
staining buﬀer set (eBioscience) was used ac-
cording to the manufacturer's instructions.
In vivo drug treatment and BM transplan-
tation
For in vivo application, ABT-737 was dis-
solved in polyethylene glycol, Tween 80,
DMSO and dextrose solution and injected
i.p. at 50 mg/kg. CsA (Enzo Life Sciences)
was dissolved in a Cremaphor EL/ethanol
solution, then diluted in HBSS and injected
s.c. at 10 mg/kg. Control mice were treated
with the corresponding vehicles. For short
term ABT-737 treatment, mice received 5
ABT-737 injections from day -3 to day -1,
before their BM was harvested and analysed
on day 0. The ABT-737 mixed chimerism
protocol was described in detail previously
[191]. The conditioning of mice consisted of
ABT-737 and CsA treatment with a total of
5 injections on days -3 to -1, and 1 daily in-
jection until day 11, or ABT-737/CsA alone
plus vehicle of the second drug, or vehicle
only. On day 0, 20x 106 donor BM cells
suspended in Media 199 containing 10 mM
HEPES, 10 µg/ml DNAse and 4 µg/ml Gen-
tamycin (called BM medium), were trans-
planted by tail vein injection and peripheral
blood chimerism was followed over time.
Blood transplantation
To investigate whether ABT-737 and CsA
treatment results in HSC mobilisation, a
modiﬁed approach described in [292] was
used. Donor mice (Ly5.1) received short
time ABT-737 + CsA, or vehicle treatment
(see above). The next day, mice were ter-
minally bled by heart puncture, and blood
of mice from the same treatment group was
pooled in EDTA-coated tubes (the same vol-
ume of blood for the two treatment groups
was collected). The blood was washed twice
in BM medium (see above), resuspended in
medium, and a low amount of EDTA was
added in order to prevent clotting. Ly5.2 BM
cells were added to cell suspension (in a con-
centration that resulted in 0.2 mio cells per
recipient) and 500 µl of BM cell/blood mix-
ture was injected i.v. into lethally irradiated
recipients (900 cGy, Ly5.1xLy5.2). Based on
the initial volume of blood, each recipient re-
ceived 250 µl Ly5.1 blood.
Thrombopoietin measurement
Mice received short time ABT-737 +/- CsA,
or vehicle treatment, and were bled 16h af-
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ter the last injection. Serum thrombopoi-
etin was measured with a Quantikine ELISA
kit according to manufacturer instructions
(RnD Systems).
Statistics
Diﬀerences between treatment groups were
assessed by one-way Anova followed by
Turkey test for multiple comparison. In ani-
mal experiments, each data point represents
results from one single mouse. P<0.05 was
considered signiﬁcant, *P<0.05; **P<0.01;
***P<0.001, n.s., not signiﬁcant. Graph Pad
Prism Software Version 5.0 was used for cal-
culations.
Results
Synergism of combined ABT-737 and CsA
treatment in syngeneic BM transplantation
To solely focus on the eﬀects of ABT-737 and
CsA on HSC engraftment, while excluding
any immunological processes such as rejec-
tion of transplanted cells, we chose to per-
form BM transplantation in syngeneic strain
combinations.
A ﬁrst syngeneic BM transplantation ex-
periment aimed at assessing the importance
of the individual components of the ABT-
737 tolerance protocol [191]. We treated
recipient animals for two weeks with ABT-
737 and CsA, ABT-737 alone or CsA alone
or only with vehicle, and 20 mio BM cells
were injected on the fourth day after starting
the treatment. A two-week treatment with
vehicle did not result in syngeneic mixed
chimerism (Figure 2.12). Presumably, 20
mio cells of whole BM suspension were not
suﬃcient to eﬃciently compete for niches in
unmanipulated hosts. Similarly, low-dose
CsA alone did not lead to engraftment of
transplanted BM cells. In contrast, ABT-737
treatment resulted in much higher chimerism
levels ranging between 3-4% in T cells and
approximately 10% in B cells and mono-
cytes. Surprisingly, combination of the two
drugs led to an even further increase of
chimerism (Figure 2.12). Synergism between
ABT-737 and CsA has been shown previ-
ously [243]. CsA reduced the half-maximal
inhibitory concentration of ABT-737 in vitro
in a concentration dependent manner and
strongly reduced Bcl-2 expression in lym-
phocytes. This resulted in signiﬁcantly de-
creased lymphocyte numbers in vivo when
the two drugs were combined, as compared
to the monotherapies [243]. Interestingly,
we observed a loss of myeloid chimerism
in ABT-737 treated animals at more than
one year after transplantation (the same was
observed in a repetition experiment, Fig-
ure 2.12 D). We plan to keep these mixed
chimeras for further long-term analysis. If
in ABT-737 treated animals chimerism is
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Figure 2.12: ABT-737 treatment promotes syngeneic chimerism
(A-D) Mice were treated for 2 weeks with either ABT-737 and CsA (white circle), ABT-737 alone (black
circle), CsA alone (white square) or vehicle (black square) and transplanted with syngeneic BM. Peripheral
blood chimerism for (A) CD4, (B) CD8, (C) B220 and (D) CD11b was measured at indicated time points,
n = 7 mice/group and data represent mean +/- s.e.m.
also lost in other lineages, this might indi-
cate that true HSCs failed to engraft upon
transplantation under ABT-737 monother-
apy, and that rather very early progenitors
sustained chimerism until their self-renewal
potential was exhausted. Analysis of the thy-
muses of such long-term chimeras more than
one year after transplantation indeed pointed
towards loss of T cell chimerism in ABT-737-
only treated animals, however DN thymo-
cytes of ABT-737 and CsA treated animals
have also lost chimerism (Figure 2.13).
To closer address the question whether
we have engraftment of true HSCs, we per-
formed a serial transplantation experiment.
Mice were transplanted with syngeneic BM
under treatment with either ABT-737 plus
CsA, ABT-737 alone, CsA alone or vehicle,
and chimerism was followed over 19 weeks
(Figure 2.13 F-I; bars show chimerism level
76
2.3 Mechanisms of irradiation-free engraftment
Figure 2.13: Assessment of long-term repopulation potential of transplanted cells
(A-I) Mice were treated for 2 weeks with either ABT-737 and CsA, ABT-737 alone, CsA alone or vehicle,
and transplanted with syngeneic BM. More than one year after transplantation, thymuses where harvested.
(A) Representative FACS plot showing gating for thymocyte populations and chimerism based on GFP
expression. Dot plots showing chimerism levels of (B) DN, (C) DP, (D) CD4 SP and (E) CD8 SP cell
populations, n = 3-4 mice/group. (F-I) In a similar experiment, 19 weeks after transplantation, BM was
harvested and transplanted into lethally irradiated recipients. (F) CD4, (G) CD8, (H) B220 and (I)
CD11b chimerism; bars show chimerism of donor mice at time of harvest and curves show chimerism after
transplantation into secondary recipients. ABT-737 and CsA treated animals (black bars/circles) and ABT-
737 only treated animals (white bars/circles), n = 3 mice/group for initial treatment and n = 6 mice/group
secondary transplantation and n = 2 mice/group for recipients of BM from CsA and vehicle treated animals
without chimerism. Data show mean +/- s.e.m. and diﬀerences were assessed with one-way Anova followed
by Turkey test.
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at harvest). BM of these mixed chimeras was
mixed and transplanted into lethally irradi-
ated recipients, and chimerism was followed
again over time. Vehicle and CsA groups
did not have any chimerism at time of trans-
plantation, but their BM was transplanted
as negative control (Figure 2.13 F-I; black
squares). Interestingly, CD11b chimerism
was in both chimeric groups lower than ex-
pected, while T cell chimerism was slightly
higher. These mixed chimeras are still avail-
able and upon measurement of long-term
chimerism, another round of transplantation
into irradiated recipients will be performed.
Hopefully, this will clarify the question of
whether the transplanted cells possess long-
term repopulation potential and thus can be
considered as true HSCs.
One point is worth noting when looking
at the above described syngeneic transplan-
tation experiments: as donor strain we have
always used B6.UBC-GFPmice that the con-
tain freely ﬂoating GFP in the cytosol of all
their cells. Theoretically, there might be low-
grade rejection of these transplanted cells,
and the positive eﬀects of ABT-737 and CsA
might be attributed to their immunosuppres-
sive action. However, other experiments that
we further performed, suggest synergistic ef-
fects of ABT-737 and CsA beyond their im-
munosuppressive eﬀects.
ABT-737 and CsA treatment does not re-
cruit HSCs into peripheral circulation
Based on the observation that Bcl-2/Bcl-
xL inhibition promotes engraftment of trans-
planted HSCs, we reasoned that such treat-
ment might disrupt the HSC niche and pro-
mote mobilisation of endogenous HSCs into
peripheral blood. Transplanted and en-
dogenous HSCs could then compete simul-
taneously for the increased number of open
niches, resulting in higher chimerism com-
pared to situations where no mobilization
takes place. To test this hypothesis, we de-
signed an experiment where Ly5.1 mice were
treated with either ABT-737 and CsA or ve-
hicle for three days. Their blood was isolated
and transplanted along with a low number
of competitor BM cells (Ly5.2) into lethally
irradiated F1 (Ly5.1xLy5.2) recipients (Fig-
ure 2.14 A). A similar approach was used
previously to prove that few HSCs can be
found in the periphery [292]. If treatment
indeed would result in HSC mobilization, in-
creased chimerism levels could be expected
upon transplantation of the blood. Ana-
lysis of peripheral blood of recipients how-
ever disproved this hypothesis, as chimerism
was lower in treated animals (Figure 2.14 B-
E). For lymphocytes, at least the initially
lower levels of chimerism are not surprising,
as many peripheral lymphocytes are present
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Figure 2.14: ABT-737 and CsA treatment does not mobilize HSCs into peripheral circulation
(A) Experimental setup: Ly5.1 donors were treated for three days with either ABT-737 + CsA or vehicle
(total 5 injections), the next day their blood was isolated, lysed, washed and transplanted along with 0.2 mio
Ly5.1 competitor BM into lethally irradiated F1 (Ly5.1xLy5.2) recipients. FACS plot shows gating strategy
for chimerism detection (gated on CD4+ cells), double positive cells are irradiation-resistant recipient-
derived T cells. (B) CD4, (C) CD8, (D) B220 and (E) CD11b chimerism. Horizontal dashed line represents
detection limit and lines represent individual mice (n = 5-6/group).
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in the transplanted blood, and ABT-737 +
CsA greatly depletes these cells. Again,
these mice are still available and a long-
term chimerism measurement will be per-
formed to deﬁnitely conﬁrm lower chimerism
in mice receiving blood from ABT-737 +
CsA treated animals. In contrast to the
syngeneic transplantation experiments where
GFP-expressing donor cells were used, in
this experimental setting rejection of trans-
planted cells can be excluded.
Bcl-2/Bcl-xL inhibition in combination
with CsA increases HSCs by absolute and rel-
ative means
The above negative ﬁndings prompted us to
directly look at the BM, in order to detect
eﬀects of the treatment in the stem cell and
progenitor compartment. Again, mice were
subjected to the four diﬀerent treatment reg-
imen for three days before their BM was ana-
lyzed by FACS the following day. Figure 2.15
shows the gating strategy used for the detec-
tion of progenitor populations and HSCs.
After gating for singlets and viable cells,
all lineage positive cells (T and B lympho-
cytes, NK cells, monocytes/macrophages,
granulocytes and erythrocytes) were ex-
cluded and only lineage negative/low cells
were used for further analysis. Among
the c-kit+ sca-1- population, diﬀerent pro-
genitors can be identiﬁed based on their
CD16/32 and CD34 expression (CMP com-
mon myeloid progenitors, giving rise to
GMP granulocyte-macrophage progenitors
and MEP myeloid-erythroid progenitors).
Unfortunately, the staining for common lym-
phoid progenitors (CLPs) repetitively failed.
Among the c-kit+sca-1+ population (called
LSKs), fractions enriched for LT-HSCs and
ST-HSCs/MPPs, respectively, can be dis-
criminated based on their Flt-3 expression
[295]. Furthermore, SLAM-HSCs are a sub-
group of LT-HSCs that additionally express
CD150 and are considered to display an even
higher self-renewal potential than LT-HSCs
[287].
The combined treatment of ABT-737 and
CsA resulted in a slightly reduced total cell
count per tibia, as mature lymphocytes were
probably killed in the BM, similarly to the
periphery (Figure 2.16 A). This reduction in
lineage positive cells was suﬃcient to result
in a signiﬁcant relative enrichment of lineage
negative cells in the BM (Figure 2.16 B).
Among these lineage negative cells, a fur-
ther enrichment of LSKs was observed (Fig-
ure 2.16 C). Taken together, ABT-737 plus
CsA treatment resulted in a slight shift of
BM cells towards less diﬀerentiated popula-
tions.
Intriguingly, SLAM-HSCs highly signiﬁ-
cantly increased by absolute and relative
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Figure 2.15: Gating strategy for HSCs and progenitor populations
After gating on singlets, viable cells are selected. A cocktail consisting of anti-CD3, -Gr-1, -CD11b, -B220
and -Ter-199 antibodies allows to gate on lineage negative/low cells within the BM. Myeloid progenitor
populations can be discriminated based on their CD16/32 (IgG Fcγ receptor II/III) and CD34 expression.
c-kit+ sca-1+ LSKs can be divided into LT- and ST-HSCs/MPPs based on their CD135 (Flt-3) expression.
SLAM-HSCs are even higher in the hematopoiesis hierarchy and are discriminated from LT-HSCs by their
additional CD150 (SLAM) expression. Gating according to [295].
means upon a three-day combined drug
treatment (Figure 2.17 A, B). This indicates
that HSCs with a high self-renewal potential
not only were resistant towards Bcl-2/Bcl-xL
inhibition, as suggested based on the liter-
ature, but that they expanded upon treat-
ment. The same eﬀect could be seen in
LT-HSCs, but less pronounced, while ST-
HSCs/MPPs changed neither by absolute
nor relative means (Figure 2.17 C, D).
Finally, we compared diﬀerences of pro-
genitor populations upon drug treatment.
While CMPs were not aﬀected by ABT-737
and/or CsA treatment, a signiﬁcant shift
from MEPs towards GMPs was observed
(Figure 2.18). Loss of MEPs was not unex-
pected, as megakaryocytes are known to de-
pend on Bcl-xL for their survival [296, 297].
The shift towards the granulocyte/monocyte
lineage might provide an explanation for
the high CD11b chimerism observed in
both, syngeneic and allogeneic transplanta-
tion upon ABT-737 treatment [191]. Fig-
ure 2.18 D provides an overview on how
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Figure 2.16: Enrich-
ment of LSKs upon
ABT-737 and CsA
treatment
(A-C) Mice were
treated for three days
with either ABT-737
and CsA, ABT-737
alone, CsA alone or ve-
hicle (total 5 injections)
and BM was analyzed
by FACS the next day.
Dot plots show the (A)
total cells per tibia, the
absolute and relative
count of (B) lineage
negative population
and (C) the LSK
population. Pooled
data of two indepen-
dent experiments,
n = 9 mice/group.
Diﬀerences between
treatment groups were
assessed with one-way
Anova followed by
Turkey test.
HSCs and progenitors are aﬀected by ABT-
737 + CsA treatment. To further investigate
the eﬀect of ABT-737 on progenitor popu-
lations, we plan to perform in vitro colony
forming assays, which will allow us to test
directly resistance of GMPs to Bcl-2/Bcl-
xL inhibition. Furthermore, colony form-
ing assays with BM cells from transplanted
mice will allow us to compare the abundance
of donor-derived progenitors in the BM by
monitoring GFP+ colonies.
Does treatment indirectly aﬀect HSC ex-
pansion?
As explained in the introduction, TPO is a
cytokine/hormone that is important for HSC
homeostasis and maintenance by directly in-
teracting with its receptor c-mpl expressed
on HSCs. Bcl-xL inhibition results in throm-
bocytopenia, thus ABT-737 treatment is ex-
pected to result in increased TPO levels, that
in turn might promote the observed HSC ex-
pansion [43]. To test this hypothesis, we
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Figure 2.17: Relative and absolute enrichment of HSCs upon Bcl-2/Bcl-xL inhibition
(A-D)Mice were treated for three days with either ABT-737 and CsA, ABT-737 alone, CsA alone or vehicle
(total 5 injections) and BM was analyzed by FACS the next day. Dot plots show the absolute and relative
cell counts of (A) SLAM-HSCs (C) LT-HSCs and (D) ST-HSCs. (B) shows representative FACS plots
illustrating the enrichment of SLAM-HSCs among LSKs in the diﬀerent treatment groups. Pooled data of
two independent experiments, n = 9 mice/group. Diﬀerences between treatment groups were assessed with
one-way Anova followed by Turkey test.
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Figure 2.18: MEP are sensitive towards Bcl-2/Bcl-xL inhibition
(A-C)Mice were treated for three days with either ABT-737 and CsA, ABT-737 alone, CsA alone or vehicle
(total 5 injections) and BM was analyzed by FACS the next day. Dot plots show the absolute and relative
cell counts of (A) CMP, (B) MEP and (C) GMP. (D) schematic summary of the ﬁndings regarding the
various stem cell and progenitor populations. CMP common myeloid progenitor, MEP myeloid-erythroid
progenitor, GMP granulocyte-monocyte progenitor. Pooled data of two independent experiments, n = 9
mice/group. Diﬀerences between treatment groups were assessed with one-way Anova followed by Turkey
test.
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treated mice for three days with ABT-737
+/- CsA, and compared the TPO concen-
tration in the sera of these mice with vehi-
cle treated animals. To our surprise, TPO
was signiﬁcantly reduced upon combination
treatment (Figure 2.19 A). This ﬁnding will
certainly require further investigation.
Our previous observation, that Tregs in-
crease by relative means upon treatment,
was conﬁrmed in the BM (Figure 2.19 B,C).
In fact, it is known that the percentage of
Tregs among CD4 cells is much higher in the
BM than in the periphery, and it has been
suggested that the BM is a reservoir for Tregs
[298, 299]. However, not much is known
about the function of these Tregs in the BM.
It will be interesting to assess, whether these
Tregs are involved in the engraftment process
of transplanted HSCs.
Discussion
The present study is based around the
ﬁnding that short-time treatment with a
pro-apoptotic drug in combination with
an immunosuppressant allows the induction
of mixed hematopoietic chimerism without
myelosuppression in both, the allogeneic and
syngeneic setting [191]. Understanding the
mechanisms that allow engraftment of trans-
planted HSCs into such minimally condi-
tioned hosts is important, especially also as
the concept of apoptosis modulation in this
context is innovative and completely unex-
plored to date. ABT-737 reduces precursor
frequency of allo-reactive naïve and mem-
ory T cells, restores sensitivity to costimu-
lation blockade in tolerance induction proto-
cols [300] and at the same time spares Tregs,
thereby shifting the balance between eﬀector
T cells and Tregs towards tolerance (Section
2.2). All these positive eﬀects may suggest
ABT-737 (or its orally available analogue
navitoclax) to be a valuable novel drug in the
transplantation setting. Assuming a condi-
tioning regimen of transplant reci-pients that
undergo combined BM and kidney transplan-
tation; navitoclax may be useful as short-
time treatment for preparing the immune
system for the transplantation, e.g. replac-
ing ATG, and at the same time it may render
the body (or the BM microenvironment) in a
status that favours the engraftment of trans-
planted cells. Navitoclax has indeed been
tested in phase I and II clinical cancer trials
as single drug and in combination therapies,
and the drug has generally been well toler-
ated by patients, with the only side eﬀect of
thrombocytopenia [283].
This project is still ongoing and various
hypotheses, that may explain the positive
eﬀects of ABT-737 and CsA treatment for
HSC engraftment, have been established and
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Figure 2.19: Assess-
ment of TPO in
serum and Tregs in
BM
After three days of
drug treatment, serum
and BM were ana-
lysed. (A) serum
TPO concentration 16h
after the last injection,
(B) relative and (C)
absolute Treg counts
in the BM. n = 4-5
mice/group for TPO
measurement and n =
8 mice/group for Treg
measurement, pooled
data of two indepen-
dent experiments.
Diﬀerences between
treatment groups were
assessed with one-way
Anova followed by
Turkey test.
tested. Thereby, we came across some fasci-
nating and unexpected ﬁndings, for example
the expansion of SLAM-HSCs or the signif-
icant decrease of TPO upon treatment. It
is diﬃcult to draw a well-deﬁned red line
along the results at this stage of the project,
thus the manuscript rather gives an overview
about all the approaches undertaken so far,
including the ones that failed or are puzzling.
Various experiments are planned and/or in
preparation to closer investigate certain ﬁnd-
ings. Very important will be to test whether
treatment results in proliferation of HSCs,
since this would be expected for populations
that increase in absolute numbers. If these
cells proliferate indeed, what drives them to
do so? I am convinced that blockade of anti-
apoptotic factors does not directly inﬂuence
the behaviour of HSCs, but that rather in-
direct mechanisms come into play. In fact, I
was absolutely convinced that the profound
thrombocytopenia induced by the combina-
tion treatment would result in high TPO lev-
els, which then in turn would act on HSCs
[243]. It was assumed that TPO promotes
quiescence of HSCs rather than proliferation
[301, 302]. However, recent research ques-
tions this dogma. I recently learned about
data presented at the Zürich Immunology
Meeting, that TPO mimetics recruit quies-
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cent HSCs into proliferation (unpublished).
During steady state, basal TPO signalling
probably promotes quiescence, while it ex-
pands HSCs under stress conditions [303].
The signiﬁcant decrease of TPO upon ABT-
737 and CsA treatment was unexpected and
for this reason, TPO levels in the serum
need to be followed at regular intervals, as
there might be an oscillation of TPO lev-
els. To closer evaluate the potential role of
TPO in promoting HSC engraftment, trans-
plantation experiments under TPO mimetic
treatment might be performed. It has been
shown that post-transplantation HSC expan-
sion highly depends on TPO [301, 304].
Another aspect that we would like to ad-
dress is the involvement of Tregs in the en-
graftment process. In the allogeneic setting,
it has been shown in several studies that
co-infusion of Tregs together with BM cells
promoted chimerism induction under low-
toxicity conditions [190, 305]. In these stud-
ies however, focus was given rather at toler-
ance mechanisms once chimerism was estab-
lished, than at the engraftment process per
se. An important study published in Science
has provided evidence that Tregs closely as-
sociate with stem cells in the BM, providing
an immune-privileged site for transplanted
allo-HSCs in unconditioned hosts [306]. Fur-
thermore, a recent study has shown that re-
cipient Tregs are required for long-term HSC
engraftment, and that they promoted prolif-
eration of HSCs in a reduced-toxicity proto-
col [307]. As we previously found that Tregs
are needed for successful transplantation of
allo-HSCs in the ABT-737 tolerance proto-
col (Section 2.2), it would be very interesting
to test whether the strong relative increase of
Tregs in the BM upon ABT-737 treatment is
functionally relevant also in syngeneic trans-
plantation. Thus, we would like to test
whether Tregs are needed beyond their im-
munosuppressive action, and whether they
are involved in HSC expansion upon treat-
ment. For such experiments, we can take
advantage of the DEREG mice that we are
breeding and that allow speciﬁc depletion of
Tregs.
Contribution of S.S.G. to the
manuscript
Designed and performed all experiments in-
dependently, prepared ﬁgures and wrote the
manuscript.
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Abstract
Dent's disease is caused by a genetic defect in a chloride-proton exchanger located in early
endosomes of proximal tubular cells of the kidneys. This defect results in dysfunctional
receptor-mediated endocytosis, and as a consequence in severe manifestations of Fanconi
syndrome. In the present study, we evaluated the potential of hematopoietic stem cell
transplantation in this disease. Clcn5 KO mice, the homologue animal model for Dent's
disease, were transplanted with healthy bone marrow cells. This treatment resulted in signif-
icant improvement of renal Fanconi syndrome four months after transplantation. Engrafted
hematopoietic lineage-derived cells closely associated with proximal tubuli and importantly,
megalin scavenger receptors were re-expressed at the apical brush border membrane of prox-
imal tubular cells. Furthermore, Clcn5 gene expression in transplanted kidneys signiﬁcantly
correlated with improvement of Fanconi syndrome. Our study thus provides evidence that
bone marrow transplantation may partially rescue the endocytic dysfunction caused by
genetic defects of a membrane bound transporter.
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Introduction
Stem cell therapy has great therapeutic po-
tential in the regenerative and therapeu-
tic setting and is attracting much atten-
tion for a wide range of conditions. Bone
marrow (BM) derived stem cells compris-
ing both, hematopoietic stem cells (HSCs)
and mesenchymal stromal cells (MSC), dis-
played reparative and angiogenic properties
in experimental models of acute kidney in-
jury, such as ischemia/reperfusion injury,
cisplatin-induced acute kidney injury or anti-
Thy1.1 glomerulonephritis [173, 206208]. In
such models, the local or systemic infusion
of MSCs exerted protective eﬀects by ei-
ther paracrine or endocrine mechanisms [206,
207]. However from a clinical perspective,
the treatment of progressive chronic kid-
ney diseases might be of greater importance
than improvements in these somewhat ar-
tiﬁcial injury models. Interesting in that
regard, BM transplantation has been shown
to be successful in reducing disease burden
in a pre-clinical model of cystinosis [212,
308]. This disease is caused by defects of
the CTNS gene that encodes a membrane
bound transporter, resulting in multi-organ
dysfunction due to accumulation of cysteine
crystals. Kidneys are severely involved in
this disease, and patients develop progres-
sive kidney failure already in childhood [309].
The transplantation of healthy BM cells im-
proved several serum and urinary parameters
in diseased mice, and although the mecha-
nism of how healthy cells derived from the
hematopoietic lineage can improve such a
disease remains somewhat obscure, the ﬁnd-
ings of these cystinosis studies may pave the
path to treatment of many other diseases un-
derlying defective membrane-bound enzymes
or transporters.
Dent's disease is a hereditary kidney dis-
ease caused by inactivating mutations of the
ClC-5 2Cl-/H+ exchanger. The disease is
X-linked and progresses to end-stage renal
disease in a majority of aﬀected males [229].
ClC-5 is highly expressed at the membrane
of early endosomes in proximal tubule (PT)
cells, the thick ascending limb and in α-
intercalated cells of the collecting duct [222].
Mouse models with Clcn5 knockout genes re-
capitulate well the human disease phenotype
and allowed detailed studies of the pathome-
chanism in Dent's disease [226, 310]. ClC-
5 has been shown to be necessary for aci-
diﬁcation of early endosomes and Cl- con-
ductance, and lack of either results in low-
molecular weight (LMW) proteinuria, glyco-
suria and hypercalciuria [225, 226, 310, 311].
These manifestations of Fanconi syndrome
are caused by loss of megalin and cubilin at
the apical membrane of PT cells [224].
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Based on the encouraging results of BM
transplantation in cystinosis, we aimed at
providing a proof-of-concept that this treat-
ment is eﬀective also in another inherited
nephropathy with a diﬀerent pathogenesis,
such as Dent's disease.
Materials and Methods
Mice
ClC-5 KO males (Clcn5-/Y) and WT litter-
mate controls (Clcn5+/Y) were used for ex-
periments. These mice were generated by
deletion of exon VI and kindly provided W.
Guggino (John Hopkins) [226]. BM donors
expressed enhanced GFP under the direction
of the human ubiquitin C promotor (UBC-
GFP), leading to ubiquitous GFP expres-
sion in all cells (The Jackson Laboratory).
All mice were on C57BL/6 background and
only males were used. Mice were bred and
housed under speciﬁc pathogen-free condi-
tions at University of Zurich and all ani-
mal experiments were performed according
to protocols approved by the local legal au-
thority (Veterinary oﬃce, Canton of Zürich,
Switzerland).
Bone marrow transplantation
ClC-5 KO and WT littermate controls were
lethally irradiated (900 cGy) with a Cs
source and reconstituted approx. 6 hours
later by tail vein injection of 10x 106 unfrac-
tionated BM cells suspended in Media 199
containing 10 mM HEPES, 10 µg/ml DNAse
and 4 µg/ml Gentamycin. BM cells were ei-
ther isolated from UBC-GFP or ClC-5 KO
donors aged 8-14 weeks. Recipients were ran-
domly distributed among treatment groups
and transplanted at the age of 10 weeks.
Peripheral blood chimerism was measured
at time of harvest. Cells were stained for
CD4, CD8, CD11b and B220 and acquired
at FACS Canto II or LSR II Fortessa.
Urinary parameters
Urine samples were collected overnight (12h)
in metabolic cages with ad libitum access to
food and drinking water one week prior BM
transplantation and 16 weeks after trans-
plantation. Urinary calcium, glucose, and
creatinine were measured with a Synchron
CX3 Delta System (Beckman Coulter) and
urinary CC16 was measured by latex im-
munoassay [312].
Collection of kidneys
Mice were anesthetized using an isoﬂurane
vaporizer and perfused through the right
ventricle with a 0.9% NaCl solution contain-
ing heparin (5000 U/ml), 1% Procain-HCL
(Lidocain) and 16% CaCl2. Then, the left
kidney was clamped and the tissue ﬁxed by
infusion of 3% PFA dissolved in 0.1M Na-
cacodylate. One half of the unﬁxed kidney
was used for protein isolation and the other
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half for RT-qPCR analysis. The ﬁxed kid-
ney was kept for 1h in 3% PFA on ice, then
in 1% PFA overnight. After washing in PBS
and soaking in 30% sucrose, the kidneys were
embedded in OCT medium.
Quantitative real-time PCR
Total RNA was extracted from half kidney
using the Aurum Total RNA Fatty and Fi-
brous Tissue Kit (Bio Rad) according to
manufacturer's protocol. DNAse I treatment
was performed to eliminate genomic DNA
contamination. 1 µg RNA was used to per-
form the reverse transcriptase reaction with
iScript cDNA Synthesis Kit (Bio Rad).
Changes in target gene mRNA levels were
determined by relative RT-qPCR with a
CFX96 Real-Time PCR Detection System
(Bio-Rad), using iQ SYBR Green Super-
mix (Bio-Rad) for detection of single PCR
product accumulation. RT-qPCR analyses
were performed in duplicate with 100 nM
of sense and anti-sense primers in a ﬁnal
volume of 20 µl. Speciﬁc primers were de-
signed using Primer3 [313]. Primers were
as followed: ClC-5 sense primer 5'-TGG
AGG AGC CAA TCC CTG GTG T-3'
and ClC-5 anti-sense primer 5'-AGA AAG
CAT CGC TCA CAC TG-3', GFP sense
primer 5'-CCA CAT GAA GCA GCA GGA
CTT-3' and GFP anti-sense primer 5'-GGT
GCG CTC CTG GAG GTA-3', and refer-
ence gene Gapdh sense primer 5'-TGC ACC
ACC AAC TGC TTA GC-3' and Gapdh
anti-sense primer 5'-GGA TGC AGG GAT
GGG GGA GA-3'. PCR conditions were
95°C for 3 min followed by 40 cycles of 15 sec
at 95°C, 30 sec at 60°C.The PCR products
were sequenced with the BigDye terminator
kit (Perkin Elmer Applied Biosystems). The
multiScreen SEQ384 Filter Plate (Millipore)
and Sephadex G-50 DNA Grade Fine (Amer-
sham Biosciences) dye terminator removal
were used to purify sequences reactions be-
fore analysis on an ABI3100 capillary se-
quencer (Perkin Elmer Applied Biosystems).
The eﬃciency of each set of primers was de-
termined by dilution curves.
Antibodies
The following antibodies were used for
immunoﬂuorescence stainings and/or im-
munoblotting: rabbit anti-GFP (Life Tech-
nologies), rabbit anti-AQP1 (Millipore),
sheep anti-megalin (a gift from Dr. P.
Verroust and Dr. R. Kozyraki, Paris),
rat anti-F4/80 (Life Technologies), ham-
ster anti-CD11c (Bio-Rad), rat anti-α-SMA
(Bio-Rad), mouse anti-β-actin (Sigma), rab-
bit anti-rab5 (Cell Signaling Technology).
Secondary antibodies were labelled with
Alexa488, Alexa633 or Dylight649.
Immunoﬂuorescence microscopy
6 µm sections were blocked for 30 min with
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3% BSA in PBS at room temperature, be-
fore slides were incubated with primary anti-
bodies (1:200) overnight at 4°C. After wash-
ing, slides were incubated with secondary an-
tibodies for 1 h at room temperature and
counterstained with Dapi before mounting
with ProLong Gold antifade reagent (Life
Technologies). Slides were visualized with a
CLSM SP8 upright Leica confocal laser scan-
ning microscope.
Immunoblotting
Proteins were extracted from kidney that
were snap-frozen and stored at -80°C after
harvest. Kidneys were lysed in RIPA buﬀer
(Life Technologies) containing protease in-
hibitors (Roche), followed by a brief soni-
cation and centrifugation at 16'000xg for 1
min at 4°C. Protein concentration was deter-
mined using the BCA protein assay (Pierce).
Samples were normalized and diluted in
Laemmli sample buﬀer (Bio-Rad), and pro-
teins were separated by SDS-PAGE and sub-
sequently blotted onto PVDF membranes.
Membranes were blocked for 30 min in 5%
non-fat dry milk solution at room tempera-
ture, followed by overnight incubation of pri-
mary antibodies at 4°C. Blots were washed
and incubated with peroxidase-conjugated
secondary antibodies, washed again and vi-
sualized by Immun-Star enhanced chemilu-
minescence (Bio-Rad). Immunoblots were
quantiﬁed by densitometry using ImageJ
software.
Statistics
To test the eﬀect of treatment, urinary
parameters at baseline and week 16 were
compared by paired Wilcoxon signed rank
test. Diﬀerences between unpaired groups
were calculated with Mann-Whitney test,
and correlation between Clcn5 mRNA ex-
pression and urinary loss of CC16 were as-
sessed with GraphPad Prism. P<0.05 was
considered signiﬁcant, *P<0.05; **P<0.01;
***P<0.001, n.s., not signiﬁcant.
Results
Increased engraftment of GFP+ cells into
KO kidneys
To test whether BM transplantation im-
proves the phenotypic characteristics of
Dent's disease in mice, we transplanted ClC-
5 KO mice with WT GFP-expressing BM
cells (treated). As controls, KO mice were
transplanted with KO cells (negative con-
trols) and WT littermates with WT GFP-
expressing cells (positive controls). Urine
was collected at baseline and four months af-
ter transplantation, and urinary volume, glu-
cose, creatinine, Ca2+ and Clara Cell protein
(CC16) were measured (Figure 2.20 A). With
the exemption of a few irradiation resistant
T cells, all mice displayed full hematopoietic
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Figure 2.20: Study design and engraftment eﬃciency of transplanted cells
(A) Experimental setup of the study: Clcn5y/- (ClC-5 KO) and Clcn5y/+ (WT) littermate controls were
used as recipients. These mice were transplanted at age 10 weeks either with WT GFP+ or ClC-5 KO BM
cells. Baseline (BL) urine collection (12h overnight) was performed the week before BM transplantation
and again 16 weeks after BM transplantation. Peripheral blood chimerism was measured at time of kidney
harvest. (B) Peripheral blood chimerism of monocytes, B cells and T cells, (C) GFP mRNA expression in
WT and KO kidney of mice that received GFP+ BM cells. (D) western blot for GFP protein expression
in kidney lysates, (E) quantiﬁcation of optical density in GFP western blot, (F) confocal image showing
GFP expression in kidneys. Statistical diﬀerences were assessed with Mann-Whitney test.
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chimerism in peripheral blood (Figure 2.20
B). Interestingly, ClC-5 KO mice displayed
higher recruitment of GFP+ cells into the
kidneys than WT mice, as measured on
mRNA and protein level (Figure 2.20 C-F).
It has been suggested, that chronic injury is
a pre-requisite to stimulate the long-term en-
graftment of BM-derived cells to the kidney
[308].
Improvement of Fanconi syndrome in
transplanted animals
Regardless of their treatment regimen, ClC-
5 KO mice displayed higher values of all uri-
nary parameters measured at baseline and
at week 16 than their WT littermate con-
trols that were transplanted with GFP BM
(note; WT parameters did not change over
time, Table 2.21). CC16 is a highly sensitive
marker for proximal tubular dysfunction and
cannot be detected in urine of healthy indi-
viduals [314]. Paired analysis showed a sig-
niﬁcant decrease of CC16 from 69.8 to 47.3
mg/g crea in treated animals. In contrast,
negative controls had a signiﬁcant increase in
urinary CC16, pointing towards further pro-
gression of the disease over time (Figure 2.22
A). This ﬁnding was underlined by compar-
ing the relative change of CC16 in treated
and control groups (Figure 2.22 B). Urine
volume did not change in treated mice, while
mice transplanted with KO cells increased
urinary volume further, again pointing to
a progression of the disease (Figure 2.22
C). Similarly, glycosuria and Ca2+/crea ra-
tio also decreased signiﬁcantly in treated an-
imals, while it rested unchanged in negative
controls (Figure 2.22 D-F). Taken together, a
clear improvement of the Fanconi syndrome
could be observed in mice transplanted with
WT BM cells compared to negative controls
that were transplanted with ClC-5 KO cells.
Notably, all mice regardless of genotype and
treatment regimen, had normal kidney func-
tion as measured by plasma urea and cre-
atinine at diﬀerent time points (data not
shown). It has been suggested that the level
of peripheral blood chimerism correlates with
kidney function in cystinosis [315]. In our
protocol, recipients where lethally irradiated
and thus BM transplantation resulted in full
hematopoietic chimerism in all mice (Fig-
ure 2.20 A). However, the engraftment level
of GFP+ cells in the kidney might correlate
with urinary parameters. But we did not ob-
serve a signiﬁcant correlation between any of
the urinary parameters and the engraftment
level (data not shown).
Partial recovery of megalin expression in
transplanted mice
CC16 is absorbed by receptor-mediated en-
docytosis in PT cells, thus the reduced uri-
nary loss of CC16 in transplanted mice sug-
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Figure 2.21: Summary of urinary parameters
Table showing mean values +/- s.e.m.
gests that the endocytic machinery is at least
partially recovered upon BM transplanta-
tion. To conﬁrm this hypothesis, we stained
for megalin in kidney sections in ClC-5 KO
mice that received GFP cells and mice that
got KO cells. As expected, mice that re-
ceived KO cells did not show any megalin
staining. In contrast, mice that were trans-
planted with WT cells re-expressed megalin
in their brush border membranes. It ap-
peared that megalin expression was higher
in regions of the kidney that showed more
engraftment of GFP+ cells (Figure 2.23 A-
D). The expression of megalin was further
conﬁrmed in western blots, where megalin
protein expression in transplanted kidneys
was intermediate to WT and KO mice that
displayed normal or very low expression, re-
spectively (Figure 2.23 E). In contrast, aqua-
porine 1 and Rab5, which are not aﬀected
by loss of ClC-5, remained unchanged in all
treatment groups (Figure 2.23 E). Impor-
tantly, Clcn5 gene expression increased sig-
niﬁcantly in treated animals, and the expres-
sion level signiﬁcantly inversely correlated
with urinary loss of CC16 (Figure 2.23 F,
G).
Engrafted cells are mononuclear phago-
cytes
To closer investigate the mechanisms that
lead to the observed improvement in Fan-
coni syndrome, we analysed the location and
identity of the transplanted cells in the kid-
ney. Besides the fact that more GFP+ cells
engrafted to the kidneys of ClC-5 KO mice
thanWTmice (Figure 2.20), the cells showed
also a slightly diﬀerent distribution pattern.
In KO mice, the transplanted cells associ-
95
2.4 BM transplantation for correction of tubulopathy
Figure 2.22: Urinary parameters of treated and control mice at BL and week 16
(A-F) Paired analysis of urinary parameters in ClC-5 KO mice treated with WT and KO cells. (A) CC16
(normalized to creatinine) (B) relative change in CC16 between measurements at BL and week 16, (C)
total urine volume, (D) glycosuria, (E) Ca2+/crea, (F) calciuria. Diﬀerences in urinary parameters at BL
and week 16 were assessed with Wilcoxon signed rank test and relative change of CC16 between treatment
groups with Mann-Whitney test.
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Figure 2.23: Recovery of megalin in brush border membranes of transplanted mice
Staining for megalin (red), GFP (green) and Dapi in mice transplanted with (A, B) GFP- or (C, D)
KO-BM cells. (E) western blot for megalin, aquaporine 1 (AQP1) and Rab5 in kidney lysates. (F) mRNA
expression of Clcn5 and (G) correlation between Clcn5 mRNA and urinary CC16. White bars correspond
to 75 µm. Mann-Whitney test was used to assess diﬀerence between treatment groups, and correlation
represents a linear regression-model with 95% CI.
97
2.4 BM transplantation for correction of tubulopathy
ated closely to the tubular epithelial cells and
their processes seemed to frame the tubuli,
whereas in WT mice the transplanted cells
sat in the interstitial space without such close
contact with the tubuli (Figure 2.24; quan-
tiﬁcation in progress).
It is highly unlikely that hematopoi-
etic cells transdiﬀerentiate into non-
hematopoietic cells. Accordingly, we did
not observe any tubular epithelial cells that
expressed GFP, all transplanted cells were
found in the tubulointerstitial space. It
might be possible that mesenchymal stromal
cells (MSCs), that were present in the BM
cell suspension upon transplantation, were
recruited to the kidneys. Such cells do
not migrate into healthy tissues, but upon
irradiation injury, increased recruitment into
peripheral organs has been observed [316].
In addition, MSCs have been shown to be
renotropic in situations of acute injury and
they may persist in kidneys for a long time
[173, 317]. For these reasons, the engrafted
cells might theoretically derive from the
MSC lineage. However by forming a network
of processes, the GFP-expressing cells phe-
notypically resembled rather dendritic cells
(DCs) or macrophages than MSC-derived
cells, which would be spindle shaped and
compact. In the kidney, it is not possible to
discriminate DCs and macrophages based
on the expression of surface markers that
are commonly used in lymphoid organs
[284, 285, 318]. As DCs and macrophages
further possess overlapping functions in the
kidney, these cells are often referred to as
mononuclear phagocytes [284]. We con-
ﬁrmed this identity by staining the kidney
sections for CD11c and F4/80 (Figure 2.25
A-F). Co-staining of these markers with
GFP allowed the conclusion that these cells
originated from the hematopoietic lineage.
To further conﬁrm this ﬁnding, we stained
the slides with the ﬁbroblast marker α-SMA.
Indeed, there was close association between
transplanted cells and ﬁbroblasts, but no
overlap of the stainings (Figure 2.25 G, H).
Discussion
For some conditions, such as diseases of the
hematopoietic system (e.g. sickle cell disease
or SCID), the potential of BM transplanta-
tion is evident, but it has also been success-
ful in certain types of lysosomal storage dis-
eases (LSDs). LSDs are a group of diseases
that are characterized by enzyme deﬁciency
in lysosomes, resulting in substrate accumu-
lation, subsequent cellular dysfunction and
apoptosis [319]. Here, healthy cells deriving
from the transplanted hematopoietic system
can engraft into various organ structures and
through the close proximity with diseased
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Figure 2.24: Distinct
distribution pattern of
transplanted cells
Staining for megalin (red),
GFP (green) and Dapi.
(A, B) WT mice and (C,
D) ClC-5 KO mice trans-
planted with GFP+ cells.
White bars correspond to
50 µm.
cells, they can replace defective enzymes by
secretion. In Hurler Syndrome for example,
HSC transplantation is being performed in
patients for more than 30 years [320]. Cysti-
nosis is also a LSD, but it is caused by de-
fects in a membrane-bound transporter, cir-
cumventing the secretion and uptake of the
functional protein. In this disease, the main
positive eﬀect of transplantation was the re-
duction of cysteine crystals in tissues, while
improvement of kidney and serum parame-
ters was only modest [212, 315]. The positive
eﬀects can possibly be attributed to phago-
cytic cells that engrafted in great numbers to
the kidneys.
In the present study, we aimed to extend
the ﬁnding that BM transplantation can im-
prove diseases that are caused by membrane-
bound transporters. In contrast to cysti-
nosis, in Dent's disease we observed a sig-
niﬁcant improvement of renal Fanconi syn-
drome, as manifested most prominently in
a decreased loss of CC16 in the urine. En-
grafted cells seemed to belong to the family
of mononuclear phagocytes based on their
co-expression of F4/80 and CD11c. These
cells are found in the tubulointerstitium and
are important for tissue homeostasis, e.g. by
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Figure 2.25: Transplanted cells are mononuclear phagocytes
Staining for GFP (green) and Dapi in ClC-5 KO mice transplanted with GFP cells and additional (A-C)
CD11c (red) and (D-F) F4/80 staining. (G) α-SMA staining (red) in ClC-5 KO cells transplanted with
KO cells, showing a vessel. (H) α-SMA (red), GFP (green) and Dapi in a kidney transplanted with GFP+
cells. White bars correspond to 50 µm.
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maintaining tolerance to renal antigens and
LMW proteins that are ﬁltered, or by clear-
ing apoptotic cells [284]. Surprisingly, the
presence of functional mononuclear phago-
cytes resulted in a partial rescue of megalin
expression in the brush border membrane of
PT cells. This indicates that the process
of receptor-mediated endocytosis might be
functional to a certain level, explaining the
decreased loss of CC16 in the urine. How-
ever at the moment, it can only be speculated
about how this rescue of megalin is achieved.
Basically, two possible explanations could
be envisaged: (1) There is no genetic defect
of megalin in ClC-5 KO mice, but rather a
defect at the cellular level due to the de-
fective endosome/lysosome pathway. Thus,
the rescue of megalin could be explained
by a constant protein transfer of this re-
ceptor from mononuclear phagocytes to ep-
ithelial cells. However, this is rather un-
likely, as functional megalin has not been
shown to be expressed in such phagocytes.
In fact, macrophages in the liver constitu-
tively express megalin mRNA, but on protein
level only the megalin C-terminal fragment
is present [321]. (2) More reasonable might
be the indirect rescue of megalin by trans-
ferring a certain amount of functional ClC-5
proteins or mRNA to epithelial cells. It has
been shown that peritoneal macrophages,
but not peripheral blood monocytes, express
high levels of ClC-5 protein [322]. Whether
DCs express ClC-5 has not been investi-
gated. It is well possible that the trans-
planted cells at least partially express ClC-5
when acquiring their tissue-resident pheno-
type. This might explain the signiﬁcant in-
crease of Clcn5 mRNA in kidneys of mice
transplanted with WT BM compared to KO
controls (Figure 2.23 E). Based on the close
proximity of transplanted cells with epithe-
lial cells, one might speculate that transfer of
Clcn5 mRNA or protein between these cells
takes place. In fact, transfer of extracellular
vesicles (EV) is considered to be a common
way of intercellular communication between
neighbouring cells [323325]. Low-level ex-
pression of functional ClC-5 transporter in
epithelial cells then may prevent complete
loss of megalin, restoring the endocytosis ma-
chinery to a certain degree. Indeed, Clcn5
gene expression kidneys of treated animals
signiﬁcantly inversely correlated with CC16
loss in the same mouse, supporting this hy-
pothesis. However, more research will be
needed to get a clearer picture of these fasci-
nating and potentially important ﬁndings.
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Apoptosis is of overriding importance for
the proper functioning of the immune sys-
tem. In particular, the intrinsic apoptosis
pathway is involved in processes such as the
elimination of self-reactive thymocytes, se-
lection of high aﬃnity clones and contrac-
tion of the Teﬀ pool after antigenic clearance
through the dynamic expression of pro- and
anti-apoptotic factors. With the advent of
BH3 mimetics that allow to speciﬁcally tar-
get certain anti-apoptotic factors, and a de-
tailed understanding of apoptosis regulation
in the immune system, previously unrecog-
nised therapeutic options can be envisaged.
This novel class of drugs could ﬁnd applica-
tion in diseases/conditions that are charac-
terized by unwanted or overshooting immune
responses.
Immunosuppressive action of
ABT-737
Our group has previously found the Bcl-
2, Bcl-xL and Bcl-w inhibitor ABT-737
to suppress allogenic T cell responses in
vitro in a concentration-dependent manner
[244]. Short-term treatment of naïve ani-
mals with ABT-737 resulted in a marked re-
duction of platelets and lymphocytes in the
spleen, thymus and the mucosa-associated
lymphatic tissue, while non-lymphoid tis-
sues such as the kidney, liver and intesti-
nal epithelial cells did show no signs of in-
creased apoptosis [244]. Thus, the action
of ABT-737 seemed to be conﬁned to cells
of hematopoietic origin. Interestingly, while
naïve cells were eﬃciently killed by ABT-
737, freshly activated T cells were refrac-
tory to apoptosis induction [61]. TCR en-
gagement leads to release of calcium from in-
tracellular stores and calcineurin activation,
which subsequently dephosphorylates NFAT.
Activated NFAT cooperates with other tran-
scription factors that are activated upon
TCR or co-stimulatory receptor signalling,
to induce the expression of genes that are
required for the diﬀerentiation of naïve T
cells into fully activated cells [326]. One of
the many genes that are activated by NFAT
is anti-apoptotic A1, which was responsi-
ble for the observed ABT-737 resistance in
activated T cells. Accordingly, this resis-
tance could be overcome by administration
of the calcineurin inhibitor CsA at the time
of antigen encounter [61]. Interestingly, also
in naïve cells, CsA and ABT-737 seemed to
have a synergistic eﬀect in apoptosis induc-
tion, as CsA reduced Bcl-2 expression and
thereby lowered the IC50 value of ABT-737.
In vivo, this fact was manifested by signif-
icantly lower lymphocyte counts upon com-
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bined drug administration.
Based on the growing understanding of the
eﬀects of ABT-737 on immune cells, sev-
eral approaches to actually manipulate the
immune system could be envisaged. When
the drug was administered under naïve con-
ditions (which is before antigen encounter
or inﬂammation), it depleted lymphocytes
and thereby reduced the precursor frequency
of potentially dangerous cells. This im-
munosuppressive eﬀect of ABT-737 was illus-
trated for example in diverse models of au-
toimmunity (SLE, collagen-induced arthri-
tis, delayed-type hypersensitivity). ABT-
737 reduced the severity of these diseases
when the treatment regimen was prophylac-
tic or started at the very ﬁrst manifestations
of the disease [327]. In a mouse model of
spontaneous colitis, ABT-737 induced lym-
phopenia went along with reduced systemic
TNF and lL-1β gene expression, and de-
creased inﬂammation in the intestine [328].
Similar results were obtained with diabetic
mice that were treated with ABT-737 for
5 days and then transplanted with an allo-
genic pancreatic islet graft. ABT-737 treat-
ment prevented the rejection of this low-
immunogenic graft, resulting in lower blood
glucose levels [241]. In contrast, the im-
munosuppressive eﬀect of ABT-737 (with or
without CsA) was not suﬃcient to prolong
survival of highly immunogenic fully MHC-
mismatched skin grafts, even when treat-
ment was started 5 days before transplan-
tation and continued until rejection. Never-
theless, treatment resulted in a signiﬁcant re-
duction of allospeciﬁc IgG and IgM antibod-
ies in the serum [244]. Rejection of MHC-I
single antigen mismatched skin grafts could
be prevented in about 50% of animals when
they received combined ABT-737 and CsA
treatment, while both drugs as single agent
did not have any eﬀect [244].
Taken together, ABT-737 has proven to
display an immunosuppressive eﬀect in vivo
through clone size reduction without aﬀect-
ing the functionality of remaining lympho-
cytes. AbbVie, the company that produces
ABT-737 and its oral analogue ABT-263, has
recently completed a clinical trial with ABT-
199 (a Bcl-2 only inhibitor not leading to
thrombocytopenia, a side eﬀect of ABT-263)
in SLE patients, presumably with the pur-
pose to reduce lymphocyte numbers and thus
proﬁt from its immunosuppressive action.
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Diﬀerences in apoptosis among cell
populations
Having observed the general reduction of
lymphocytes upon ABT-737, we aimed at
closer investigating apoptosis regulation in T
cell subsets that are particularly important
in the transplantation ﬁeld; Tm and Tregs.
Preformed Tm are involved in graft rejection
and preclude clinical translation of success-
ful tolerance strategies in rodents. We have
shown that during the transition of activated
T cells to the memory stage, the relative
expression of anti-apoptotic factors changes.
The resistance factor A1 was strongly down
regulated in Tcm and to a lesser extent in
Tem, while the importance of Bcl-2 for sur-
vival seemed to increase. These dynamic
changes were reﬂected in the susceptibility to
ABT-737 induced apoptosis. Tm were con-
siderably more sensitive to apoptosis than
early-activated T cells [300]. Moreover, when
applied at time of transplantation, ABT-737
could reverse the accelerated rejection medi-
ated pre-existing allo-speciﬁc Tm, leading to
similar rejection kinetics as observed in naïve
mice [300].
Furthermore, we compared Bcl-2 family
protein levels among FoxP3+ Tregs and
naïve CD4 Teﬀs. When unstimulated, Treg
expressed slightly more Bcl-xL protein, while
the other factors were similar among the
two cell populations. Nevertheless, Tregs
displayed approximately 10x higher resis-
tance to ABT-737 induced apoptosis in vitro.
When stimulated with IL-2, Treg resistance
increased signiﬁcantly due to strong upreg-
ulation of Mcl-1 and A1. Our ﬁndings are
consistent with a recent study that identi-
ﬁed Mcl-1 as the predominant survival fac-
tor in Tregs. There, genetic deletion of Mcl-1
resulted in speciﬁc loss of Tregs among the
CD4 population [70]. In vivo application
of ABT-737 to naïve mice resulted in lym-
phopenia, but importantly, the proportion of
Tregs among the CD4 population increased,
leading to a change in the balance of Tregs
versus Teﬀs.
In addition to these two examples of diﬀer-
ential apoptosis regulation among diﬀerent
T cell populations, it has recently been re-
ported that plasmacytoid and conventional
dendritic cells (pDC and cDC) present a
fundamentally distinct expression pattern of
anti-apoptotic Bcl-2 family members. Bcl-
2 and Bcl-w are highly expressed in pDC,
while A1 is only expressed in cDCs [329].
Thus, cDC were highly resistant towards Bcl-
2 blockade with ABT-199 in vitro, and in
vivo application of ABT-199 resulted in se-
lective depletion of pDC while cDC numbers
were maintained [329].
These examples clearly illustrate that dif-
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ferent subpopulations may depend on diﬀer-
ent survival factors. In many pathologic con-
ditions, certain cell populations are of pre-
dominant importance and speciﬁc targeting
of these cells would be useful. With the ever-
growing repertoire of Bcl-2 inhibitors, the
possibilities to eliminate a speciﬁc popula-
tion from the immune repertoire are mani-
fold. As such, BH3 mimetics may not only
be a novel class of drugs for general im-
munosuppression as it has been suggested,
but rather a high-precision tool to speciﬁ-
cally target cells. However, in order to fully
proﬁt from the therapeutic options oﬀered
by BH3 mimetics, our understanding of the
regulation of the intrinsic apoptosis pathway
in cell subpopulations and under certain dis-
ease states needs to grow considerably. Es-
pecially also in human cells, where very lit-
tle is known to date. We tested the eﬀect of
ABT-737 on peripheral blood lymphocytes
to see whether we can achieve a similar in
vitro enrichment of Tregs as in mouse cells,
but unfortunately, this was not the case.
Exploit the growing understanding of
lymphocyte apoptosis for novel
immunomodulatory therapies
This knowledge eventually allowed us to
exploit the immunomodulatory properties
of ABT-737 in more sophisticated toler-
ance protocols. The extent of Tm reduc-
tion was suﬃcient to overcome the barrier
they pose to tolerance induction. Donor
skin grafts were rejected faster than con-
trol grafts in mice containing donor-reactive
Tm when they were treated with DST and
CD154/CD40 blockade, showing that the
tolerance protocol did not have any ef-
fect in primed mice. In contrast, a short
course of ABT-737 in addition to DST com-
pletely reversed the picture and resulted
in profound donor-speciﬁc hyporesponsive-
ness [300]. This ﬁnding suggested that not
only the Tm barrier is overcome with ABT-
737 treatment, but that further mechanisms
come into play.
DST/costimulation blockade-induced hy-
poresponsiveness has been shown to be as-
sociated with diverse mechanisms, such as
T cell anergy, deletion and regulation by
Treg cells [279, 330, 331]. Costimulation is
not only needed for T cell proliferation and
cytokine production, but also for prolonged
survival by inducing Bcl-xL expression [191,
332]. On the other hand, Bim is induced in
response to TCR engagement, and costimu-
lation blockade further increases Bim expres-
sion [191]. Thus, costimulation blockade re-
duces viability of allo-activated CD8 T cells
by reducing Bcl-xL and increasing Bim ex-
pression, and it seems that this process of
clonal deletion under CD154 blockade could
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be further potentiated by Bcl-xL blockade
with ABT-737 [191]. Regarding regulation,
Tregs are required for maintenance of periph-
eral tolerance towards allo-antigens. Tregs
develop de novo upon antigen-encounter un-
der CD154 blockade, and CTLA-4 is required
for long term survival of skin grafts under
these conditions [134, 279]. We have shown
that Tregs are extremely resistant towards
ABT-737 treatment in such an environment.
Thus, addition of ABT-737 to the established
DST protocol resulted in (1) more eﬃcient
deletion of allo-reactive T cells and (2) at
the same time boosted Treg-mediated sup-
pression. This led to an impressive donor-
speciﬁc hyporesponsiveness in a strain com-
bination where DST plus CD154 antibodies
otherwise was not suﬃcient to prolong skin
graft survival.
GVHD has been characterized as an im-
balance between the eﬀector and regulatory
arms of the immune system [333] . When
Tregs are depleted from the transplant inocu-
lum, GVHD worsens, while adoptive transfer
of Tregs ameliorated the disease [334]. Treat-
ment of transplant recipients with ABT-737
and low-dose CsA is reasonable, as it re-
duces lymphocyte numbers while Tregs are
spared, thus the balance between Tregs and
Teﬀs is restored. In combination, these two
drugs act as immunosuppressants and allow
eliminating also TCR stimulated Teﬀs. The
possibility to establish mixed chimerism and
allo-tolerance with a short induction pro-
tocol consisting of ABT-737, low-dose CsA
and costimulation blockade without myelo-
suppression is remarkable [191]. Here, all the
above discussed aspects of ABT-737 medi-
ated immune-regulation act in concert.
Potential applications of
Bcl-2/Bcl-xL inhibition in clinical
transplantation
The beneﬁcial eﬀects that we have observed
in our experimental research with ABT-737
should at least partially be conﬁrmed in hu-
man cells before clinical translation of our
concepts could be envisaged. Important in
this regard would be the conﬁrmation of
Tm sensitivity to Bcl-2/Bcl-xL inhibition.
If this is the case, the most promising and
widespread application of ABT-737 (or the
bioavailable analogue navitoclax) would be
the induction therapy in highly sensitized
organ recipients. Treatment is expected to
result in clone size reduction of Tm, lym-
phopenia and potentially a tolerogenic en-
vironment due to large amounts of apop-
totic bodies. Importantly, lymphopenia is
reversible within a few days after discontin-
uation of treatment. This represents a huge
advantage compared to other T cell depleting
agents in clinical practice like ATG, which
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induce sustained, and in the case of an infec-
tion potentially dangerous, lymphopenia.
Regarding tolerance induction, plans ex-
ist to combine navitoclax with established
tolerance protocols in non-human primates.
This will prove whether navitoclax displays
similar tolerogenic properties in higher an-
imals as ABT-737 in mice, and whether it
also supports engraftment of HSCs. If this
is the case, preparatory irradiation of HSC
recipients might be reduced or replaced. If
successful, these studies could pave the way
for addition of navitoclax to established tol-
erance induction protocols in kidney trans-
plant recipients in the future [194, 196].
Another potential application ﬁeld for Bcl-
2/Bcl-xL inhibition might be adoptive T cell
therapy. TCR-stimulated T cells upregulate
A1 and thereby become strongly resistant to-
wards ABT-737 induced apoptosis [61]. This
fact could be exploited by stimulating a pa-
tient's T cells in vitro with the antigen of in-
terest (e.g. a tumor or viral antigen). Subse-
quent incubation with ABT-737 would easily
allow to speciﬁcally select antigen-speciﬁc T
cells in the culture. These cells could then be
expanded further and transferred back to the
patient, for example upon cytomegalovirus
infection post-transplantation.
The therapeutic potential of BM
transplantation in treating chronic
kidney diseases
There have been numerous studies over the
past 15 years that tested the eﬀectiveness of
BM cells as therapy in a wide variety of con-
ditions aﬀecting the kidneys. And there has
been considerable controversy about the po-
tency of this treatment approach. In that
regard, it is important to note that it is diﬃ-
cult to directly compare acute disease models
with chronic progressive models, and HSCs
with MSCs [308].
BM-derived stem cells have been shown to
engraft to the kidneys and help improve re-
nal function, in both, acute and chronic kid-
ney diseases. For example, these cells were
shown to diﬀerentiate into mesangial cells in
a Thy1.1 nephritis model in rats [335], and
systemic infusion of resulted in improved kid-
ney function after acute kidney injury [336].
Similarly, human HSCs were shown to have
beneﬁcial eﬀects in kidney I/R injury in mice
when infused systemically. These cells were
recruited to the kidney parenchyma, per-
itubular capillaries and a few to the perivas-
cular space. This recruitment was associated
with increased repair of the microvasculature
and tubular epithelial cells, leading to re-
duced mortality and improved kidney func-
tion [337]. And as discussed in detail in the
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introduction, in a pre-clinical model of cysti-
nosis BM transplantation resulted in engraft-
ment healthy hematopoietic lineage cells to
the kidney, which was accompanied by im-
proved kidney function [212]. In contrast,
protection through paracrine eﬀects (e.g. the
release of large amounts of VEGF) was at-
tributed to MSCs [208, 338]. Taken together,
kidney repair by stem cells is a complex pro-
cess, and it is diﬃcult to draw conclusions
about the therapeutic beneﬁt of this thera-
peutic approach at this stage.
When discussing the potential of stem cell
therapy for kidney diseases, it is not only im-
portant to discriminate between acute and
chronic conditions and the stem cell type
used, but it is also essential to discuss the
mode of treatment. It is comprehensible that
systemic infusion of BM-derived cells around
the time of injury can have immediate pro-
tective eﬀects. However, when looking at
chronic conditions that are caused by genetic
defects, such as cystinosis or Dent's disease,
such short-term treatment approaches can-
not be suﬃcient to improve kidney function
in the long-term. Indeed, the group that in-
vestigated the cystinosis model has explicitly
compared the therapeutic eﬀect of unfrac-
tionated BM, isolated HSCs and MSCs, and
they found only temporary improvement of
renal function with MSC infusion [212]. In
my opinion, a source of healthy cells with-
out the genetic defect needs to be available
for continuous recruitment to the defective
organ. And the only possibility to estab-
lish such a pool of cells is the transplan-
tation of HSCs, which can give rise to all
types of blood cells such as T and B lym-
phocytes, eosinophils, neutrophils, basophils,
DCs and monocytes/macrophages. Impor-
tantly, these cells are not stationary, but
they circulate through the body and thus
can get in contact with the diseased or-
gan, which is a pre-requisite for engraftment.
Once recruited to the kidney, it is still elu-
sive how these cells can restore functional
defects. The previously suggested trans-
diﬀerentiation into/or fusion with the target
cells (in our case proximal epithelial cells) is
questionable.
The tubulointerstitium contains many dif-
ferent BM-derived cells. It has been shown
that mostly CD45 expressing cells occupy the
peritubular interstitial space in the cortex of
rat kidneys [339]. Macrophages are tissue-
resident phagocytic cells that long have been
considered to be mainly immune cells and
their presence was thought to be deleteri-
ous and equalled to inﬂammation. More
recent research however, has revealed their
involvement in tissue homeostasis and repair,
regeneration and resolution of inﬂammation
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[340, 341]. For example, a study has shown
that M2-polarised macrophages actively pro-
moted repair of tubules and angiogenesis
[342]. In cystinosis, WT macrophages have
been shown to form tunnelling nanotubes to
diseased neighbouring cells, which might al-
low the exchange of cystinosin-bearing lyso-
somes [343]. However, the proposed mecha-
nism still remains somewhat obscure. DCs
are another tissue-resident, highly heteroge-
nous hematopoietic lineage-derived cell pop-
ulation that resides in the tubulointerstitium
of the renal cortex. They form long cyto-
plasmic processes that extend between and
around tubules [339, 344]. In addition it has
been suggested that renal DCs can directly
interact with renal cells such as epithelial
cells and podocytes [285]. It is important
to note, that most research that was aimed
at elucidating the role of macrophages or
DCs in the kidney, was performed by ei-
ther looking at F4/80 or CD11c expressing
cells. However, it is now evident that the
classiﬁcation of tissue-resident phagocytes in
the kidney is more complex. Several dis-
tinct phagocytic subpopulations have been
described [345]. These cells show overlap-
ping classical macrophage- or DC-functions
in vivo and most of them co-express CD11c,
F4/80 and MHCII [284]. Thus, markers that
allow discriminating macrophages and DCs
in lymphoid organs, are less useful in non-
lymphoid tissues such as the kidney. For
these reasons, talking about mononuclear
phagocytes is more appropriate.
In our study of Dent's disease, we observed
a partial rescue of megalin in the brush bor-
der membranes of PT cells of transplanted
mice, which might explain the reduced loss
of CC16 in the urine. CC16 is a cubilin lig-
and, a receptor that is co-expressed with me-
galin and is also lost in Dent's disease. As
shortly discussed in the experimental part, it
has been shown that peritoneal macrophages
highly express ClC-5, while monocytes do
not [322]. This suggests that tissue-resident
phagocytes in the kidney might also express
ClC-5. This possibility is supported by the
fact that Clcn5 gene expression signiﬁcantly
increased in KO mice that were transplanted
with WT cells. I believe that transfer of
functional protein and/or Clcn5 mRNA via
extracellular vesicles (EVs) is taking place
between the closely entangled mononuclear
phagocytes and the epithelial cells. In fact,
exchange of EVs has been suggested to be the
third mode of communication between neigh-
bouring cells, besides direct cell-cell contact
and the secretion of molecules [323]. As di-
rect investigation of this process in vivo is
challenging, most research on EVs has been
undertaken in vitro. However, very recently
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an in vivo study has shown that aggressive
tumor cells transfer mRNA to less malignant
cells via EVs, which in turn also become more
malignant [324]. DCs and macrophages both
constitutively secrete EVs in vitro, thus it is
well possible that material from these cells
is transferred to epithelial cells in our model
[346, 347].
Is clinical translation of HSC
transplantation an achievable goal
for diseases such as Dent's?
When considering HSC transplantation as
potential therapy in non-malignant condi-
tions, the pros and cons have to be balanced
carefully. The more devastating a disease,
the more severe side eﬀects deriving from
HSC transplantation are acceptable. Dent's
disease is certainly less severe than cystinosis
or some other LSDs, where HSC transplan-
tation is being performed already. For this
reason, for HSC transplantation to be a real
treatment option for diseases such as Dent's,
the toxicity of conditioning regimen of recip-
ients needs to be reduced signiﬁcantly. Ef-
fort is given at developing such protocols for
mixed chimerism induction for transplant re-
cipients, and for HLA-matched HSC recipi-
ents, the Stanford protocol is quite successful
already [194]. However, more than half of the
patients displayed only transient chimerism
that was lost within one year. Interestingly,
this loss of chimerism did not aﬀect toler-
ance towards the transplanted kidney, a phe-
nomenon called split tolerance [194]. When
considering to use such a reduced condition-
ing approach for a renal disease where con-
tinuous replenishment of interstitial cells by
BM-derived cells is presumably needed, such
a loss of chimerism might pose a problem.
For example, turnover of renal DCs is only
about 14 days under homeostatic conditions,
thus persistent chimerism is needed [348].
On the other hand, full chimerism is less de-
sirable due to an increased risk of GVHD.
In order to answer the question whether
HSC transplantation will be used in clinics
to treat diseases like Dent's in the future,
many more studies will be needed. Clinical
protocols for HSC transplantation have to be
advanced to further reduce toxicity of condi-
tioning. At the same time, mechanisms that
lead to loss of chimerism in patients need to
be understood and possibly prevented, for
example using DST . Furthermore, with the
help of pre-clinical models, studies aimed at
understanding the mechanisms of improve-
ment of diseases like Dent's or cystinosis have
to be undertaken. Importantly, BM trans-
plantation has to be performed also in allo-
geneic strain combinations and with proto-
cols that induce mixed chimerism. Here, it
will be important to correlate the chimerism
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level with the outcome of the disease to see
whether mixed chimerism is suﬃcient for this
purpose.
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Key Points
• Immunological tolerance can
be achieved by direct
modulation of the intrinsic
apoptosis pathway in
peripheral lymphocytes.
Induction of mixed hematopoietic chimerism results in donor-specific immunological
tolerance by apoptosis-mediated deletion of donor-reactive lymphocytes. A broad clinical
application of this approach is currently hampered by limited predictability and toxicity of
the available conditioning protocols. We developed a new therapeutic approach to induce
mixed chimerism and tolerance by a direct pharmacological modulation of the intrinsic
apoptosis pathway in peripheral T cells. The proapoptotic small-molecule Bcl-2 inhibitor
ABT-737 promoted mixed chimerism induction and reversed the antitolerogenic effect of
calcineurin inhibitors by boosting the critical role of the proapoptotic Bcl-2 factor Bim. A
short conditioning protocol with ABT-737 in combination with costimulation blockade and low-dose cyclosporine A resulted in
a complete deletion of peripheral donor-reactive lymphocytes and was sufficient to induce mixed chimerism and robust systemic
tolerance across full major histocompatibility complex barriers, without myelosuppression and by using moderate doses of bone
marrow cells. Thus, immunological tolerance can be achieved by direct modulation of the intrinsic apoptosis pathway in peripheral
lymphocytes—a new approach to translate immunological tolerance into clinically applicable protocols. (Blood. 2013;122(9):1669-1677)
Introduction
Induction of allograft tolerance, a state in which the immune system
accepts donor organs but normally responds to foreign antigens,
represents the ideal solution for preventing rejection after solid-organ
transplantation without immunosuppression-related toxicity. Among
the different experimental models to induce tolerance, very few were
successful in large animals and only one strategy—namely, the
induction of mixed chimerism by combined transplantation of a solid
organ and hematopoietic stem cells from the same donor—was
successful in clinical pilot studies.1
The main mechanism of tolerance in mixed chimeras is central
deletion of newly arising donor-reactive lymphocytes induced by
the presence of donor-derived antigen-presenting cells in central
lymphatic organs.2,3 Preexisting mature donor-reactive T cells are
not exposed to this tolerization process and need to be removed
from the T-cell repertoire by a conditioning therapy to prevent
rejection. In the ﬁrst clinical mixed chimerism studies, peripheral
T-cell tolerization was obtained by unselective lymphocyte depletion
through irradiation or profound T-cell depletion by antibodies.4-7 This
approach was effective, but inevitably induced pancytopenia and with
some protocols also engraftment syndrome. Moreover, in nonhuman
primates and patients, hematopoietic chimerismwas not always stable
over time, and in some protocols chimerism was only transiently
detectable (apparently without precluding tolerance maintenance).4,5
Other groups reported the establishment of full chimerism, a condition
that, however, bears a high risk for graft-vs-host disease.6
The hope for a selective and less toxic option to clonally delete
peripheral donor-reactive T cells was provided by the development of
immunomodulatory strategies based on costimulation blockade.
Blocking CD28/CD80/CD86 and CD154/CD40 signaling induces
anergy and deletional tolerance by activation of the apoptosis cascade
in alloreactive T cells.3,8,9 However, this strategy displayed a reduced
efﬁcacy in combination with standard immunosuppression by cal-
cineurin inhibitors10,11 and was not sufﬁcient to induce tolerance in
case of a high donor-reactive T-cell precursor frequency.12
Resistance to anti-CD154-induced or CTLA4Ig-induced tolerance
in mice overexpressing the antiapoptotic factor Bcl-xL indicates
that the regulation of the intrinsic apoptosis pathway by the
Bcl-2 family is pivotal in this setting.13,14 The recent advent of
selective Bcl-2 family inhibitors offers new pharmacological
options to modulate these physiological processes. Of particular
clinical interest are the small molecules ABT-737 and ABT-263
(navitoclax),15,16 rationally designed molecules with antineoplas-
tic17 and immunomodulatory properties.18-20 ABT-737 acts as
a “sensitizer BH3-only protein”: it inhibits the antiapoptotic Bcl-2
factors Bcl-2, Bcl-xL, and Bcl-w and enhances the effect of
proapoptotic endogenous “activator BH3-only proteins,” such as
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Bid or Bim.15 ABT-737 has a selective proapoptotic activity on
peripheral lymphocytes and platelets, but does not induce myelo-
suppression, as shown by the unaffected numbers of granulocytes
and erythrocytes in peripheral blood.18,20 This activity proﬁle
resulted in a favorable therapeutic index for ABT-263 in ﬁrst clinical
cancer trials.21 Moreover, ABT-737 inhibited allogeneic immune
responses through apoptosis induction in donor-reactive T cells.20
This effect wasmarkedly increased in combinationwith cyclosporine
A (CsA), because calcineurin inhibition prevented resistance of
activated T cells to ABT-737 in the ﬁrst days after antigen rec-
ognition by blocking the expression of the antiapoptotic factor Bcl-
2A1, which is not antagonized by ABT-737.22 Furthermore, CsA
reduced the expression of Bcl-2 in lymphocytes and therefore
increased the proapoptotic effect of ABT-737 without affecting its
selectivity proﬁle.23
In this study we evaluated Bcl-2 inhibition as a novel option to
induce donor-speciﬁc tolerance in the context of mixed chimerism
protocols. We found that Bcl-2 inhibition promoted tolerance by
supporting the deletion of donor reactive T cells in combination
with costimulation blockade. The tolerogenic effect of ABT-737
on peripheral lymphocytes was mediated by a pharmacological
boosting of the proapoptotic factor Bim, which was identiﬁed as
a critical player for establishment ofmixed chimerism.By targeting the
intrinsic apoptosis pathway, we developed a novel protocol to achieve
complete deletion of donor-reactive T cellswith aminimal toxicity and
to induce robust systemic tolerance without myelosuppression,
Methods
Mice
C57BL/6 (B6, H-2b), CBA (H-2k), BALB/c (H-2d), BM3.3 (CBA, H-2k), and
Bim knock-out mice (Bim2/2, H-2b) were housed in speciﬁc pathogen-free
conditions at the University of Zu¨rich. The BM3.3 mouse24—which expresses
on all CD8 T cells a transgenic T-cell receptor (TCR) selective for a naturally
processed octapeptide bound to the allogeneic major histocompatibility com-
plex (MHC) class I molecule H-2Kb—was kindly provided by A.-M. Schmitt-
Verhulst.25 Bim2/2 mice were kindly provided by Andreas Strasser.26 All
animal experiments were performed according to protocols approved by
the legal authority (Veterinary Ofﬁce, Canton of Zu¨rich, Switzerland).
Conditioning and bone marrow (BM) procedures
Different conditioning protocols were tested as indicated. In general, B6-
recipient mice received 1.5 or 3 Gy total body irradiation (TBI) from
a 137Caesium irradiator on day 21 with respect to bone marrow trans-
plantation (BMT). Hamster anti-mouse CD154 (MR1, 2 mg; purchased from
Bio-X-cell, West Lebanon, NH) was administered intraperitoneally (i.p.) 6 to
12 hours before transplantation with 253 106 fully MHC-mismatched CBA
BM cells by tail vein injection. In some experiments, CTLA4Ig (abatacept,
0.5mg; provided by Bristol-Myers Squibb, NewYork, NY) was administered
at day 2 after BMT. ABT-737, provided by Abbott Bioresearch (Worcester,
MA), was dissolved in polyethylene glycol, Tween 80, dextrose solution, and
dimethylsulfoxide and injected intraperitoneally at 50 mg/kg. CsA (Sigma-
Aldrich, Buchs, Switzerland) was dissolved in ethanol and cremaphor EL
(Sigma-Aldrich), then diluted in phosphate-buffered saline and injected
subcutaneously at 10mg/kg. Both ABT-737 and CsAwere administered daily
from day23 to day 12; on day22 and day21, mice received 2 injections for
a total of 100 mg/kg of ABT-737 and 20 mg/kg of CsA. On day 0, ABT-737
and CsA were not administered. To monitor the deletion of donor-reactive
CD8 T cells, we adoptively transferred 203 106 syngeneic BM3.3 splenocytes
to CBA recipients before starting the conditioning protocol with B6 BM cells.
The transgenicH-2Kb reactiveBM3.3CD8T cells weremonitored over time in
peripheral blood in a ﬂuorescence-activated cell sorter (FACS) using the
clonotypic antibody Ti98,27 kindly provided by A.-M. Schmitt-Verhulst, and
stained with a secondary phycoerythrin (PE) rat anti-mouse IgG, purchased
from Becton Dickinson (Basel, Switzerland).
Skin grafting
Mice were shaved and anesthetized with ketamine/xylazine. Full thickness
tail skin (about 1 cm2) from CBA (BM donor) or BALB/c (3rd party) mice
were grafted 3 to 6 weeks after BMT and considered rejected when,10% of
the graft remained viable. In some experiments a second skin grafting was
performed using the same procedure.
Flow cytometric analysis of chimerism and detection of
allospecific antibodies
Flow cytometric (FACS) analyses were performed with a BD-FACSCanto
(Becton Dickinson, Basel, Switzerland). Chimerism was analyzed in white
blood cells at different time points after BMT, in spleen and thymus as
indicated. Donor-derived cells were identiﬁed by ﬂuorescein isothiocyanate
(FITC)–conjugated anti-H-2Dk or anti-H-2Kk (Becton Dickinson). The cells
were counterstained with anti-CD4-PE, anti-CD8-APC, anti-B220-PE, anti-
CD11b-APC, anti-CD11c-APC, anti-CD49b-PE (for natural killer [NK] cells)
antibodies purchased from eBioscience (Frankfurt, Germany). Background
signal measured in a naı¨ve B6 mouse was subtracted to determine the per-
centage of donor-derived cells. Allospeciﬁc antibodies were measured in
indirect FACS: CBA, and Balb/c splenocytes were incubated with recipients’
serum (1:5 dilution inFACSbuffer) and subsequently stainedwith a secondary
anti-mouse FITC-conjugated IgG antibody (eBioscience). Mean ﬂuorescence
intensity was determined in FACS gating on CD8-positive cells.
Mixed lymphocyte reaction (MLR)
MLRwere performed in 96wells plates with responder splenocytes stimulated
by splenocytes from BM-donor, 3rd party, or syngeneic mice at a ﬁnal
concentration of 43 106 cells/mL inRoswell ParkMemorial Institutemedium
containing 10% fetal bovine serum, penicillin 100 U/mL, streptomycin 100
mg/mL, and 2-mercaptoethanol 50 mM. T-cell proliferation was measured by
incorporation of 3H-thymidine (PerkinElmer, Waltham, MA) added to the
culture on day 4 after stimulation. For the selective analysis of alloreactive
CD8 T cells in vitro, BM3.3 spenocytes were stimulated with CD8 T-cell-
depleted splenocytes from B6 (allogeneic) or CBA (syngeneic) mice and
analyzed in FACS gating onCD8T cells. After cell permeabilization, the level
of different Bcl-2 factors in alloreactive CD8 T cells was detected in FACS, as
previously described.23 Bcl-2 was stained using an anti-mouse Bcl-2-PE from
Becton Dickinson, Bcl-xL with an Alexa Fluor 488 conjugated antibody from
Cell Signaling Technology (Danvers, MA). Mcl-1 was detected with a mono-
clonal rabbit anti-mouse Mcl-1 antibody from Abcam (Cambridge, United
Kingdom), Bim with a polyclonal rabbit antibody detecting total Bim (EL,
L, and S isoforms) purchased fromCell Signaling, and then stainedwith a FITC
anti-rabbit IgG (eBioscience). Splenocytes were sorted by automatic magnetic
cell separation using an autoMACS proseparator according to the protocols of
Miltenyi Biotec (Bergisch Gladbach, Germany). For polyclonal stimulation of
splenocytes, anti-CD3 and anti-CD28 antibodies were used (eBioscience).
Cell viability was measured by propidium iodide exclusion in FACS.
Statistics
Student t test was used to compare values between groups. A P value, .05
was considered signiﬁcant. Graph Pad Prism Software version 5.0 (San
Diego, CA) was used for calculations.
Results
Tolerogenic effect of Bcl-2 inhibition by ABT-737
The effect of Bcl-2 inhibitors on BM engraftment and tolerance
induction was ﬁrst assessed by adding a short course of ABT-737
(50 mg/kg/day, from day 23 to day 12 after BMT) to a reduced
conditioning protocol consisting of low-dose TBI (1.5 Gy) on the
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day before BMT, a single injection of anti-CD154 (MR1, 2 mg)
and 25 3 106 fully MHC-mismatched CBA BM cells to B6
recipients. ABT-737 increased the percentage of chimeric mice and
induced a higher level of chimerism in all hematopoietic cell
lineages (Figure 1A). All chimeric animals accepted donor-type
skin grafts for more than 100 days and promptly rejected third-
party grafts (BALB/c) (Figure 1B). In a second experiment, mice
were treated with the same conditioning protocol including ABT-
737, MR1, and BM cells, but without TBI. Although this protocol
was not sufﬁcient to allow BM engraftment (Figure 1A), skin
transplantation (performed 6 weeks after BMT) revealed a marked
and lasting donor-speciﬁc hyporesponsiveness in comparison with
mice treated with MR1 and BM only (median survival time, 42 vs
96 days) (Figure 1C). Nevertheless, donor grafts were eventually
rejected (graft survival 21, 21, 54, 96, .100, .100, and .100
days). Thus, inhibition of Bcl-2, Bcl-xL, and Bcl-w was not
detrimental for survival and engraftment of donor-derived hemato-
poietic stem cells. Furthermore, ABT-737 in combination with
CD154 blockade led to some degree of donor-speciﬁc hypores-
ponsiveness, but it was not sufﬁcient to induce stable tolerance in an
irradiation-free conditioning protocol.
We previously demonstrated that the proapoptotic effect of
ABT-737 on naı¨ve and activated lymphocytes can be potentiated in
combination with CsA.22,23 Therefore, we added a short course of
low-doseCsA (10mg/kg/day subcutaneously) to themixed chimerism
protocol introduced above (1.5GyTBI,MR1, 253106BMcells from
CBA donors). In previous studies, treatment with CsA alone had an
antitolerogenic effect and resulted in a reduced number of tolerant
mice and lower chimerism levels (Figure 2A-B).8,10,11 However, the
combination of CsA with ABT-737 completely prevented this
phenomenon and induced a high level of chimerism (Figure 2A;
supplemental Figure 1 for kinetics of multilineage chimerism) and
donor-speciﬁc tolerance in all recipients, as shown by the long-term
survival of donor-type CBA skin grafts (Figure 2B). Importantly, the
combination of ABT-737 with CsA not only prevented the anti-
tolerogenic effect of calcineurin inhibitors, it resulted in an even
higher chimerism level in comparison with ABT-737 alone, thereby
reversing the antitolerogenic effect of CsA in a paradoxical synergism
(Figure 2A). The mechanism underlying this clinically important
ﬁnding was further investigated.
The critical role of the proapoptotic factor Bim in
deletional tolerance
Because ABT-737 inhibits antiapoptotic Bcl-2 factors with high
selectivity,15 its tolerogenic effect is likely to result from a direct
interaction with the regulation of the intrinsic apoptosis pathway in
alloreactive lymphocytes. We hypothesized that ABT-737 might
reverse the antitolerogenic effect of CsA by compensating a dysregu-
lation of the intrinsic apoptosis pathway in activated CD8 T cells
determined by signal 1 inhibition.28 First, we aimed to identify an
antiapoptotic factor of the Bcl-2 familiy, whose expression in donor-
reactive T cells was reduced underMR1 alone, but not in combination
with CsA. To monitor the regulation of Bcl-2 factors in a homoge-
neous population of alloreactive CD8 T cells, we took advantage of
the BM3.3 transgenic mouse, which expresses on all CD8 T cells
a transgenic TCR speciﬁc for the MHC class I molecule H-2Kb and
can be detected by the clonotypic antibody Ti98. BM3.3 splenocytes
were stimulated with CBA (syngeneic) or B6 (allogeneic) splenocytes
under the effect of CsA and MR1 in classical MLR experiments, and
the expression of different Bcl-2 factors was measured in FACS.
Among the most important antiapoptotic Bcl-2 factors, only the
expression of Bcl-xL was reduced under the effect of MR1, but this
process was not reversed in combination with CsA (Figure 3A). This
Figure 1. ABT-737 facilitates mixed chimerism in-
duction. B6 recipients (H-2b) were treated with a condi-
tioning protocol including TBI (1.5 Gy), MR1 (2 mg), and
25 3 106 fully MHC-mismatched BM cells from CBA
donors (H-2k). Six weeks after BMT, skin transplantation
from CBA and BALB/c (3rd party, H-2d) donors was
performed. (A) Adding a short course of ABT-737 to the
conditioning regimen (ABT; 50mg/kg/day, fromday23 to
day 12 after BMT) resulted in a higher number of chimeric
animals and significantly increased the percentage of
donor-derived cells in different cell lineages in peripheral
blood leukocytes (PBL; 10 weeks after BMT). CD11b
for neutrophils; CD49b for natural killer cells; *P , .05;
**P, .01.N57. (B) After skin transplantation all chimeric
mice accepted donor grafts and promptly rejected 3rd-
party grafts, demonstrating that donor-specific tolerance
had been induced.N5 7-8 per group. (C) Using the same
experimental protocol but without TBI, we obtained a
pronounced donor-specific hyporesponsiveness, but
tolerance was not achieved, as shown by the slow
rejection of donor skin grafts over time. N 5 7-8 per
group. Representative results of 2 independent experi-
ments are shown. tpl, transplantation.
BLOOD, 29 AUGUST 2013 x VOLUME 122, NUMBER 9 TOLERANCE INDUCTION BY APOPTOSIS MODULATION 1671
For personal use only.on October 23, 2015. by guest  www.bloodjournal.orgFrom 
Appendix
116
ﬁndingwas consistent with the previously reported critical role of Bcl-
xL in thismodel,13 but did not explain the effect of CsA andABT-737.
However, we found that CsA had a major impact on the regulation of
Bim, a fundamental proapoptotic Bcl-2 factor in T cells. Alloantigen
stimulation induced a transitory upregulation of Bim in CD8 T cells
(Figure 3B). The initial upregulation phase was dependent on signal 1
(and was blocked by CsA), whereas the subsequent downregulation
was inﬂuenced by costimulatory signals. As a result, the level of Bim
remained low in cells activated in the presence of CsA, and—starting
at day 3 after stimulation—was signiﬁcantly higher in CD8 T cells
treated with MR1 (Figure 3C). This correlated with the viability of
polyclonally stimulated alloreactive CD8 T cells: costimulation block-
ade did not inﬂuence alloreactive CD8 T cell viability during the ﬁrst
2 days of culture (not shown), but a progressive loss of viability in
alloreactive CD8T cells devoid of costimulationwas registered at days
3 and 4 after stimulation. This process was completely dependent on
Bim, as shown in experiments using Bim2/2 CD8 T cells under the
same experimental conditions (Figure 3D). Notably, the dysregu-
lation of Bim under the effect of CsA was not inﬂuenced by MR1
(Figure 3C).
The critical role of Bim for deletional tolerance during mixed
chimerism inductionwas conﬁrmed in vivo by applying an established
conditioning protocol (TBI 3 Gy, MR1) to Bim2/2 recipients. In
comparison with wild-type (WT) animals, Bim2/2 mice displayed
a marked resistance to mixed chimerism induction (Figure 3E). This
was reﬂected in skin graft survival: in Bim2/2 mice the majority of
donor-type CBA skin grafts were rejected within 50 days in
comparison with indeﬁnite survival inWTmice (Figure 3F). Notably,
ABT-737 failed to promote tolerance when added to the same
conditioning protocol in Bim2/2 recipients (Figure 3F-G). These data
are consistent with the involvement of Bcl-xL andBim in anti-CD154-
dependent deletional tolerance, support the thesis that the antitolero-
genic effect of CsA is related to a dysregulation of Bim, and indicate
that ABT-737 promotes deletional tolerance and reverses the
antitolerogenic effect of CsA by enhancing the function of Bim. This
novel mechanism for inducing tolerance was explored to aim for
a myelosuppression-free tolerance-induction protocol.
Irradiation- and myelosuppression-free tolerance induction by
targeting the apoptosis pathway
WT B6 mice were treated with ABT-737 (50 mg/kg/day) and low-
dose CsA (10 mg/kg/day) for 2 weeks starting at day23 with respect
to BMT, and an additional dose of both drugs was administered on
day22 in order to achieve more pronounced peripheral lymphocyte
depletion. Subsequently,MR1was injected 6-12 hours before 253106
BM cells from fully MHC-mismatched CBA donors. This protocol
led to multilineage mixed chimerism in 29 out of 33 mice in 5
independent experiments. Similar to previous attempts of mixed
chimerism induction without myelosuppressive conditioning,29 the
level of donor chimerism was rather low in comparison with TBI-
based protocols (Figure 4A-B). However, chimerism remained
stable over time (supplemental Figure 2): 33 weeks after BMT,
we measured a 4.4% of donor-derived CD4, 2.7% CD8, and 15.6%
CD11b in the spleen. Interestingly, the B-cell compartment did not
show anymacrochimerism, either in the spleen or in peripheral blood
at any time point after BMT. Donor-type CBA skin grafts were
accepted indeﬁnitely with a maximal observation time of 269 days,
whereas all third-party grafts (BALB/c) were promptly rejected,
therefore demonstrating donor-speciﬁc tolerance (Figure 4C).
Notably, the additional dose of ABT-737 on day 22 was not
sufﬁcient to induce mixed chimerism without CsA (supplemental
Figure 3)
Although the effect of CTLA4Ig on the regulation of Bcl-2 factors
in vitro was promising (supplemental Figure 4), the success of this
protocol was dependent on inhibition of the CD40/CD154 signaling,
because the same conditioning regime failed to induce mixed
chimerism and tolerance, when MR1 was replaced by CTLA4Ig
(0.5mgonday 2 after BMT;Figure 4C). Themechanisms of tolerance
induction and maintenance in mice treated with this protocol were
further investigated.
Robust peripheral and central deletional tolerance
First, tolerization of preexisting peripheral alloreactive T cells was
assessed using the transgenic BM3.3 system described above.
Before starting the tolerance induction protocol, 20 3 106 BM3.3
splenocytes were transferred into syngeneic CBA recipients, which
allowed monitoring alloreactive BM3.3 CD8 T cells in blood over
time using the clonotypic antibody Ti98. In mice treated with the full
conditioning protocol including ABT-737 (50 mg/kg/day), low-dose
CsA (10 mg/kg/day), MR1, and 25 3 106 B6 BM cells, donor-
reactive CD8 T cells completely disappeared from the peripheral
T-cell repertoire in the ﬁrst 2 weeks and did not recover after resolution
of lymphopenia (Figure 5A). In contrast, in mice treated with the
same pharmacological conditioning regimen, but without BMT,
Figure 2. ABT-737 reverses the antitolerogenic effect
of CsA. B6 recipients (H-2b) were treated with a condi-
tioning protocol including TBI (1.5 Gy), MR1 (2 mg), and
25 3 106 fully MHC-mismatched BM cells from CBA
donors (H-2k). Six weeks after BMT, skin transplantation
from CBA and BALB/c (3rd party, H-2d) donors was
performed. (A)CsA (10mg/kg/day, fromday23 to day 12
after BMT) had a deleterious impact on mixed chimerism
induction, but this effect was reversed in combination with
ABT-737 (ABT, 50 mg/kg/day, from day 23 to day 12
after BMT), as shown in the level of chimerism in different
hematopoietic cell lineages in peripheral blood leuko-
cytes (20 weeks after BMT). Notably, the chimerism level
in the combination group was even higher than in the
group treatedwithABT-737 alone. **P, .01; ***P, .001;
N5 7-8. (B) Most recipients receiving CsA alone rejected
CBA skin grafts, whereas all mice treated with a combi-
nation of CsA and ABT-737 accepted CBA and promptly
rejected BALB/c skin grafts. N 5 7-8/group.
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Ti981 cells were markedly reduced, but still detectable in peripheral
blood. The complete deletion of Ti981 cells in mice exposed to the
full protocol was conﬁrmed by FACS analysis of the spleen after
rechallenging the recipient mice with B6 splenocytes (106 cells IV)
(Figure 5B-C). Thus, exposure to donor-derived BM cells under the
effect of MR1 and ABT-737 induced a complete peripheral deletion
Figure 3. Bim is required for induction of mixed chimerism. BM3.3 splenocytes were stimulated in vitro with CD8-depleted B6 (allo) or CBA (syn) splenocytes. The
expression of different Bcl-2 factors in transgenic alloreactive BM3.3 CD8 T cells was monitored by FACS. (A) In comparison with allostimulated cells without additional
pharmacological treatment, after 4 days of MLR, cells exposed to MR1 expressed higher levels of Bcl-2 and Mcl-1 and lower levels of Bcl-xL. The expression of these
antiapoptotic factors was not influenced by an additional treatment with CsA. Percentages of mean fluorescence intensity (MFI) values in comparison with allostimulated cells
without pharmacological treatment are shown. (B) Allostimulation induced a transient upregulation of Bim, with a peak after 2 days of culture. CsA inhibited the initial
upregulation of Bim, and MR1 prevented its downregulation in the late activation phase. (C) As a result, after 4 days the level of Bim was low in cells stimulated in the presence
of CsA and high with MR1. Statistical comparison with syn: *P , .01. (D) The relevance of these processes on CD8 T-cell viability after polyclonal stimulation was assessed
culturing WT and Bim2/2 splenocytes in the presence of anti-CD3 with anti-CD28 antibodies or without anti-CD28 and MR1. After 4 days, absence of costimulation reduced
the viability of WT CD8 T cells, but the same phenomenon was not observed using Bim2/2 cells, suggesting that the downregulation of Bim (C) was important for the viability
of activated T cells. **P , .01. (E) In vivo, a standard conditioning protocol (3 Gy TBI, MR1, 25 3 106 CBA BM cells) induced mixed chimerism in all WT B6 mice, but was not
successful in the majority of Bim2/2 mice, as shown by the levels of chimerism 15 weeks after BMT and (F) by the rejection of CBA skin grafts. Similar results were obtained if
ABT-737 was added to the same conditioning protocol (E-F). Statistical comparison WT vs Bim2/2: *P , .05; ***P , .001; N 5 6-7 per group.
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of alloreactive T cells during the mixed chimerism induction phase,
and this was not impaired by CsA.
Second, the mechanism of long-term maintenance of tolerance
was investigated in mice receiving our irradiation-free protocol.
Mixed chimeras maintain donor-speciﬁc tolerance through central
deletion of donor-reactive T cells, and the presence of donor-derived
antigen-presenting cells in the thymus is critical in this setting.30
Using the above-mentioned irradiation-free protocol, we consis-
tently detected about 5% of donor-derived antigen presenting cells
(CD11c1) in the thymus as demonstrated by thymic FACS analysis
33 weeks after BMT (Figure 6A), a ﬁnding consistent with central
clonal deletion. The presence of a sustained systemic tolerance was
further conﬁrmed by different immunological tests: donor-speciﬁc
B-cell tolerance was demonstrated by the absence of donor-speciﬁc
IgG alloantibodies, whereas 3rd party–reactive IgG was readily
detectable several weeks after skin grafting (Figure 6B). A lack of
donor-speciﬁc T-cell responses was measured in classical MLR ex-
periments (Figure 6C), conﬁrming at a functional level a complete
deletion of donor-reactive T cells from the peripheral repertoire.
Finally, 58 days after the ﬁrst skin transplantation, tolerant mice were
rechallenged with a second skin graft from donor and 3rd-party
control. All mice accepted the secondary CBA graft and rejected the
BALB/c graft (Figure 6D-E). Taken together, a 2-week conditioning
protocol with ABT-737 and CsA in combination with MR1 induced
mixed chimerism and stable systemic T- and B-cell tolerance without
myelosuppressive treatment and with moderate doses of BM cells.
Discussion
In this study we explored the intrinsic apoptosis pathway as a novel
pharmacological target to induce mixed chimerism and allograft
tolerance. We observed a critical role of the proapoptotic Bcl-2 family
member Bim for deletional tolerance using costimulation blockade,
and we therapeutically exploited this ﬁnding using the BH3-mimetic
ABT-737 to establish a new irradiation- and myelosuppression-free
protocol to inducemixed chimerismwith amoderate dose of BMcells.
The tolerization of the peripheral T-cell compartment in mixed
chimerism induction protocols based on costimulation blockade
depends on the complex regulation of apoptosis in T cells after
antigen recognition.13 Focusing on the intrinsic pathway, the initial
upregulation of Bim is counteracted by a simultaneous regulation
of antiapoptotic factors and is required for T-cell activation.28,31
Three to 4 days after antigen-recognition stimuli by costimulatory
Figure 4. Myelosuppression-free tolerance induc-
tion with ABT-737 and CsA. B6 recipients (H-2b) were
treated with an irradiation-free conditioning protocol
including ABT-737 (50 mg/kg/day), CsA (10 mg/kg/day)
from day 23 to day 12, costimulation blockade (CSB)
with MR1 (2 mg on day 21), and 25 3 106 fully MHC-
mismatched BM cells from CBA donors (H-2k). Four to
6 weeks after BMT, skin transplantation from CBA and
BALB/c (3rd party, H-2d) donors was performed. (A-B)
A significant myeloid (CD11b1) and T-cell chimerism,
but no chimerism in the B-cell compartment, was
measured in peripheral blood (FACS at week 10 after
BMT shown in panel A) and in the spleen (FACS at 33
weeks after BMT shown in panel B). N 5 7 per group.
Representative results of 5 independent experiments
are shown. (C) Donor skin grafts were indefinitely ac-
cepted by 29 out of 33 mice in 5 independent experi-
ments, whereas 3rd-party grafts (BALB/c) were promptly
rejected. Combined data of 5 independent experiments
are shown. N5 33. The same conditioning protocol failed
to induce tolerance, when MR1 was replaced by CTLA4Ig
(0.5 mg on day 2).
Figure 5. Peripheral deletion of alloreactive CD8 T cells. Tomonitor a well-defined
population of alloreactive CD8 T cells during tolerance induction with ABT-737 and
CsA, we adoptively transferred CBA recipients (H-2k) with BM3.3 splenocytes
(transgenic TCR specific for H-2Kb on all CD8 T cells) and subsequently treated with
our irradiation-free conditioning protocol including ABT-737 (50 mg/kg/day), CsA
(10 mg/kg/day) from day23 to day 12, MR1 (2 mg), and 253 106 fully BM cells from
B6 donors (H-2b). In a control group, BM cells were not administered (conditioning
only). (A) Transgenic donor-reactive BM3.3 CD8 T cells (Ti981) were reduced in both
groups, but only in mice receiving the full protocol was a complete deletion achieved.
Statistical comparison of the 2 groups: *P , .05; **P , .01; N 5 5. (B-C) After
rechallenging with donor antigens (106 B6 splenocytes IV at day 37 after BMT), Ti981
cells were readily detectable in the conditioning-only group, but had completely
disappeared from the peripheral T-cell repertoire after exposure to the full protocol.
**P , .01; N 5 5 per group.
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molecules and interleukins are required to maintain cell survival by
a downregulation of Bim and an upregulation of Bcl-xL.32,33 In the
absence of an adequate antiapoptotic signal through costimulation,
Bim prevails and activated T cells die by apoptosis.
Bcl-2 inhibitors offer the opportunity to selectively interact with
these mechanisms. In our model, ABT-737 promoted peripheral
T-cell tolerization by at least 2 complementary effects. First, it reduced
the precursor frequency by a peripheral depletion of lymphocytes.
Second, it led to a more efﬁcient clonal deletion of alloantigen-
reactive T cells by directly boosting the critical role of Bim in com-
bination with anti-CD154. Additional effects of Bcl-2 inhibitors on
regulatory T cells cannot be excluded. The beneﬁcial effect of the
combination of ABT-737with CsA ismultifactorial. CsA potentiated
the proapoptotic effect of ABT-737 on lymphocytes and blocked the
upregulation of A1, thereby preventing resistance to ABT-737 in
T cells after antigen recognition.22,23 On the other hand, ABT-737
reversed the antitolerogenic effect of CsA by compensating the
missing upregulation of Bim after allostimulation under calcineurin
blockade (Figure 3). As a result, the combination of CsA and ABT-
737 resulted in a paradoxical synergistic effect. This ﬁnding is of
critical clinical relevance: because graft lost because of acute re-
jection cannot be ethically accepted in the modern transplantation
era, a clinically applicable tolerance induction protocol has to foresee
a combination of initial standard immunosuppressive and tolerance-
induction regimes in a preventive or therapeutic setting, ideally
without the a priori exclusion of calcineurin inhibitors.34
A short induction phase with ABT-737, CsA, andMR1 induced
a complete deletion of peripheral donor-reactive T cells and
allowed the engraftment of a sufﬁcient number of donor-derived
stem cells to maintain a durable mixed hematopoietic chimerism.
Notably, because hematopoietic stem cells express high levels of
Mcl-1,35 ABT-737 does not induce apoptosis in this cell population
and is not expected to “create space” in stem cell niches, a factor that
was originally thought to be required for BM engraftment.36,37 A
signiﬁcant level of chimerism without myelosuppressive condition-
ing was previously achieved using megadoses of BM, but has never
been reported using clinically applicable BM doses.29 Because our
conditioning protocol was sufﬁcient to induce a stable level of
chimerism .5% with moderate doses of BM, we speculate that
ABT-737 and CsA might promote BM engraftment by inﬂuencing
the complex interaction of immunological, stromal, and stem cells
in the stem cell niche38 or by promoting the physiological niche
recycling.39 These aspects might assume a general relevance for
BM transplantation and the underlying mechanisms merit further
investigation.
The sustained detection of donor-derived granulocytes over more
than 8 months clearly indicated that engraftment of donor stem cells
or very early progenitor cells had occurred. However, the level of
hematopoietic chimerism was not uniform among different cell
lineages with a complete absence of donor-derived B cells and higher
levels of granulocytes. This could be explained by the engraftment of
myeloid-biased hematopoietic stem cells.40,41 The donor-derived
Figure 6. Robust, systemic tolerance after mixed chimerism induction with ABT-737 and CsA. B6 recipients were treated with an irradiation-free conditioning protocol
including ABT-737 (50 mg/kg/day), CsA (10 mg/kg/day) from day 23 to day 12, MR1 (2 mg), and 25 3 106 BM cells from CBA donors. Six weeks after BMT, skin
transplantation from CBA and BALB/c donors was performed. (A) FACS analysis 33 weeks after BMT revealed a significant percentage of donor-derived antigen-presenting
cells (CD11c1) in the thymus, but not in T cells and in T-cell precursors (DN, double negative; DP, double positive). (B) Serum samples were collected 60 days after skin
transplantation and analyzed by indirect FACS using CBA and BALB/c cells: a complete absence of CBA-reactive IgG and a normal seroconversion toward BALB/c were
measured. MFI, mean fluorescence intensity. Statistical comparison between mixed chimeras (MC) and a group of naı¨ve mice is shown. *P , .05; N 5 5. (C) Thirty-three
weeks after BMT, recipient mice were killed and their splenocytes stimulated in vitro with irradiated B6 (syn), CBA (BM donor), and BALB/c (3rd party) splenocytes in
a classical MLR. T-cell proliferation analysis, measured by 3H-thymidin incorporation, revealed a complete lack of T-cell reactivity against CBA and a normal response toward
BALB/c. CPM, counts per minute; ***P , .001; N 5 5 per group. (D) A group of mice received a second skin graft 58 days after initial transplantation. All BALB/c grafts were
rejected within 10 days, whereas CBA grafts were accepted for more than 40 days without signs of rejection. N 5 7 per group. (E) Photograph of a representative example at
day 100 after first transplantation.
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hematopoiesis was sufﬁcient to maintain a pool of donor-derived
antigen-presenting cells in the thymus to establish central deletional
tolerance and—in a clinical perspective—may be favorable, because
it reduces the risk of graft-vs-host disease.
The tolerance induction protocol described here provides a
solution to several problems currently precluding a broad clinical
application of the mixed chimerism approach. The general toxicity
of the conditioning regimen is low in comparison with protocols
including myelosuppressive drugs or TBI.4 In phase I clinical trials,
ABT-263 displayed a favorable toxicity proﬁle, and its application
for a short conditioning therapy seems to be adequate also for
nonmalignant conditions.21 Depleting antibodies—notably more
efﬁcient in mice than in humans42—are not required, but a blockade
of the CD40/CD154 pathway was critical in our model. The recent
report of antibodies blocking CD40 may represent an ideal solution
for blocking this pathway without the thromboembolic side effect
reported in primates after exposure to anti-CD154.43-46 Importantly,
in contrast to previous reports of mixed chimerism induction without
myelosuppression,29,47 our conditioning protocol was successful
using a clinically relevant dose of BM cells and without additional
cell-based therapy.
In summary, we established a novel and reliable approach to
induce mixed chimerism and allograft tolerance by pharmacolog-
ical modulation of the intrinsic apoptosis pathway. This approach
allowed induction of mixed chimerism using a nontoxic, non-
myelosuppressive conditioning protocol with potential clinical
applicability.
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